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Chapter 1 
INTRODUCTION 
In preparation for submission: 
Van den Bemd GJCM, Pols HAP, Van Leeuwen JPTM. Mechauistic aspects of vitamin D 
analog action. 
II 

1. INTRODUCTION 
Nuclear hormones play a key role in embtyonic development, growth and 
differentiation of cells and tissues, and in maintenance of homeostasis. They exetl 
their action via a large group of nuclear, transctiption factors gathered in the 
nuclear receptor superfamily ~~. 0'''''" 199Q). This superfamily consists of 
receptors for estrogen, glucocorticoid, mineralocotlicoid, androgen, progesterone, 
but also contains receptors for vitamin D, retinoids, fatty acids, and thyroid 
hormone. Futlhetmore, a large number of so-called orphan receptors are included 
for which ligands and functions are at the moment unknown (!(1i'W<r 1999). 
A. VITAMIN D RECEPTOR-MEDIATED GENE REGULATION 
The vitamin D receptor (VDR) Ul>Iill..llli. """""" "88. H,"~I" 1998) is a 50-60 kDa receptor 
protein that becomes active after binding of its ligand: the secosteroid 1,25-
dihydroxyvitamin D3 (I,25-(OH)2D3) (For details on 1,25-(OH)2D3 formation see 
Section AA.I.). In its activated form, the VDR regulates transctiption of vatious 
genes involved in bone metabolism and in maintenance of calcium and phosphate 
homeostasis ( • .;.h,1 1989. 0<1."", 1997). In addition to these classic functions, binding of 
1,25-(OH)2D3 to the VDR initiates a complex of biochemical processes that 
modulates proliferation and differentiation of cells rlllhl99!l. W,lIm 1991· ~ v" "" B,rnd 
ll!QQa) 
A.I. VITAMIN D RECEPTOR EXPRESSION 
The VDR is expressed in various tissues and cells (see Table 1.1). VDRs are both 
present in the cytoplasm and in the nucleus IW,II.. 1986), However, it is still 
controversial whether unliganded VDRs reside in the cytoplasm or in the nucleus 
(Barsony 1999) 
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Table 1.1. Cells, tissues, and or!!ans containing vitamin D receptors 
Adapted from: H.ikk.1m, Walters 1992, BQuilloijl99S,Norman 1997 
targettisslies related to classic vitamill D jilllctioll 
Bone (bone man'ow, cartilage, osteoblasts, osteoclast presursors) 
Intestine 
Kidneys 
Parathyroid glands 
target tisslies related to 1I0llclassic vitamill D jilllctioll 
Adipose Mnscle 
Adrenals Ovmy 
Brain Pancreas J3-cells 
Breast 
Colon 
Endothelium 
Epididymis 
Ganglion 
Hair follicle 
Liver 
Lung 
Lymphocytes (activated) 
Monocytes 
Ma/igl/al/l cells 
Breast carcinoma 
Cervical carcinoma 
Gall bladder carcinoma 
Parotids 
Pituitary 
Placenta 
Prostate 
Retina 
Skin (keratinocytes, melanocytes, fibroblasts) 
Stomach 
Testis 
Thyroid 
Utel1ls 
Lung carcinoma 
Osteosarcoma 
Prostate carcinoma 
A.2. VITAMIN D RECEPTOR STRUCTURE 
The VDR and other members of the nuclear receptor superfamily share a basic 
stl1lcture consisting of a variable N-tenninal region, a shOlt and well conserved 
cysteine-rich central domain and a relatively well-conserved C-tenninal region 
(Figure l.l). 
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Figure 1.1. Schematic structure of VDR, retinoid X receptor a (RXRa), and 
estrogen receptor a (ERa). 771e specific jill/ctiolls oj the dOll/aills A through Fare 
indicated. P indicates a pllOsphOJylatioll site. 
The cysteine-rich domain (domain C in Figure 1.1) contains two characteristic 
zinc-binding clusters of amino acid residues that are responsible for DNA binding 
of the receptor. C-tenllinal of the DNA-binding domain lies the hinge region 
(domain D) that gives the VDR its flexibility. The ligand binding domain of the 
VDR (designated E) consists of 12 a helixes containing regions involved in 
nuclear translocation, receptor dimerization, and ligand-dependent transcriptional 
activation (AF-2). The AF-2 domain of the VDR is located on helix 12 between 
amino acids 417 and 420 (J,rulka 19971, but also tyrosine 236, lysine 246, and lysine 
264 within helix 3 play an impoliant role in cofactor binding and ligand-dependent 
transactivation (Nakajima 1998, Jimio!"z·la@ 1999, Kraic-hdy 1999). Another region imp0l1ant for 
transactivation (i.e. AF-I) lies in the N-terminal AlB domain. The AF-I domain 
functions in a ligand-independent manner and has been identified in most nuclear 
hormone receptors, although the VDR probably lacks AF-I function. Compared to 
estrogen receptor (ER), retinoid X receptor (RXR), and retinoic acid receptor, the 
VDR AlB domain is short and its removal does not affect VDR function (~l22.lJ. 
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However, elements between amino acids 14 and 23 in the N-telminal region of the 
VDR are imp0l1ant for optimal transcriptional activity and binding to the basal 
transcription factor lIB (TFIIB) (I,m", 1998l. The function of the C-telminal F domain, 
which is not present in all receptors (e.g. the progesterone receptor), has not yet 
been elucidated. 
A.3. FUNCTION OF 1,25-DIHYDROXYVIT AMIN D3 
Classic filllctioll of 1,25-dihydl'oxyvitomill D3 
The hormone 1,25-(OH)2DJ is the natural ligand for the VDR. The classic action 
of 1,25-(OH)2DJ involves regulation of calcium and phosphate homeostasis and 
bone metabolism. Increased 1,25-(OH)2DJ levels induce elevation of the calcium 
concentration in the blood by increasing calcium absorption from the intestine by 
stimulating transcaltachia and the production of calbindin D-9k, a protein 
involved in calcium transport from the intestinal lumen through the enterocytes 
into the blood stream "Irom 1992l. Fm1hermore, 1,25-(OH)2DJ increases calcium 
reabsorption in the kidney. 
For optimal regulation of calcium and bone metabolism interaction of 1,25-
(OH)2DJ with parathyroid hormone (PTH) is crucial. PTH takes care of the rapid 
(within minutes) response to changes ill serum calcium levels, whereas longer 
term control of homeostasis is maintained by 1,25-(OH)2DJ. PTH not only 
regulates calcium homeostasis indirectly via 1,25-(OH)2D3 (Section AA.I) but 
also directly increases calcium reabsorption in the kidney. 
When uptake of dietaty calcium via the intestine does not suffice, 1,25-
(OH)2D3 can stimulate the release of calcium from bone, which is the major 
store of calcium in the body. Calcium release 11'om bone is also increased by 
PTH, by a stimulatmy effect on the number, activity, and life span of 
osteoclasts, the bone resorbing cells (more details on bone are discussed below). 
A third hormone, calcitonin, secreted by C-cells in the thyroid gland, is also 
involved in regulation of the serum calcium concentration. Calcitonin stimulates 
the 1,25-(OH)2D3 concentration and decreases 24-hydroxylase activity. In 
addition, the number and activity of osteoclasts is reduced by calcitonin U'ink!:lmm 
lllil. The expression of receptors for calcitonin in newly fmmed osteoclasts is 
regulated by 1,25-(OHhD3 "1;,,,,1991). 
I ,25-(OH)2D3 plays a major role in bone metabolism (~l. The bone forming 
cells, the osteoblasts, and the bone resorbing cells, the osteoclasts, are constantly 
remodelling bone (Niiw'ido 1986). 1,25-(OH)2D3 is acting on osteoblasts via their VDRs 
and regulates their growth and differentiation. The synthesis of several bone 
matlix proteins by osteoblasts (e.g. osteocalcin, osteopontin, osteonectin, type I 
procollagen, alkaline phosphatase) is under control of 1,25-(OHhDJ. The role of 
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most of these proteins is not completely clear and ranges from cell matrix 
attachment to control of mineralization. The synthesis of celiain cytokines and 
growth factors (e.g. transforming growth factor P (TGFI3), insulin-like growth 
factor I) by osteoblasts is also regulated by 1,25-(OH)2DJ (""",,,"h 1987. "'bwl> 1991). 
Mature osteoclasts lack the VDR and are indirectly regulated by 1,25-(OH)2DJ via 
stimulated secretion of specific factors (osteoclast differentiation factor) by the 
osteoblasts (MrSb"b, 1987. Ore,,"'" 1999). 1,25-(OH)2DJ regulates differentiation of 
osteoclast progenitors into mature osteoclasts (S,d, )992). Studies using cocultures of 
osteoblasts liom VDR knockout mice and wild-type spleen cells (as a source of 
osteoclast progenitors) showed that 1,25-(OH)2DJ-mediated osteoclast fonnation 
was abolished, indicating that the VDR in osteoblasts is essential for 1,25-
(OH)2DJ-stimulated osteoclast formation. The VDR was not required for 
osteoclast fOimation stimulated by PTH and interleukin 10. CThk"I> 1999). A key role of 
the VDR in regulating calcium and phosphate homeostasis by 1,25-(OH)2DJ was 
fmiher demonstrated by findings of hypocalcaemia, hypophosphatemia, 
hyperparathyroidism, and severely impaired bone fOl1l1ation in the VDR knock out 
mice (Yoshizawa 1997), 
NOllclassic jilllctioll of 1,25-diltydroxyvitalllill DJ 
As shown in Table 1.1, the VDR is also expressed in cells and tissues not directly 
involved in calcium and bone metabolism - so-called nonclassic target tissues. 
Also in various malignant cell types the VDR is expressed. 1,25-(OH)2DJ exerts 
growth regulatory and differentiation inducing effects on these cells and tissues 
(Reiche! 1989,.MLl22.Q, Walters 1992, Van dm Bernd 2Q(Xla), In the section below these nonc1assic effects 
of 1,25-(OH)2DJ will be discussed briefly. 
The growih of various nOimal cells (e.g. keratinocytes, epithelium and stromal 
cells) is reduced by 1,25-(OH)2DJ while their differentiation is stimulated (Smi!b.J.2M. 
R,gak, 1991 !hlLLm). In addition, 1,25-(OH)2DJ regulates growth and differentiation of 
various malignant cell types. Abe et af. and Colston et af. demonstrated that 1,25-
(OH)2DJ inhibited proliferation and stimulated differentiation of mouse myeloid 
leukemia cells and human melanoma cells ill vivo ~. Co'"" !98o. Furthelmore, 
1,25-(OH)2DJ prolonged the survival time of mice inoculated with myeloid 
leukemia cells (Ilona" 19&1" suppressed the ill vivo growth of human melanoma, colon 
cancer and breast cancer solid tumor xenografts (Ei=," )987. Ei=a 19SO" and inhibited the 
number of lung metastases after implantation of lung carcinoma cells into mice -
]2,\1). These cell growih inhibitOlY effects of 1,25-(OHhDJ were also observed ill 
vitro in hematopoietic tumor cells, primaty breast cancers, and breast cancer cell 
lines (~. Koerner 19&4, Mang,!sdQrf 1984, ChQuve! 1986, Eisll13n 1986, "ink·Van Wijngaaruen 199-1). More detailed 
information on 1,25-(OH)2DJ effects on tumor cell growth and differentiation can 
be found elsewhere /Pols 199-1, Van Lf\"llW"n 1997, van dm Bernd 1000a), 
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The discovelY that VDRs are expressed in monocytes and activated lymphocytes 
(!l!!ill!Lllli) has led to the search for an immunomodulatOlY role of I ,25-(OH)2D3 (I=ir< 
lm. HewisoD 199". These studies revealed that 1,25-(OH)2D3 stimulates differentiation 
of monocytes into mature macrophages and inhibits the proliferation of T and B 
lymphocytes (K"m" !9S4). Monocytes and macrophages activate lymphocytes by 
secretion of cytokines; e.g. interleukin I a, interleukin I p, interleukin 6, and tumor 
necrosis factor a. Activated T cells produce interleukin 2, interferon y, 
Iymphotoxin, and granulocyte-macrophage colony-stimulating factor that in return 
fmiher activate the macrophages. The growth and differentiation of T cells into T 
helper cells and cytotoxic T cells and of B cells into immunoglobulin producing 
plasma cells depends on the production of these cytokines and the expression of 
their receptors. 1,25-(OH)2D3 down-regulates the production of certain cytokines 
by monocytes/macrophages and lymphocytes (Bh,lI, 1984. Sh,lI, I".), probably by 
shOliening the half-life of their encoding mRNA rIn"" 19S8. MGl1" 1992>, but also by 
blocking the transcription of genes encoding for these cytokines \Alro)'ill.\. Tow," 1999). 
Furthermore, 1,25-(OH)2D3 decreases the production of immunoglobulin by B 
Iymfocytes ill vitl'o, probably by an inhibitOlY effect on the T cell and 
monocytes/macrophage helper nmctions ("Oil" (99(). Also ill vivo, 1,25-(OH)2D3 has 
itmnunoregulatOlY activity. In mice, 1,25-(OH)2D3 suppressed graft rejection of 
transplanted skin allografts (Chi"'hi' (991) and blocked development of experimental 
autoimmune encephalomyelitis « ,mire (991). The cell proliferation inhibitOlY propel1y 
of 1,25-(OH)2D3 together with its immunomodulatory effects are of interest in the 
treatment of psoriasis, a skin disease characterized by abnonnal growth and 
differentiation of epidermal cells and local inflammation with infiltration of 
neutrophils and T lymphocytes (Hn(1£' "89). Also treatment of autoimmune diabetes 
with 1,25-(OH)2D3 was repOlied (""hi,,, ""I. 
A.4. VITAMIN D RECEPTOR: 
TRANSCRIPTIONAL ACTIVATION 
Interaction of a nuclear honnone receptor with its ligand triggers a cascade of 
events resulting in transcriptional activation or suppression of specific target 
genes. 
Events that modulate gene transcription: 
• Synthesis, transpOli, and metabolism of receptor ligand 
• Binding of ligand to the receptor 
• Dissociation of heat shock proteins 
• PhosphOlylation of the receptor 
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• Dimerization of the receptor 
• Translocation ofthe receptor to the nucleus 
• Interaction with DNA 
• Complex formation with basal transcription factors and cofactors 
~ 
Enhanced or decreased target gene transctiption 
0-__ ....,.. 4.1 
• 
• 
Figure 1.2. Schematic presentation of the cascade of events resulting in the 
regulation of gene transcription. Major sleps in Ihe cascade are indicaled by IIII11/bers 
Ihal refer 10 Ihe Sections A.4.1.-A.4.B. and A.5. for Ihe VDR, and B.4./-B.4.B. and B.5.[or Ihe 
ER. 
19 
A.4.1. SYNTHESIS, TRANSPORT, AND METABOLISM OF 
1,2S-DIHYDROXYVITAMIN D3 
The hormone 1,25-(OH)2DJ is the active fonn of vitamin DJ and the natural ligand 
for the VDR. Its inactive precursor vitamin DJ is produced in the skin out of 7-
dehydrocholesterol under influence of ultraviolet B photons (290-315 Illll). 
Furthermore, dietalY uptake (fatty fish, fish oil, vitamin DJ fortified food) is a 
source of vitamin DJ. Subsequently, vitamin DJ is first hydroxylated in the liver at 
the C-25 position to form 25-hydroxyvitamin DJ (25-(OH)DJ) and secondly by 
renal la-hydroxylase at the C-I position to form biologically active 1,25-(OH)2DJ 
(Figure 1.3). 
PTH, but also other factors (calcitonin, estrogens; see Sections A.3. and B.3.) 
influence 1,25-(OH)2DJ synthesis in the kidney (K,",,";m, 1981). The production of 
1,25-(OH)2DJ and PTH is stimulated by low calcium levels in the blood, but 1,25-
(OH)2DJ and PTH also directly regulate each others synthesis via a negative 
feedback loop. PTH stimulates la-hydroxylase in the kidney while 1,25-(OH)2DJ 
has a direct inhibitOlY effect on the production and secretion of PTH by the 
parathyroid glands IGombg(;" 1972.~. "''In (992,). In addition, 1,25-(OH)2DJ down-
regulates la-hydroxylase activity (R,k"d IOS9). 
1,25-(OH)2DJ and 25-(OH)DJ are transported in the blood bound to vitamin D 
binding protein (DBP), that also functions as a storage for vitamin D compounds 
(H,dd,d !9Rl). In plasma, only 0.4% of 1,25-(OH)2DJ and 0.04% of 25-(OH)DJ is 
present in an unbound fOlID. The largest fraction (>85%) is bound to DBP. The 
rest is bound to albumin (> 10%) and low density lipoproteins (H,dd,d 19991• Also other 
vitamin DJ metabolites are bound by DBP. DBP has the highest binding affmity 
for 25(OH)DJ (Kd 10.9 M), followed by 24,25-(OH)2DJ and 25,26-(OHhDJ (Kd 
10"8 M) and vitamin DJ and 1,25-(OH)2DJ (Kd 10.7 M). Upon dissociation from 
DBP the hormones are available for entry and biological action in target cells. In 
this way DBP determines bioavailability and activity of vitamin D compounds, 
since only free vitamin D cOl11pounds are considered to be biologically active i!likl< 
~) 
It is not likely that DBP plays a role in protecting the organism against toxic 
levels of vitamin D compounds since it was shown that the DBP knock out mouse 
was less sensitive for vitamin toxicity than the wild type mouse (~I. On the 
other hand, vitamin D depletion resulted in hypelparathyroidism and bone 
abnormalities associated with vitamin D deficiency in the DBP knock out mouse, 
whereas wild type mice were not affected. This indicates that the major role of 
DBP is protection of the organism against vitamin D deficiency by providing a 
pool of vitamin D compounds with prolonged SelUl11 half-Iifes. 
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Figure 1.3. Formation and degradation of 1,25-(OH),D3 
21 
In order to protect the organism against toxic levels of vitamin DJ (and its 
metabolites) fm1her hydroxylation takes place, eventually leading to fOlmation of 
inactive products that can be excreted from the body. The first step is 
hydroxylation at the C-24 position. Both 25-(OH)DJ as well as 1,25-(OH),DJ 
become 24-hydroxylated by the same enzyme (CYP24), although 1,25-(OH),DJ is 
10 times more efficiently hydroxylated than 25-(OH)DJ (L0!!<L.!.222). CYP24 is 
expressed at high levels in the kidney, but also in most other target tissues (e.g. 
bone, intestine, skin) 24-hydroxylase activity has been found (lQn,,--12W. 1,25-
(OH),DJ is an inducer of its own 24-hydroxylation and PTH acts synergistically on 
this process in osteoblast-like cells (Yon L"""," )996 Am,b,,,bl 1998). In addition, 
hydroxylation at C-26 plays an important role in the metabolism of vitamin D3 
metabolites. TIle reason for the existence of two metabolic pathways is unclear. 
The 26-hydroxylation pathway might be a backup pathway for the 24-hydroxylase 
pathway <funti.l992). It is also not clear whether metabolites formed via 24- or 26-
hydroxylation are active or just intel111ediate products in the catabolic cascade of 
25-(OH)DJ and 1,25-(OH),DJ. Fact is that additional hydroxylation at C-24 or C-
26 leads to a decrease in the affinity for the VDR (Van H,m 1988), but it was also found 
that 24,25-(OH),DJ might playa role in mineralization of bone (Om;l, J978.~.S<brn 
12W and in regulation of intestinal calbindin D-9k production (H<mro;',,,, 1996\. 
Fm1helmore, 24,25-(OH),DJ exerts nongenomic regulatOlY effects on protein 
kinase C activity (S,l,;, 12')6). Recently, the possible role of 24,25-(OH),DJ in bone 
metabolism was reviewed by Van Leeuwen et al. (Y;m 1 ,,'W," 20(0). The 1,25-(OH),DJ 
metabolite 1,24,25-(OH)JDJ has stimulatOlY effects on intestinal calcium 
absorption ~). 25,26-(OH),DJ has intestinal calcium transp0l1 activity ~ 
.l21l)), and the end product of the C-26 hydroxylation pathway, la,25R(OH),-
26,23S-lactone-DJ probably has specific effects on bone cells and cm1ilage (~ 
12.M,~,.Arn.il.221, !shizuka 1997) 
Recently, a third metabolic pathway was identified in human keratinocytes, 
human colon carcinoma cells, rat osteoblastic cells and bovine parathyroid cells 
that metabolizes 1,25-(OH),DJ into 1,25-(OH),-3-epi-DJ (lWd, 1924. Di""of 1998. Brown )2'99. 
s;,,·c,lJorn )922). Interestingly, the activity of the different metabolic pathways might 
depend on the stage of cell differentiation (Dig bQfl9'lS'. 
A.4.2. VITAMIN D RECEPTOR LIGAND BINDING 
A key event in receptor activation is the ligand-induced change in receptor 
confOlmation <Alli!nJ.22l) which has been described for several members of the nuclear 
receptor superfamily (Simons !989,.!&ngi22,1. Beekman 199J,~, Keidel 199-1, Kuil 1994, Nayeri 1995,~). 
The ligand-binding domain of nuclear hormone receptors consists of 12 a helixes. 
Upon ligand binding the position of the AF-2-containing helix 12 changes in such 
a way that it covers the ligand-binding pocket, closing the so-called mouse trap. 
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The closed ligand-binding pocket exposes sites for interaction with specific 
cofactors, and triggers the cascade of events leading to transcriptional activation. 
Possibly directly linked to the confOimation of the receptor is its stability: the 
folding of the protein will determine its susceptibility to proteases in the cell and 
tllis will influence intracellular clearance of the receptor. In general, binding of 
ligand to the receptor will lead to a receptor conformation with decreased protease 
sensitivity. This will result in an increased stabilization of the receptor in 
comparison to the unliganded state (K,mpw',," 1992.~, Art",", 1993). In Chapter 3, 1,25-
(OH),D3- and 1,25-(OH),DJ analog-induced VDR stability will be discussed in 
more detail. However, ligand interaction does not always lead to increased 
receptor stability. Several steroids and antiholTIlOnes bind to the androgen receptor 
and cause nuclear translocation but fail to induce increased receptor stability 
(K""p,i"," 1992), and in the human breast tumor cell line T-47D ligand binding to the 
VDR results in decreased receptor half-life compared to the unliganded situation 
tsh<Lllli). Another example of ligand-induced decrease in receptor stability will be 
discussed in Chapter 6. 
Another mechanism by which the biological activity of nuclear hOiTIlOneS is 
mediated is by regulation of their receptor levels in target tissues. For several 
nuclear hOlTIlOneS a direct correlation between their receptor level and some 
biological responses was obselved (V,,'orb'" 1987). (For ER see Section B.4.2.). 1,25-
(OH),D3 is able to up-regulate its own receptor level, both ill vivo ~.~. 
~.S3ndgten 1990 • .!J.l.2221, and ill vitro {~.~~, Van Leeuwen 1996,Soh-gen 1997,ill.2:221, 
This homologous receptor up-regulation has been rep0l1ed to result 1iom an 
increased transcription rate of the VDR gene (Sol",," 1997), an increased mRNA 
stability and/or an increased receptor half-life ~. Albaur 1291, Santi5Q·Mere 1991, QaYoodi 1995), 
/11 vivo and ill vitro studies with human skin and cultured human keratinocy1es 
suggested that 1,25-(OH),D3 has no effect on VDR gene transcription but 
increases VDR levels by blocking ubiquitin/proteasome-mediated degradation of 
the VDR (Lili22). 
Also heterologous regulation of VDR by a wide variety of factors has been 
shown, for instance PTH (~, Van le<'uwen 1992,~, Krishnan 1995, Van Leeuwen 1996, Annbrechll998), 
PTH-related peptide U'Jl!.U.2,l!, v" ',,,,,w," 1992), growth hormone tchml221), glucoc0l1icoids 
(~, Domodi 1995', epidermal growth factor (v" ,,,,ow," 199!1, TGFp tsli!i!Llm), phorbol 
esters (Reinhard! 1994), forskolin rVan Leeuwen 1992), prostaglandin E2 (Van L«uweo 19'-:12), retinoic acid 
(~, Daroodi 19951, ER ligands (!..i.d...l.2.U, E:;.;aJt"jra [993, ~, .chm...1.22Z. lli..1222l, androgen 
receptor ligands (E,,,ki,, 19931, progesterone receptor ligands (Ibm""'i 199", and 
phosphorus (SriuwdJoom 1995), 
The biological relevance of this change in VDR number needs to be established, 
since the number of 1,25-(OH),DJ-responses that parallel the VDR content in the 
target cells is only limited. III vivo studies with ovariectomized rats showed that 
estrogen- and growth hormone-induced rise in intestinal VDR levels was 
accompanied by an increase in intestinal calcium absorption, transcription of the 
calbindin 9k gene, and alkaline phosphatase activity in response to 1,25-(OHJ,DJ 
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(!;hm.l221. !.hl.l2221. In addition, the increase of VDR levels in intestine and bone might 
explain hypercalciuria, increased intestinal calcium absmption and enhanced bone 
resmption as observed in idiopathic hypercalciuric rats (Li 1993,. Kri,,,, 19961• The 
observation in rats that homologous up-regulation of the VDR is observed in 
kidney and intestine but not in tissues not directly involved in regulating plasma 
calcium homeostasis (testis, heart, lung) is speculative for a functional role of 
homologous VDR up-regulation (G""" 19981. Also ill vitro studies a relationship 
between VDR levels and biological response was found. For instance, correlation 
exists between VDR levels and the extent of inhibition of collagen synthesis by 
1,25-(OH),D3 in osteoblast-like cells from mice and rats ~. ~I. Also in 
osteoblasts a direct relationship between I ,25-(OH),Dr, TGFp-, epidermal growth 
factor-, and PTH-induced changes in VDR level and 24-hydroxylase activity was 
found <Ch<ILlW. =-. Kri,hM' 1992. Am!h",h( 1998. Sl;;illW1. Enhancement by 1,25-(OH),D3 of 
glucocm1icoid-induced expression of aromatase cytocln'Ome P 450 in primary 
cultured human osteoblasts was found to depend on their VDR level 'Th''''' 19961• The 
antiproliferative activity of 1,25-(OH),D3 was associated with VDR expression in 
skin lesions of patients with psoriasis (~I, and the sensitivity of three 
osteoblast-like osteosarcoma cell lines for the growth regulating potency of 1,25-
(OH)2D3 was cOlTelated with the number of VDRs in each cell line (Do',h (gg'l. 
However, this is not a general mle, since no relation was found between VDR 
content of pancreatic cancer cells or prostate tumor cells and the antiproliferative 
effect of 1,25-(OH)2D3 (K"" 1996. Z1m~, 19971. A dissociation between VDR levels and 
1,25-(OH)2DJ action was also observed by Staal et al. showing that the TGFp-
induced rise in VDR content of osteoblast-like cells ill vitro was accompanied by 
decreased induction of osteocalcin and osteopontin production by 1,25-(OH)2D3 
~) 
As already mentioned, 1,25-(OH)2D3-induced VDR up-regulation might be 
due to inhibition of proteasome-mediated VDR degradation (LI 19991• However, the 
proteasome is probably also involved in 1,25-(OH),Dr induced down-regulation 
of the VDR. It was shown that 1,25-(OH),D3 dose-dependently stimulated 
interaction of VDR with cofactor SUG I, a component of the 26S proteasome, 
and that 1,25-(OH)2D3-induced binding of SUGl to VDR enhanced VDR 
degradation by proteasomes. A similar process might also play a role in E,-
mediated turnover ofthe ER (''',"yom, 19981• 
A.4.3. DISSOCIATION OF HEAT SHOCK PROTEINS 
In the cytoplasm, some of the members of the nuclear receptor superfamily 
(androgen receptors, ERs, glucocm1icoid receptors, mineralocorticoid receptors, 
progesterone receptors and peroxisome proliferator-activated receptors) are 
associated with heat shock proteins (H,,,, 199'1. The heat shock proteins might have a 
regulatmy role in the action of the receptors, and they might be involved in 
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protection of the receptor during synthesis and transpOit to the nucleus. Until 
recently, it was thought that the VDR was not associated with heat shock proteins. 
However, Swamy et at. and Craig et at. showed that specific residues in the hinge 
region and ligand-binding domain of the VDR might fonn interaction sites of heat 
shock proteins 70 and DnaK and that an inhibitor of heat shock protein 90 reduced 
1,25-(OH),D3-mediated gene activation in osteoblasts IS","" 1999. ~I. Upon 
ligand binding, heat shock proteins dissociate fi·om the receptor, allowing the 
receptors to bind to specific sites in DNA and interact with cofactors, where they 
can transactivate target genes. However, removal of heat shock proteins alone is 
not sufficient to obtain transcriptionally active receptors 10·'''11" 1990.~.ll"'hill21l. 
A.4.4. VITAMIN D RECEPTOR PHOSPHORYLATION 
An additional step in the cascade leading to receptor activation is phosphOlylation 
of the receptor IA""oohI9 1289. QrJLImI. Functional consequences of nuclear hOimone 
receptor phosphOlylation are not completely clear. Honnone binding activity, 
translocation, transcription factor binding and interaction with DNA might be 
influenced by phosphorylation. In addition, dimerization and receptor half-life 
might also be affected IK91"" 1<)<)". The VDR is a phosphoprotein that is fillther 
phosphOlylated under influence of I ,25-(OH),D3. The VDR can be phosphorylated 
at multiple sites by several kinases (Figure 1.1) IB,,,," 1991). For instance, human 
VDR is selectively phosphorylated by protein kinase C at serine 51 between the 
two zinc-binding amino acid clusters clllcial to its transactivation fimction and by 
casein kinase II at serine 208 near the ligand-binding domain and probably 
involved in positive modulation of transactivation lfuiill..lm. )'mo1\o (!l91 .. )9m'\o 1996). A 
cAMP-dependent protein kinase also plays a role in VDR phosphOlylation and 
enhances I ,25-(OH),D3-dependent transcriptional activation (D'mi,h 1WI. r9"'" 19'JJl. 
A.4.S. VITAMIN D RECEPTOR DIMERIZATION 
The 'classic' nuclear hOimone receptors (ERs, glucocOiticoid receptors, 
progesterone receptors) fonn homodimers and in this form they regulate gene 
transcription. In contrast, the VDR and several other members of the nuclear 
receptor superfamily (e.g retinoic acid receptors, thyroid hormone receptors, 
peroxisome proliferator-activated receptors) predominantly operate as 
heterodimers by binding to RXR IKII","" 1992 'm" 1991. S,h"lm" 1<)<)81, although VDR 
homodimers were also described (C~lb", 1991. ,,,,d,,,, 1994. K,;I" 1994· ~I. The biological 
relevance of these VDR homodimers is uIlce11ain (MacPtlnald 1995, lemon 1996, Thlrnpson 1998a), 
Some investigators claim existence of heterodimers of VDR and retinoic acid 
receptor IS'h~d" 1<)<)11 or VDR and thyroid hormone receptor IS,hOd" 1994), although this 
was questioned recently fRaval·Pand~'a 1998, Thomp;on 1998), 
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1,25-(OH),D3 is a strong enhancer of VDRlRXR dimerization "',,00,,1d 1995._ 
1997l, whereas the ligand of RXR, 9-cis retinoic acid, negatively modulates this 
action of 1,25-(OH),D3: it suppresses heterodimerization of VDR and RXR and 
stimulates the formation of RXR hOlllodimers (~hcDOnald 1993, Cheskis 1994, Chgkis 1995, ~ 
.!mol. Another RXR-specific ligand (CD2809) also has an inhibitOlY effect on 1,25-
(OHJ,D3 action. This RXR ligand decreases the 1,25-(OH),D3-induced increase of 
VDR levels in human keratinocytes and inhibits ill vitro VDRlRXR binding U=n 
.!mI. FUl1hemlOre, ill vivo 9-cis retinoic acid and the RXR-specific ligand LG 153 
attenuate the transcriptional induction by 1,25-(OH),D3 (M""",,ld 1993. I <ow' 19961, In 
contrast, others have rep0l1ed no effect If<rr'" 199'.l!c&.l22l1 or a synergistic effect of 9-
cis retinoic acid on I ,25-(OH),D3 action le"lIx" 1993.S,0k< 19951. 
A.4.6. VITAMIN D RECEPTOR TRANSLOCATION 
It was shown that in cells cultured in the absence of ligand, the VDR resides 
mainly in the cytoplasm. Upon exposure to 1,25-(OHJ,D3, a rapid (within a few 
minutes) translocation of VDRs to the nucleus takes place (B=" 1990!. These 
observations were later confirmed in living cells using 1,25-(OH),D3 attached to a 
fluorescent dye IB,"PO' 199]1. In addition, trafficking of VDR both into and out of the 
nucleus - a process called nucleocytoplasmic shuttling - is observed. The role of 
nucleocytoplasmic shuttling is not known, but it might be important for receptor 
modification and certain biological activities of the nuclear hormone receptor in 
the cytoplasm. Trafficking across the nuclear envelope is not a specifc VDR 
feature, since the same phenomenon can be observed for the ER, progesterone 
receptor, and glUCOC0l1icoid receptor (GuiochQn-Man!rll996), 
A.4.7. VITAMIN D RECEPTOR-DNA BINDING 
For the VDR and several other nuclear hormone receptors (e.g. progesterone 
receptors, glucoc0l1icoid receptors) ligand binding is a prerequisite for ill vivo 
DNA binding I"roy<' 1987. 'km 1990). The dimerized receptor interacts with DNA at 
specific sites, the so-called hormone responsc element in the promoter region of a 
target gene. In general, the homlOne response element consists of two palindromic, 
inve11ed palindromic or direct repeat hexameric nueleotides spaced by 0 through 5 
base pairs. The hOiTIlOne response elements of the receptors for androgen, 
progesterone, glucoc0l1icoid, and mineraloc0l1icoid consists of the consensus 
sequence TGTTCT, whereas the consensus binding motif for VDR, ER, retinoic 
acid receptor and thyroid hormone receptor is AGGTCA. Although the receptors 
show substantial resemblance in stmcture and bind to related DNA stmctures, 
there is a complex mechanism to specify gene activation and to diminish the risk 
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of false activation of gene transcription. The spacing between half-sites as well as 
minor differences in nucleotide sequence of half-sites and flanking sites play a 
cl1lCial role in achieving tlus selective hormonal response (UmcSQnQ !99l,Towers \993 hlillkL.I2.2l, 
~I. The impOliance of nucleotide half-site sequences in detelmining the 
binding efficiency of the VDR will be ftniher examined and discussed in Chapter 
4. 
For several VDR target genes a functional vitamin D response element (VDRE) 
has been defined (Table 1.2). However, for numerous other target genes, specific 
VDR binding sites have not yet been identified (H""h 19941. VDREs generally consist 
of two imperfect direct repeat hexameric nucleotides spaced by 3 base pairs (DR3 
type VDRE) and although the consensus sequence AGGTCA is still recognizable 
considerable heterogeneity in half-site sequences exists (Table 1.2). In most cases, 
the proximal (3'-) half-site is the binding site for the VDR, whereas the distal (5'-) 
half-site is the binding site for its dimer paliner RXR (C'"N" 1996. llrr.J.99J;. :;,.,uml. 
However, for the chicken carbonic anhydrase II VDRE the prefered polarity of 
binding of VDR and RXR for the proximal and distal half-sites seems reversed 
(!lllll2-lmI. Besides DR3-type VDREs, DR4-type VDREs and inverted palindromic 
motifs spaced by 9 nucleotides (IP9) have been characterized as functional 
VDREs. FUlihemlOre, VDR binding to direct repeats with a spacing of 6 
nucleotides, a palindrome without spacing and an invelied palindrome with a 12-
nucleotide spacing has been reported i[rulb"" 19911. 
Mos! of the VDREs listed in Table 1.2 are positive regulatOlY sites: binding ofa 
1,25-(OH)2D3-VDRJRXR complex to such a VDRE will lead to increased 
transcription of the cOlTesponding gene. However, also negative regulatOlY sites 
have been characterized: binding of the VDR complex to e.g. the human and avian 
PTH VDRE, mouse osteocalcin VDRE, and rat bone sialoprotein VDRE leads to 
suppression of gene transcription I]),''''Y 199"- wm. U" '" 1996. llilLl2211. How the VDR 
negatively modulates gene transcription is still unclear and probably not similar for 
all 1,25-(OH)2D3 suppressed genes. The rat bone sialoprotein gene for instance, 
contains a VDRE that overlaps a general transcription regulation site (TATA box). 
As a consequence, VDRJRXR binding to this VDRE will prevent the TATA box 
binding protein from binding and thereby blocks gene transcription (!ill2l.Kirol'l2Q). 
Another possible mechanism is that the VDRE sequence of the suppressed gene 
is in such an orientation that the VDR occupies the distal 5' half-site instead of the 
proximal 3' half-site as seen with VDREs of positively modulated target genes, 
leading to inactive gene transcription. The cellular context (e.g. presence or 
absence of certain cofactors) might also interfere in the repression of gene 
transcription. The human PTH gene mediated transcriptional repression in 
response to 1,25-(OH)2D3 in pituitmy GH4CI cells, whereas no transctiptional 
repression was observed when the human PTH gene was transfected into 
osteoblast-like ROS 17/2.8 cells (Th·"""99"1. 
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Table 1.2. 
1,2S-Dihydroxyvitamin Drregulated genes and nucleotide sequences of 
vitamin D response elements identified in these genes 
GENE 
Positive VDREs: 
DR3 elements 
Chicken J3j integrin 
Chicken carbonic anhydrase II 
Human 24-hydroxylase (proximal) 
Human 24-hydroxylase (distal) 
Human 5' -lipoxygenase 
Human Na + Iphosphate co-transporter 
Human osteocalcin 
Human cdk inhibitor p21 WAF! 
Human placenlallactogen 
Human TGFp2 (proximal) 
Human TGFp2 (distal) 
Mouse oSleopolllin 
Pig osfeopontin 
Rat atrial natriuretic factor 
Rat calbindin D-9k 
Rat 24-hydroxylase (proximal) 
Rat 24-hydroxylase (distal) 
Rat osteocalcin 
Rat osteopontin (proximal) 
Rat osleopontin (distal) 
DR4 elements 
Mouse ealbindin D-28k 
Mouse Pit-I 
DR6 elements 
Human osteocalcin 
Human fibronectin 
Human phospholipase C-yl 
Mouse fibronectin 
Rat 24-hydroxylase 
IP9 elements 
Human calbindin D-9k 
Mousec-fos 
Rat osteocalcin 
Negali"e VDREs: 
Chicken PTH 
Chicken protein kinase A inhibitor 
Human intcrfcron-,( 
Human PTH 
Mouse osteocalcln 
Rat bone siaioprotein 
Rat PTH related peptide (proximal) 
Rat PTH related peptide (distal) 
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NUCLEOTIDE SEQUENCE (Ret) 
5'-GAGGCA gaa GGGAGA-3' (QlQJm) 
5'-GGGGGA aaa AGTCCA-3' (~) 
5'-AGGTGA gcg AGGGCG-3' (!Jim.lm) 
5'-GAGTTC ace GGGTGT-3' <lJJmJm) 
5' -AGGGCA aag GGTGGA-3' «()rlhi:m 1226) 
5'-GGGGCA gea AGGGCA-3' (Tak!::!ani 1222) 
5' -GGGTGA aeg GGGGCA-3' (MQuiooll 12~2) 
5' -AGGGAG att GGTTCA-3' <!.illflU226J 
5' -AGCTGA etc AGGTGG-3' (S\~~allQlllm ) 
5'-AATGAA gtt GGTGGA-3' (Yl!!..l22.2) 
5' -TGTAGA aea AGTAGA-3' (~) 
5' -GGTTCA ega GGTTCA-3' ~) 
5' -GGGTCA tat GGTTCA-3' (Zhang 1992) 
5' -AGGTCA tga AGGACA-3' (Kahle!! 1222) 
5' -GGGTGT egg AAGCCC-3' (D~[}'ii~h 1992) 
5' -AGGTGA gtg AGGGCG-3' (Oh)'~!Il~ 12:24) 
5' -GGTTCA geg GGTGCG-3' (lurulka 1994) 
5' -GGGTGA atg AGGACA-3' (Il~Ma)' 1222) 
5' -AGGTCA cae AGGGCA-3' ffiiQilllm) 
5' -AGGTCA tat GGTTCA-3' (B..ilW.Ll.22S.) 
5' -GGGGGA tgtg AGGAGA-3' «:illllJl2.l) 
5' -AGTTCA tgag AGTTCA-3' (Rhcxles 122]) 
5' -TGGTGA ctcace GGGTGA-3' (!~!::m!::r 12S2) 
5' -GGGTGA cgtcac GGGGGA-3' (fu!.h:.l.22.Q) 
5' -AGGTCA gaccac TGGACA-3' (Xk.122l) 
5' -GGGTGA egtcac GGGGTA-3' (&!1ti22!i) 
5' -GGTCGA gcccag GGTTCA-3' Ul:!!hlen 122~) 
5' -TGCCCT tccttatgg GGTTCA-3' (Schril.-lerl225) 
5' -TGACCC tgggaaccg GGTCCA-3' (Sdyildcr 1227) 
5' -TGCACT gggtgaatg AGGACA-3' (SchrMn 1925) 
5' -GGGTCA gga GGGTGT-3' (Liu shl '22M 
5' -ATGTTG etg AGGTCA-3' (Bow]iYlQ-QQ]!i'!mith 1227) 
5' -TGGGCA taa TGGGTC-3' (gp~) 
5' -GGTTCA aag CAGACA-3' (D.:may 12223) 
5'-GGGCAA atg AGGACA-3' (I ian [997) 
5' -AGGGTT tat AGGTCA-3' (K.im..l.22Q) 
5'-AGGTTA etc AGTGAA-3' (~) 
5' -GGGTGG aga GGGGTG-3' (Kremer 192M 
The nucleotide sequence of the VDRE is also of major importance in regulating 
gene transcription. The nucleotide sequence of the VDREs clearly influences the 
conformation of the VDRlRXR complex ~). Obviously, this conformational 
change can influence subsequent steps (binding of transcription factors and 
cofactors) leading to gene transcription. The imp0l1ance of nucleotide sequences 
was also illustrated by the work of Koszewski e/ al. demonstrating that only minor 
differences in nucleotide sequence within half-sites detelmined the direction of 
transcriptional modulation. They showed that introduction of selective mutations 
of only two nucleotides within the proximal half-site of the avian PTH VDRE 
changed the negatively modulated gene into a positively modulated gene 'KQ~""ki 
.l222) 
Besides honnone response elements, other DNA elements like the activating 
protein-l (AP-l) element might playa role in nuclear hormone receptor-mediated 
gene transcription. The AP-l element is the DNA binding site for the proto-
oncogene protein products fos and jun ''''"K"'' 1988\. Fos and jun are transcription 
factors that play an important role in promoting cell growth. There is evidence that 
nuclear hormone receptors interact with the AP-I element or its binding proteins. 
For the ER (lEh..l221>, glucoc0l1icoid receptor (l.lhill2l', retinoic acid receptor (pI,},' 1991>, 
and also for the VDR interaction with the fos/jun pathway has been described. In 
the human ostcocalcin gene, the distal region of the VDRE is closely juxtaposed to 
an AP-I binding site (~) and the rat osteocalcin VDRE contains an internal 
AP-I site (Om (990). In the VDRE/AP-l domain both cell differentiation and cell 
proliferation regulatory elements are integrated: On the one hand, binding of fos 
andjun to the AP-l element might inhibit binding ofVDRlRXR to the VDRE and 
consequently blocks transcription of the VDR responsive gene, on the other hand 
interaction of VDR with fos and jun at an AP-I site might suppress proto-
oncogene activities like stimulation of cell growth. Freedman and co-workers 
showed that interaction of VDR with fos/jun also has an impact on immune 
responses. They showed that VDR suppressed formation of a complex between 
AP-I binding elements fos and jun and T cell specific transcription factor NF ATp 
and suggested that this blockade might underly the inununosuppressive activity of 
I 2S-(OH) D (Almy 1995 Tnw," 1999) In addition synergism between fos J'un and the , 2 3 ., , , 
VDR has been desclibed. It was found that the VDR and AP-l binding factors 
synergistically induced transcription of a reporter construct containing an 
osteopontin VDRE and an AP-l binding site. Also transcriptional synergism was 
observed for VDR and the transcription factors SP 1, nuclear factor-I, and octamer 
transcription factor-I (Li!JJW). 
AA.8. VITAMIN D RECEPTOR-COFACTOR BINDING 
Binding of a receptor to a hOimone response element results in a specific 
conformational change of the receptor (EI·A>b1Y (989. Thn<.I'-lW.~. SlMlli22.ll'lwUm) and 
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in bending of DNA CNard!lllj 1993, Nanlulli !99Ja Nardll1!i !99S,~,KjJJ1JTle!_reh:UJ 1996,Robhw)fl 1928,Kjmmei.lehan 
12221, providing a structure suitable for gene transcription regulation. After binding 
of the receptor dimer to a hOllllone response element other transcription factors 
(TFs) can bind and interaction with the basic TAT A transcriptional machinery will 
occur. Transcriptional activation requires assembly of TFIID, TFIIA, TFIIB, 
TFIIF, TFIIE, TFIIH, and RNA polymerase II that form the preinitiation complex. 
A nuclear hOlmone receptor dimer bound to a hOlmone response element can 
interfere in formation and/or stability of the preinitiation complex and thereby 
interferes in regulation of gene transcription (Klein,H;',,,, 1998). As already described, 
both stimulation and repression of gene transcription can be the result. 
The ligand-binding domain of the VDR interacts with the general 
transcription factor TFIIB and this interaction leads to cooperative activated 
transcription after stimulation with I ,25-(OH)2D3 (""0,,,,, 1995. HI"" (995). In addition 
to basic transcription factors, other co factors (coactivators and corepressors) 
interfere in the transactivation process (1""" (998). For example, steroid receptor 
coactivator-I (SRC-I) and glucocorticoid receptor interacting protein 1 (GRIPI) 
can bind to the VDR and other nuclear hormone receptors (thyroid hormone 
receptor, retinoic acid receptor, RXR, mineralocorticoid receptor, glucocorticoid 
receptor, ER) and thereby enhances transcriptional activation in a receptor 
ligand-dependent manner (H'", 1997. ",,"y,m, (997). Other cofactors (transcription 
associated factor (II) 135, VDR interacting proteins (DRIPs), RAC-3, suppressor 
of gall (SUG I), receptor interacting protein 140 (RIP 140)) interact with the 
VDR at the AF-2 domain (yom Bauer 1996, Masuyama 1997, Menrus 1997, Rachel 1998, Rachez 1999), The 
AF-2 domain is clUcial for transcriptional activation by cofactors. Specific 
mutations in the AF-2 domain did not affect ligand binding, heterodimerization 
with RXR, and VDRE binding, but gene transcription and interaction with 
cofactors (SUG I, SRC-I and RIP 140) were abolished (",,"y,m, 1997. ",ml" 1997. !JilLlm). 
However, how cofactors exactly interfere in gene transcriptional regulation 
remains to be elucidated. Some of these cofactors might be involved in 
cln'omatin remodelling. DNA is stored in the nucleus as nucleosomes: DNA 
wrapped around a complex of the histones H2A, H2B, H3, and H4. The amino 
acid tail domain of the histones sticks out of the nucleosomes and can interact 
with cofactors that possess histone acetyltransferase (HAT) activity causing 
acetylation of lysine-rich domains of the histones. As a result DNA relaxes and 
the nucleosomes get less tight. In this way, the receptor complex gains access to 
transcription regulatory sites in the DNA (Gru",I,;n (997). DRIPs and SRC-I possess 
HAT activity (S,,,w 19n Rae'" (998) and interaction of these factors with the AF-2 
domain of the VDR results in increased transcriptional activation activity of the 
VDR (Qi!!.!.2..2..B., Rachel: 1998), 
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A.S. NONGENOMIC EFFECTS OF 
1,2S-DIHYDROXYVITAMIN D3 
1,25-(OH),DJ also exells effects that seem to be not mediated via an interaction of 
the VDR with the genome (Cll""" 1938, ~). These nongenomic processes include: 
the rapid changes in intracellular calcium (I ie~rherr 1987. Canrey 1989, 0\jtelli 1990, ~, Farach-
~1]2j, ;;,mere 1991) and the rapid stimulation of Ca'+ transport in the intestine 
(transcaltachia) (De 801m' 1990). FUllhennore, 1,25-(OH),DJ can rapidly stimulate 
phosphoinositide metabolism (I j,ocrJw!T 1989, Ci,;r.rrl 19901, leading to activation of protein 
kinase C 0'll!!Ll22!l); an impOilant regulator of cell proliferation and differentiation 
(f"", 1990). Recently, in chondrocytes a membrane-associated VDR has been 
identified that might play a role in the activation of protein kinase C by 1,25-
(OH),DJ (N,mm 1998). In addition, also for 24,25-(OH),DJ a specific membrane 
receptor seems to exist 1Mm" 1999). Although discovelY of the membrane receptors is 
challenging their impOilance in other nongenomic effects of vitamin D metabolites 
and the way these membrane receptors might interact with the nuclear VDR-
mediated pathway remains to be established U'k<Llm). 
A.6. 1,2S-DIHYDROXYVITAMIN D3 ANALOGS 
As discussed in Section A.3., besides its classic action on bone, intestine, kidney, 
and parathyroids, 1,25-(OH),DJ exells effects on cells and tissues not directly 
related to bone and mineral homeostasis. These growlh and differentiation 
regulatOlY effects are potentially of clinical interest. However, high doses of 1,25-
(OH),DJ necessmy to achieve these effects may result in hypercalcemia and 
hypercalciuria 1!(o,m" 1985. "I,m 1990). This has stimulated the search for synthetic 1,25-
(OH),DJ analogs with selective biological activity. The main goal was to develop 
analogs with an activity profile in favor of the effects on tumor cell growth, 
differentiation, and/or immunosuppression compared to the calcemic effects (-
1m.. Binderup 1992, rru..um. BnIlHlQU 1995, Van I ml\\!"O 1997, Yan d,'n BenK! 2()()03). In addition, analogs tuight 
also be useful in the treatment of metabolic bone diseases (e.g. due to an increased 
anabolic effect on bone or the potency to lower PTH levels without affecting the 
serum calcium concentration) iliillill..!.22). 
A.6.1. BIOLOGICAL EFFECTS 
AND CLINICAL APPLICATIONS 
In the past 15 years numerous 1,25-(OH),DJ analogs have been developed. Most 
changes to the I ,25-(OH),DJ structure (80% of the 820 modifications tabulated in 
the review by Bouillon e/ at.) are side chain modifications. Around 10% are A ring 
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modifications, 2% are B ring modifications and 10% are CID ring modifications 
18,,,;11,, 1995'. In general, 1,25-(OH)2DJ is still recognizable in the analog stmcture. 
However, recently it was shown that also nonsecosteroidal compounds (bis-phenyl 
derivatives and analogs lacking C and D rings) exelt VDR modulating activities 
and mimic 1,25-(OH)2DJ effects on cell growth and differentiation (Ymru)'fl998. Elo<hm 
1m). Although these compounds may be promising as therapeutics for cancer and 
psoriasis, this thesis will focus on VDR ligands with a chemical stmcture based on 
the structure of 1,25-(OH)2DJ, the side chain modified-analogs in particular. 
The changes in the 1,2S-(OH)2DJ side chain structul'e include: 
(See Figure 1.4 for chemical stmctures) 
• ShOltening of the side chain 
e.g. 26,27 -din or-I ,25-(OH)2DJ 
• Elongation of the side chain 
e.g. 20-epi-22-oxa-24a,26a,27a-tri-hoIl10-1 ,25-dihydroxyvitamin DJ (KH I 060), 
24a,26a,27a-tri-homo-1 ,25-dihydroxyvitalllin DJ (CB966) 
• Substitution of a carbon atom with an oxygen atom 
e.g. 22-oxo-1 ,25-(OH)2DJ (OCT), 
20-epi-22-oxa-24a,25a-di-homo-1 ,25-dihydroxyvitamin D, (KH I 049), KH 1 060 
• Substitution of a hydrogen atom with a fluorine 
e.g. I ,25-(OH)2-26,26,26,27,27 ,27 -hexafluoro-DJ (l,25-(OH)rF6-D,), 
1 ,25-(OH)2-16-ene-23-yne-26,26,26,27,27,27-hexafluoro-D, (RO 24-5531) 
• Addition of hydroxyl groups at carbon atom 22, 23, 24 or 26 
e.g. 1,23,25-trihydroxyvitamin DJ (l,23,25-(OH),DJ) 
• Moving the 25 hydroxyl group to another position in the side chain 
e.g. I ,24S-dihydroxy-22-ene-25,26,27-cyclopropylvitamin DJ (MC903) 
• Introduction of double or triple bonds between carbon atoms 
e.g. I ,25-(OHh-16-ene-23-yne-D, (RO 23-7553), RO 24-5531, 
24a,26a,27a,-tri-homo-22,24-diene-I,25(OH)2D, (EB I 089) 
• Altered stereochemishy (epimerization) at carbon atom 20 
e.g. 20-epi-1 ,25-(OHhDJ (MC 1288), KH\060 
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Figure 1.4. Examples of 1,25-(OH),D3 analogs. Side chaill modificatiolls call be 
illtrodlleed separately (e,g, OCT, MCJ288), or ill combillation (e,g, KHJ060, E8J089), 
Furthermore, side chain modifications call be combilled with alteratiolls at other sites of tlte 
J,25-(OHJ,DJ moleellie (e,g, RO 23-7553), 2j3-(3-Hydrmypropoxy)-J,25-(OHJ,DJ (ED-71) and 
J,25-(OH)rJ6-ene-DJ (RO 24-2637) are showlI as examples of allalogs with modifications ollly 
at the A Gild D ring. respectively. 
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The newly synthesized 1,25-(OHJ2D3 analogs were extensively studied ill vitro 
with respect to their effect on: 
• Cell proliferation (A.!&..l.2.lil, Bjndmm 199B, Nonnan 1990. Bindrnm 1991, ~.llitnIT..lm,Yink.yan Wiirwaaruen 
1m.~, Puthjer 1926, Kawa 1996) 
• Cell differentiation (Binder'll !991.~,Mathiasen 1991,~,Munker 1996,M®.!:ti22.Q,MlJrkHaosen 1996) 
• Immunomodulation mjOOenm 1991, ~) 
• PTHIPTH-related peptide synthesis (!lmillLl.2.!2.~) 
• Bone resorption (~,.Mi.l.22l, Wiberg 1995) 
• Osteoclast recmitment (w;b"" 1995) 
• Intestinal calcium transport 1l\'m!ill2.l) 
• Bone mahix protein synthesis (Pemale!!' !991,furuJ.22!,Ryhlnen 1996) 
• 24-Hydroxylase activity 1£olill2l) 
In Table 1.3 the therapeutic potential of some of the 1,25-(OHJ2D3 analogs in the 
treatment of immunological disorders and/or hyperproliferative diseases based on 
ill vivo experiments are sununarized. Furthermore, Table 1.3 summarizes analogs 
with properties that might be beneficial in the treatment of hyper- and 
hypoparathyroidism and osteoporosis. 
Table 1.3. III vivo effects of 1,25-(OH)2D3 analogs and their potential clinical 
applications 
ANALOG 
CB966 
E81089 
KHlO60 
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IN VIVO EFFECT 
tumor growth inhibition 
Immunosuppression 
tumor growth inhibition 
tumor gro\\1h inhibition 
tumor growth inhibition 
tumor growth inhibition 
tumor growth inhibition 
tumor metastasis inhibition 
inmlUlloSllpprcssioll 
immunosuppression 
immunosuppression 
THERAPEUTIC ROLE 
breast cancer 
organ transplantation 
breast cancer 
colon cancer 
epithelial cancer 
Jcydig cell carcinoma 
pancreas cancer 
prostate cancer 
inmmnoiogicai disorders 
type I diabetes 
organ transplantation 
(ReQ 
~,Cilllm..l.m, 
Llm:ilm. VM\\'rdlro 129$ Kmhmh 1'1191 
"""""'" IS Ahhhli 1m) 
\fuillW 
~
Itj1!m m l 'j921 
I~h'hi<u 1995.C.., .... ""1> 1998) 
MC903 immunosuppression psoriasis CK[]!gNlkl99!1 
tumor grm\1h inhibition breast cancer ~,~ 
MCI288 inmlunosuppression organ transplantation ~.~ 
inmlunosuppression arthritis  
inmlUllosuppression type I diabetes ~) 
OCT immunosuppression immunological disorders ~) 
tumor gro\\1h inhibition breast cancer CA1>ill2l,~, 
Ah,:.HwJmctil 12'H.MalSUffii'!9 1m) 
tumor growth inhibition pancreatic cancer ~,~) 
tumor grO\\1h inhibition lung cancer lillW.W) 
tumor growth inhibition pharynx carcinoma ~ 
decreased tumorigenesis colon cancer ~ 
decreased tumorigenesis intestinal carcinoma ~ 
RO 23·7553 tumor growth inhibition leukemia ~ Shttf!Jfdd!9?6) 
tumor growth inhibition prostate cancer IScb'loMlZ !295\ 
tumor growth inhibition retinoblastoma lSlktl.W.1 
R024·2637 immunosuppression organ transplantation ~isnli!timl 
RO 24·5531 decreased tumorigenesis breast cancer 
-decreased tumorigenesis colon cancer ill'!lilm) 
decreased tumorigenesis seminal vesicle carcinoma (ll1ill..J2lli 
decreased tUlllorigenesis prostate cancer ~ 
1 ,25-(OHh-F6-D3 correcting hypocalcemia hypoparathyroidism fS~l.1lstLlca 1991) 
ED·71 increased bone mineralization osteoporosis ~.~, 
Sild;!W3 lliruUmi 1m) 
OCT suppression ofPTH production hyperparathyroidism ISht'i'Qi.h' 1992 Mrn~['EAU,~ 1m) 
Although large quantitative differences in potency between 1,25-(OH)2D3 and 
cel1ain analogs are observed, all the analogs discussed above exet1 activities 
qualitatively comparable to 1,25-(OH)2D3, i.e. they decrease cell proliferation and 
stimulate cell differentiation. This is in fact a general finding, although recently 
antagonistic activities were subscribed to 1,25-(OHh-26,23-lactone D3 and its 
analogs. The lactone analogs inhibited 1,25-(OH)2D3-induced osteoclast formation 
(Ami122ll, and stimulated proteoglycan and collagen synthesis in chondrocytes from 
rabbits, whereas I ,25-(OH)2D3 had an inhibitory effect Il,h"">' 1992). 
A.6.2. STRUCTURE-FUNCTION ANALYSIS 
General characteristics with respect to stmcture-function relationship will be 
summarized. More detailed infotlllation on this topic can be found elsewhere (lfurrmn 
l22Q,~, HOI lilian 1995,~, Bindenm 1997,! IskQkQvil; 1991; and references therein), 
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Shortening and lengthening of the side chain 
Shortening of the side chain by one carbon eliminates its potency ill vivo and 
decreases its potency il/ vitro ten fold. In contrast, lengthening of the side chain 
results in an increased ill vitro and ill vivo activity. Elongation of the side chain 
with one carbon results in an increased potency of the analog to inhibit cell 
proliferation, whereas its calcemic effect is diminished. The dissociation between 
calcemic effect and the cell growth inhibitory effect is further increased after 
elongation with two carbon atoms. Lengthening by three carbon atoms results in a 
complete loss of il/ vivo activity, whereas some ill vitro effects are only modestly 
reduced. Elongation by four or more carbons results in complete loss of biological 
activity. 
Substitution of an oxygen atom 
Substitution of an oxygen atom at carbon 22 in the side chain (OCT), leads to a 10 
times increased cell differentiating activity compared to 1,2S-(OH)2DJ' whereas 
the calcemic activity is SO-IOO times reduced. In general, hydroxylation at the 
carbon atom adjacent to the oxagen atom results in fonnation of metabolic 
unstable products. Indeed, OCT is rapidly degraded into the unstable hexanor-
I a,20-dihydroxyvitamin DJ and hexanor-20-oxo-1 a-hydroxyvitamin DJ. KH 1139, 
a combination of elongation (as in CB966) and substitution of an oxygen atom (as 
in OCT) is ISO times more potent than 1,2S-(OH)2DJ in inhibiting cell growth, 
whereas its calcemic activity is tln'ce times lower. 
Substitution of fluorine 
Substitution of one fluorine at carbon 24 results in an analog with 3 times lower 
cell differentiating and calcemic activity compared to 1,2S-(OH)2DJ. In contrast, 
substitution of two fluorines at carbon 24 increases the capacity to induce cell 
differentiation 10 times without affecting the calcemic activity. Introduction of 6 
fluorine groups at carbon 26 and 27 further increases cell differentiating activity 
and increases calcemic activity IO-fold compared to 1,2S-(OH)2DJ. In general, 
substitution of fluorine for hydrogen at carbon 23, 24, 2S, 26 or 27 might diminish 
susceptibility to hydroxylases, resulting in longer half-life of the analog. 
Introduction of double or triple bonds 
Introduction of a double or triple bond in the side chain results in a moderately 
increased effect on cell growth inhibition and a diminished calcemic activity 
compared to 1,2S-(OH)2DJ. Introducing two double bonds (at carbon 22 and 24; 
EB I 089) further increases the potency of the analog to inhibit cell proliferation, 
whereas its calcemic effect is 3 times lower than 1,2S-(OH)2DJ. In general, 
introduction of double or triple bonds might affect 24-hydroxylase activity, either 
directly (by blocking the carbon 24 position) or indirectly (because of a 
J6 
conformational change of the side chain that diminishes susceptibility to 
hydroxylases). The double bond at carbon 16 (RO 24-2637) increases the cell 
growth inhibitory activity 100 times, while the calcemic activity is only 
moderately increased. Combining this modification with a triple bond in the side 
chain (RO 23-7553) lowers the calcemic activity 6 times. 
20-Epi configuration 
Analogs with 20-epi configurations have an increased biological potency 
compared to corresponding compounds with a normal 20S configuration. For 
instance, MCI288 which only difference with 1,25-(OH)2D3 is its 20-epi 
configuration, is 100 times more potent in inhibiting cell proliferation, but only 2 
times more calcemic than 1,25-(OH)2D3. The analog KHI139, except for its 20S 
configuration identical to KH1060, is 45 times more potent than 1,25-(OH)2D3 in 
inhibiting proliferation, whereas KH 1060 is 31,000 times more potent than 1,25-
(OH)2D3' The potency of these analogs is even more evident in innnunosuppresion 
tests, where the activity of 1,25-(OH)2D3 is overridden several 1,000 times. 
However, the therapeutic potential of these 20-epi-analogs is limited by an 
increased calcemic activity. A combination of double bonds (RO 24-2637) and 20-
epimerization (MCI288) results in formation of an analog (l,25-(OH)2-16-ene-20-
epi-D3) with a cell differentiation activity similar to that of MC1288, but a 80 
times lower calcemic activity than 1,25-(OH)2D3. The calcemic activity of the 20-
epi form of RO 23-7553 is even fmiher dinlinished (200 times lower than 1,25-
(OH)2D3)' 
A.6.3. POSSIBLE MECHANISMS FOR THE SELECTIVE 
ACTION OF 1,2S-DIHYDROXYVITAMIN D3 ANALOGS 
It is not possible to provide a general mechanism of action to explain the changes 
in biological profile of every 1,25-(OH)2D3 analog. In fact, any modification in the 
1,25-(OH)2D3 molecule will lead to formation of a ligand with a changed 
mechanism of action, i.e. the ligand may differently interact with one or more of 
the steps leading to transcriptional activation depicted in Figure 1.2. In the section 
below, possible steps that could determine the selective biological activity of a 
1,25-(OH)2D3 analog are summarized. It is vety likely that not just one of these 
sites of modulation is differently affected by an analog, but that subsequent steps 
in the cascade are affected as well. 
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I. RECEPTOR NUMBER, AFFINITY, CONFORMATION, AND HALF-
LIFE 
Presence of a functional VDR seems to be essential to observe effects of 1,25-
(OHhD3 and its analogs on bone metabolism and cell proliferation (J)QkQh 19&4._ 
l2.S..6:, Ejsman 1937, Elslner 1994, HNllIod 1996, Unll!1nd 19900, Yosbilawa 1997, Zhuang 1997, Takeda 1999), As already 
mentioned in Section A.4.2., 1 ,25-(OH),D3 up-regulates expression of the VDR. In 
addition, 1,25-(OH),D3 analog-induced VDR up-regulation was also reported (fuI> 
m.LP<m"'" 199i). However, the biological relevance of this increase in VDR content is 
not completely resolved. 
Receptor affinity, as measured by classic ligand displacement, is of little value 
in predicting the biological potency of an analog (See also Chapter 2, Yink.v" W;;ogM;d" 
lm). Analogs with extremely low affinity are usually weak activators but for 
analogs with moderate to high VDR affinity there is no cOlTelation between 
receptor affinity of an analog and its biological activity (ISm" 199'. lmill..l22.\. M"k" 1996. !'<kg 
199Q.~. ~I; i.e. analogs with low VDR affinity may have high biological 
activity, and vice versa. The fact that compared to 1,25-(OH),D3 only very few 
analogs have an increased affinity for the VDR, supp0l1s the notion that VDR 
affinity is not the only factor to explain the biological activity of an analog (!l!lliilli!n 
1.225:, !\fork Hansen 1996) 
Ligand-induced changes in VDR confOimation are believed to be cmcial for 
transactivation of the receptor (P,,,, 199\1. I ,25-(OH),D3 binding results in 
repositioning of helix 12 and closure of the mouse trap fOimed by the ligand-
binding pocket, causing a change in the three dimensional stmcture of the VDR. 
Modifications of the 1,25-(OH),D3 molecule will lead to different contact sites 
within the ligand-binding pocket of the VDR and induces a different folding of the 
VDR. This is nicely illustrated by a rep0l1 of Liu et al. showing that deletion of 
helix II and 12 of the VDR resulted in loss of 1,25-(OH),D3 binding, whereas 
binding of MC 1288 or KH 1060 was not affected. These 20-epi analogs of 1,25-
(OHhD3 interact with helix 5 of the ligand-binding pocket, instead of helix II and 
12 which contact the side chain of 1,25-(OH),D3 (LilLl991I. Since it was shown that 
the conformation of unliganded VDR possibly prevents binding of SRC-I and 
GRlP-I and blocks DNA interaction 1H<>nU991. """"m, 1997), it is hypothesized that 
ligand-induced conformational changes can result in exposure of specific sites of 
the receptor (e.g. the AF-2 domain) important for interaction with cofactors and 
DNA binding eN"'" I99MI. Liu et al. speculated that the increased potency of 20-epi 
analogs of 1,25-(OH),D3 might be due to different interactions with AF-2 residues 
in helix 12: 20-epi analogs do not bind directly to the AF-2 residues and allow 
optimal folding and exposure of coactivator binding sites, while 1,25-(OH),D3 and 
analogs with a normal side chain orientation actually make contact with the AF-2 
region and as a consequence probably induce VDR folding and exposure of 
coactivator binding sites that results in relatively lower VDR transactivation [!.ill 
122l) 
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Ligand-induced conformational changes of the VDR will affect its stability. 
Similar to the enzymes used in limited protease digestion analysis to study 
receptor confonnational changes, the efficiency of enzymes in the cell involved in 
receptor processing will be affected by ligand-induced folding of the receptor (i.e. 
the accessibility of cleavage sites). The VDR confomJation induced by MC1288 or 
KH 1060 is more stable and exelts increased transcriptional activity (1ilL12W. In 
Chapter 3, the effect of the 20-epi-analog KHI060 on VDR confOlmation and 
stability is studied in more detail. 
II. RECEPTOR PHOSPHORYLATION 
Since phosphorylation might be impOltant for VDR activation <llii<h.lW. "'""'h 1993 """" 
1m I,m"" "91, ~. """"-"'01, it is plausible that the increased biological activity of 
some 1,25-(OH)2D3 analogs could be attributed to their capability to induce VDR 
phosphOlylation. Although it was reported that 1,25-(OH)2D3 analogs can induce 
VDR phosphOlylation, a relationship with their specific biological activity could 
not yet be established (],ru&, 1993'1. 
III. RECEPTOR DIMERIZATION 
Most of the 1,25-(OH)2D3 target genes with identified VDREs are regulated by 
VDRIRXR dimers, although also functional VDR homodimers have been 
described (0"1"",, 199". FOImation of VDRJRXR and VDRlVDR dimers is regulated 
by 1,25-(OH)2D3. It is obvious that an increased (or decreased) formation of 
dimers will influence the rate of gene transcription. The increased potency of the 
20-epi 1,25-(OH)2D3 analog MCI288 for instance might be explained by its 
increased stimulatOlY effect on dimerization ofVDR and RXR ~I. This might 
be a factor of general importance since Zhao et al. demonstrated, using the two-
hybrid system, that the heterodimerization potency of most analogs con'elated with 
their transcriptional activity (llli!o...l.221l. One of the exceptions is ED-71, showing 
strong dimerization potency but relatively low tranactivation activity ==1. 
It was reported by Carlberg et al. that VDR homodimer-mediated gene 
transcription via a DR6-type VDRE showed higher ligand sensitivity than 
VDRlRXR heterodimer-mediated gene transcliption via a DR3-type VDRE (~ 
.!mI. It is possible that celtain 1,25-(OHhD3 analogs specifically stimulate 
fonnation of either dimer type and in this way selectively regulate gene 
transcription. 
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IV. TRANSLOCATION OF THE RECEPTOR TO THE NUCLEUS 
Recently it was shown that the dose-response curve of an analog to activate gene 
transcription is similar to the dose-response curve to stimnlate translocation of 
VDR to the nucleus Uiliz..lml. The AF-2 domain seems to be an essential element in 
this process and it is therefore feasible that specific interactions with an analog will 
influence VDR translocation to the nucleus and subsequent activation of the VDR. 
Therefore, analogs could be developed that block VDR translocation, and in this 
way these analogs could be used to antagonize the effect of 1,2S-(OH)2DJ. 
V. DNA INTERACTION 
The VDR interacts with specific responsive sites in the DNA, and by doing so it 
induces remodelling of chromatin to fascilitate interaction with the preinitiation 
complex. Vitamin D analog-selective effects on this DNA bending will affect 
subsequent activation steps (e.g. cofactor interaction) and this will likely influence 
the biological potency of this analog. 
The increased biological activity of an analog might be explained by induction 
of an increased VDR affinity for the VDRE. For instance, the increased DNA 
binding afflllity of 1,2S-(OH),-F6-DrVDRlRXR compared to 1,2S-(OH),DJ-
VDRlRXR is put forward as a possible explanation for its increased potency to 
inhibit the growth of leukemic cells Un.llli!lli2.~I. It was also suggested that this 
feature could playa role in the increased biological potency of 20-epi analogs like 
GSISOO, MC1288, and KH1060 ""!b;W" 1998.f<kRW1. 
In most cases, the VDRE is of the DR3 type, but also other VDRE types have 
been described (see Section A.4.7.). The selective action of ceItain 1,2S-(OH)2D) 
analogs might be the result of their increased effect on gene transcription via 
VDREs of a specific type. For instance, the increased inhibitory effect on cell 
proliferation by the 1,2S-(OH),D) analog EBI089 might be explained by its 
increased stimulatOlY effect on gene transcription limn IP9 elements. Based on 
these findings Carlberg and coworkers proposed that transcription of genes 
involved in cell growth regulation might be under control ofIP9 VDREs rN""d 1995. 
Schr.1der 1997) 
VI. COFACTOR INTERACTION AND CELLULAR CONTEXT 
Selective modulation by 1,2S-(OH),DJ analogs of VDR interaction with basic 
transcription factors that influence fOimation/stability of the preinitiation complex 
or with cofactors that modulate DNA relaxation, rate of gene transcription, or 
VDR stability (e.g. SUG I) might be involved in the selective biological activity of 
1,2S-(OH),DJ analogs. OCT induces such selective interaction of VDR with 
coactivators: Unlike 1,2S-(OH),DJ and the analogs ED-71 and 1,2S-(OH),-F6-DJ 
which induce interaction of VDR with SRC-I, AlB, and TIF2, OCT only 
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potentiates interaction with TIF2 (ThY",,,, (999). The increased potency of the 20-epi 
analogs MCl627 and MC1288 is possibly linked to the ability of these compounds 
to recl11ite and bind DRIP205, a subunit of the DRIP coactivator complex (Y@g(999). 
In addition to this, quantitative and qualitative differences in distribution of 
cofactors might provide an unique environment leading to cell- or tissue-specific 
effects of 1,25-(OH),D3 analogs. 
Recently, tissue-specific variant transcripts of the VDR gene were identified and 
it was suggested that these different transcripts encode for different VDR isofOlms 
that might contribute to tissue-specific effects of I ,25-(OH),D3 (QQW.m). 
VII. LIGAND lVillTABOLISM 
Ligand metabolism is another impOliant factor that might interfere with selective 
effects of the 1,25-(OH),D3 analogs. The rate at which the 1,25-(OH),D3 analog is 
inactivated depends on: 
• Vitamin D binding protein binding and cellular uptake 
DBP binding can work two ways: low DBP binding can result in rapid clearance, 
while unbound ligand can lead to greater accessibility to target cells. The low 
affinity for DBP might playa role in the increased biological potency of MCl288 
(Di""rth (99lJ. The 1,25-(OH),D3 analog OCT is as potent as 1,25-(OH),D3 in many 
biological responses. However, its decreased DBP binding results in reduced 
sel11m half-life and might explain why OCT is less calcemic than 1,25-(OH),D3 
(Bro,m (993). Cellular uptake of an analog is probably cell- or tissue-specific, and 
might therefore underly tissue-specific effects of analogs. The low bone 
mobilizing activity of OCT ill vivo for instance might be explained by reduced 
uptake of OCT in comparison to 1,25-(OH),D3 by bone, while uptake of OCT in 
other organs (small intestine, parathyroid glands, kidney, and liver) is increased 
compared to 1,25-(OHJ,D3 (K,h"",,; (9911. On the other hand, the high affinity of ED-
71 for DBP might explain its increased half-life (~I. 
• Catabolic susceptibility of the analog 
Modifications in the stl11cture of 1,25-(OH),D3 might result in a decreased or 
increased susceptibility of the analog for catabolic pathways, leading to an 
increased or decreased half-life of the analog, respectively. The fluor groups in 
1,25-(OH),-F6-D3 as well as double or triple bonds in the side chain (e.g. RO 23-
7553) might inhibit hydroxylase activity, resulting in increased half-life of the 
analog iTh",'" 1934. l!lli1Ll99.l). In contrast, the modifications in MC903 lead to rapid 
disappearance from the circulation U'clil99.lI. Analogs with an increased resistance 
against metabolic degradation could be used in the treatment of hypocalcemia (e.g. 
dihydrotachysterol), whereas the rapidly metabolized analogs might be useful for 
shOli term, local effects (e.g. MC903) (lillill21J. 
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• Intrinsic metabolic capacity of the target cell 
Tissue-specific rates of catabolic activity might also underly the selective activity 
of analogs. Celiain tissues might have a more effective mechanism to degrade the 
analog into nonactive compounds, whereas in other tissues the analog accumulates 
and exerts its activity for a longer period of time. In keratinocytes OCT is 
degraded more rapidly than 1,25-(OH),DJ illllilU22.H, while in monocytes OCT is 
more stable than 1,25-(0I-I),DJ IK=lmorn 1993), possibly explaining the decreased and 
increased potency of OCT in keratinocytes and monocytes, respectively . 
• Activity of metabolites of analogs 
The metabolites ofthe analogs fonned may also be active and can contribute to the 
biological activity of the mother compound ov",",,,, 199'.DllwQrth 1997). The 1,25-(OH),DJ 
analog RO 24-2637 for instance, is metabolized into 1,25-(OH),-16-ene-24-oxo-
DJ. This metabolite is stable and its effect on growth and differentiation of a 
human myeloid Icukemic cell line is comparable to its parent compound. In 
contrast, the equivalent metabolite of 1,25-(OH),DJ, 1,25-(OH),-24-oxo DJ, is 
rapidly degraded to inactive calcitroic acid Iffm@ 1994. Slo·(',ldm 19961. More aspects on 
the biological activity of metabolites of 1,25-(OH),DJ analogs will be discussed in 
Chapter 5. 
VIII. NONGENOMIC EFFECTS 
The selective action of 1,25-(OH),DJ analogs might also be the result of their 
changed capability to exeli nongenomic effects. For instance, the transient 
transcaltachia activity of OCT might explain its decreased calcemic activity 
compared to 1,25-(OH),DJ IF,rnch.(),w, 1993). Also other analogs with low calcemlc 
activity (MC903, RO 23-7553) have low transcaltachia activity IZh" 199'). 
Conversely, the 25-(OH)DJ analog 25-(OH)-16-ene-23-yne-DJ is a strong 
stimulator of transmembrane calcium influx, whereas it only binds weakly to the 
nuclear VDR and has little transcriptional activity """h·C""" 199n. In this respect, the 
findings obtained with I P,25-(OH),DJ are also of interest. This analog lacks any 
transcriptional activity and binds to the VDR with velY low affinity. However, 
I P,25-(OH),DJ is a potent antagonist of a 1,25-(OH),Dr mediated nongenomic 
effect (opening of Ca'+ channels in osteoblast-like cells) (NQ"",' 1991'. Therefore, 
studying the properties that detennine the preference of an analog for binding the 
nuclear or the membrane-associated fonn of the VDR (N<"m 1998) might help to 
develop analogs with selective genomic or nongenomic potencies (~). 
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B. ESTROGEN RECEPTOR-MEDIATED GENE REGULATION 
The nuclear hormone 17p-estradiol (E,) is a major regulator of growth, 
differentiation, and function of numerous tissues including tissues of the female as 
well as the male reproductive system. Also in bone and the cardiovascular and central 
nervous system E, plays an impOitant role. The effects of E, are primarily mediated 
by the ER; a member of the nuclear receptor superfamily that exists as two subtypes: 
ERa (molecular weight 60-66 kDa) IOrero 1986) and the more recently cloned EM 
(molecular weight 51-61 kDa) (Kuil?!'r 1296, Mosselman 1996,fumblay 1997), 
B.I. ESTROGEN RECEPTOR EXPRESSION 
ERa and ERP are expressed in a wide variety of cells and tissues lej"" 1995• "oi", )999). 
Although in many tissues both subtypes are expressed there are also differences in 
tissue distribution and cellular localization within certain tissues IKoi", 1999). For 
instance, within the rat ovaty ERP is observed in granulosa cells and not in 
interstitium and thecal cells. In contrast, ERa is expressed in theca and interstitial 
cells, and not or only weakly in granulosa cells (Kl!iJ<rj99Q.Sillm. Fj",,,,ri,k 1999). Also, certain 
regions of the rat brain mainly express ERP and virtually no ERa and vice versa 
(S"","", 1991). In the rat bone, prostate and in Sertoli cells and spelmatocytes in the testis, 
ERP is more abundant than ERa, whereas the opposite is found in kidney, pituitary, 
adrenal, and in stromal and epithelial cells of the endometrium (=-tW. "yi.-, )991. -
1995. S'"ndm )998. V" Pdl )999). The tissue-specific distribution of ERa and ERp is species-
specific, e.g. ERP is detected in pituitaries from rats IK"i", 1991) and humans (8""","Ix,,,, 
1991), but not in mice (0"" 19m. In addition, expression of ER subtypes is cell 
differentiation-dependent, as observed ill il/ vitro cell culture models using human, 
rat, atld mouse osteoblasts (Arts \997,QnQ£..!2'll,I<bihash j 1998), 
Furthennore, of both ER subtypes several isofOims are detected. In mouse bone 
manow cultures, nonnal rat pituitalY cells and human pituitalY tumors, as well as in 
human testis different ER isoforms are expressed (Shupnik 1998, ~, Gruber 1999, Pasqualini \999). 
Among others, a rat ERP isoform (ERP2) with a much lower affinity for E, than the 
initially reported ERP was found which is expressed in many rat tissues (P","," 1998. 
H,,,,"i,, )999). In the review by Kuiper et al. this and other ERP isoforms are summarized 
and discussed in more detail ("oi", 1999). 
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B.2. ESTROGEN RECEPTOR STRUCTURE 
Figure 1.5 shows the basic stlUcture of ERa and ERP, which consists of six major 
domains; A through F. ERa and ERP share this stmcture with the VDR and other 
members of the nuclear receptor superfamily. Domain C is important for receptor 
dimerization and contains two zinc-binding clusters of amino acid residues that bind 
to DNA sequences in the vicinity of the promoter of target genes, so-called estrogen 
response elements (EREs). The C-terminal zinc-binding amino acid cluster is 
involved in non-specific DNA binding, whereas the N-terminal zinc cluster seems 
important in discriminating and specifying ER binding to EREs ~. MM!<Lllli). The 
ligand binding domain (E) contains sites involved in nuclear translocation and 
dimerization. In addition, AF-2 is located in the ligand binding domain. AF-2 acts as 
a docking site for coactivator proteins and transcription factors that form the 
preinitiation complex ,M,K,,", '99') (See also Section BA.8.). Unlike the VDR, the ER 
can also be activated in a ligand-independent fashion by AF-I located in the N-
temlinal AlB domain, ~,Monica 1993, !gnar-Tffi\\brirlge 1993, Buoone 19961 (see also Section B.6.2., 
part VI). However, one must not consider these AFs as two independently operating 
sites of receptor activation but rather as cooperative activating elements (I'!!=lm). The 
ligand binding domain (E) and the DNA binding domain (C) is separated by a hinge 
region (D). The function of the F domain is not completely clear. It was demonstrated 
that deletion of the F domain had no influence on transcriptional activation by E, (K,mM 
=. P""',I (993), ER stability (P,"<1 (99 lJ, and phosphorylation state of the ER (P,kdo! 1993) 
However, it was suggested that the F domain is involved in agonistic/antagonistic 
action of certain antiestrogens 11>'901'" 19'1\ Ni,h,l, )998) and in interaction with specific 
cofactors 1l'ili!tl222). 
ERa and ERP are encoded by different genes located on different chromosomes 
(human chromosome 6 and 14, respectively), but show considerable homology: 96% 
in the DNA binding domain and about 60% in the ligand binding domain (",,,,Im" 1996). 
However, the amino terminal AlB domain containing AF-I, hinge region and F 
domain show little homology (Figure 1.5.). 
B.3. FUNCTION OF 17~-ESTRADIOL 
Reproductive organs, bone, cardiovascular ~J'stelll, and cognitiol/ 
The function of estrogens (E" estriol and estrone) is velY diverse and includes effects 
on female as well as male reproductive organs (utems, vagina, OVaty, testis, and 
prostate), and is also impol1ant for development of female secondaty sex 
characteristics. In addition, development and maintenance of the skeleton, and 
function of the cardiovascular system, brain, and nervous system are importantly 
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influenced by estrogens. The synthesis of growth factors and their receptors (e.g. 
insulin-like growth factors T and II, colony stimulating factor T, TGF a and ll, insulin-
like growth factor I receptor, epidermal growth factor receptor), peptide hormones 
(prolactin, luteinizing hormone, follicle stimulating hormone), protooncogenes (e.g. 
c-myc, c-fos, c-jun, ras), heat shock proteins (heat shock protein 27 and 90), and 
steroid hormone receptors (e.g. glucocOlticoid receptors, ERs, VDRs, progesterone 
receptors) is influenced by estrogens (!.hljW.KQrn,h 199J,~). 
ERa 
gene 
ERP 
gene 
NB Ie I 
20% 95% 
NB Ie I 
o E F 
60-66 kDa protein 
30% 60% 20% 
0 E F 
~ 
51-61 kDa protein 
Figure 1.5. Schematic structure and homology of ERa and ERll. The percelllages ill 
amino acid homology are depicted. The jimctioJls of domains A through F are described ill Sectioll 
B.2. 
The impOltance of Ez for bone becomes most apparent after menopause, when the 
dramatic fall in E2 and estrone levels lead to an imbalanced ratio between bone 
fOlmation and bone resorption, resulting in an increased net bone loss. Furthennore, 
increased malabsorption of calcium could underly postmenopausal bone loss. Also in 
males estrogens play an impOltant role in bone metabolism. The enzyme aromatase 
cytochrome P 450 converts androgens into estrogens (Figure 1.6). It was shown that 
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men lacking tills enzyme due to a gene mutation had low bone density and delayed 
bone maturation (Mori,him, 19951, and that treatment of these patients with E, improved 
bone mineral density ~I. 
Bone is an impOltant target tisssue of E, and in osteoblasts and osteocytes ERa and 
ERP has been demonstrated (Hoyl,,' 1997. ML!221.llllil<..l.22l. Vi<hl 19991. The presence of ERs in 
osteoclasts remains controversial. A preosteoclastic cell line expressed ERa, but no 
ER expression was observed in mature osteoclasts (Orcffo 19991• Administration of 
estrogens (estrogen replacement therapy) or a combination of estrogens and 
progestins (hormone replacement therapy) can reduce the risk of developing 
postmenopausal osteoporosis /I i,ds" 1976. "",k·I"", 19881. E, treatment results in improved 
calcium absorption in postmenopausal women. As an explanation for this effect E,-
stimulated production of 1,25-(OH),D3 was proposed (C,,';"o 19771• However, in rats 
others observed increased absorption of calcium and phosphotUS in the intestine 
without an alteration in setUm levels of 25-(OH)D3, 1,25-(OH),D3, and PTH -
199'. !.i<Ll2221, and our own laboratOly and Chen et al. repOlted that the E,-mediated 
increase in calcium absorption was accompanied by a decrease in 1,25-(OH),D3 
selUm levels ~. ==1. Interestingly, in the study by Chen et al. and in the study 
of Liel et al. E, treatment resulted in a significant increase in intestinal VDR 
expression compared to ovariectomized or sham operated rats (!JJ<rLl221. Li<Ll2221. 
Therefore, both a direct effect of E, andlor an E,-stimulated responsiveness to 1,25-
(OH),D3 might explain the stimulating effect of E, on calcium absol1)tion. 
Furthermore, interaction of E, and calcitonin could be involved in the reduction in 
bone mass after menopause. Calcitonin is an inhibitor of osteoclastic bone resorption. 
Postmenopausal women treated with E, demonstrated increased blood levels of 
calcitonin and an increased veltebral bone mass compared to placebo treated women 
(Aw",,,"; Iml. The anti resorptive action of E, nJight also be mediated by the induction of 
osteoclast apoptosis lK,m,," 19971, or by a decreasing effect on the synthesis of bone 
resorption-inducing cytokines like interleukin I, interleukin 6, and tumor necrosis 
factor a (Kassem }996, lilka 199;0. 
In addition, a direct anabolic effect ofE, on bone forming cells (osteoblasts) might 
playa role in the beneficial effect of E, on bone mass. A stimulatOlY effect of E, on 
proliferation and differentiation of osteoblast-like cells derived from male and female 
adult trabecular bone was reported lS,h"" 19921• In femoral bone tissue from elderly 
female rats E, and the isoflavonoids daidzein and genistein increased DNA and 
calcium content, and stimulated alkaline phosphatase activity <l1l!!.lm1. 
It has been suggested that estrogens might have a beneficial effect on the 
cardiovascular system. After menopause, low density lipoproteins rise, which may 
result in an increased risk for cardiovascular diseases (myocardial infarction and 
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cerebrovascular accidents). Administration of estrogens may decrease low density 
lipoprotein levels, may increase high density lipoproteins (!&l" .. l22.lJ, and thereby may 
reduce the rate of cardiovascular diseases (O=",·CQMQ[ 1991. Srunpr" 1991). In addition, direct 
effects of estrogens on vessel wall might play an impottant role (u.r"u 19971• 
Estrogens might also playa role in cognition. It was found that hormone replacement 
therapy improved cognition and was associated with a decreased incidence of 
Alzheitner's disease (Shf'mjn 1996,PJ£.1ninj_HjJI (996), 
The central role of E2 and its receptors in the functions mentioned above became 
evident studying mice that lack either a functional ERa or ERp. The ERa knock out 
(aERKO) mouse clearly demonstrated the importance of E2 in feltility. Both male 
and female aERKO mice are infeltile and their reproductive organs are reduced in 
size n,,"''' 1291. Illli..l2211. The feltility of the female ERP knock out (PERKO) mouse is 
reduced because of a diminished ovarian efficiency, whereas the male PERKO mouse 
only shows abnormalities (hypelplasia of the bladder and prostate) at older age iK= 
tml. The male PERKO mouse displays no bone abnonnalities compared with wild 
type mice. However, the cottical bone mineral content of adult female PERKO mice 
is increased due to increased radial bone growth. It was suggested that ERp might 
have repressive fimction in regulating bone growth during female adolescence 1_ 
19921 
Also in humans insight into the function of E2 and ER was gained with 
observations obtained with an ERa deficient male. The ERa gene of this patient 
contains a single base pair mutation in exon 2 and codes for a t!Uncated ERa protein 
lacking the DNA and ligand binding domain. The patient had low bone mineral 
density, immature epiphyses and tall stature. The bone mineral density did not 
improve and the growth plates did not close after ~ therapy. Interestingly, the patient 
developed normally until puberty. This suggests that other pathways can compensate 
the lack of a fimctional ERa or that ~ is not a key regulator in prepube11al 
development. However, the ERa-mediated pathway seems elementmy for bone 
metabolism during and after puberty (Smi!!l.lml. 
The importance of estrogens in male bone homeostasis is also illustrated by 
observations of severe osteoporosis and continued linear growth in men with 
mutations in the aromatase gene. The aromatase enzyme complex conve11s androgens 
(testosterone) to estrogens. Treatment of these aromatase deficient men with 
estrogens increases bone mineral density and closure of the epiphyses. 
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Cell growtlt 
The stimulatOlY effect on growth of the utelUs is a classic effect of E,. Growth of 
other cells, both normal and malign is directly influenced by E,. It was for instance 
found that estrogens have a mitogenic effect on the ER-positive breast cancer cell line 
MCF-7 IUPOm" 1976). Development of celiain breast and endometrial tumors is 
stimulated by estrogens (Bm;'''" 199Z1• One possible explanation for these observations 
might be that celiain estrogen metabolites show carcinogenic activity. Estrogens can 
be metabolized into 4-hydroxyestradiol and it was shown that this metabolite is a 
source of free radicals. These free radicals might damage DNA and tumors could 
arise I~. Due to metabolic stability of 4-hydroxyestradiol high concentrations in 
celiain tissues could develop. 
B.4. ESTROGEN RECEPTOR: 
TRANSCRIPTIONAL ACTIVATION 
The transcriptional activation activity of the ER is initiated by interaction with ligand 
(See Figure 1.2 and the cascade of events mentioned in Section AA.). Kuiper e/ 01. 
reported that both receptor subtypes bind a large variety of compounds (estrogens, 
antiestrogens, some androgens, phytoestrogens, and envirOimlental estrogens) iKlliJl<! 
12211. However, the natural ligand for both receptor subtypes is E,. 
B.4.1. SYNTHESIS, TRANSPORT, AND METABOLISM 
OF 17fl-ESTRADIOL 
Like 1,25-(OH),D3, E, is synthesized out of cholesterol (see Figure 1.6). E, is mainly 
produced by granulosa cells in the follicles, but also in adrenal glands, liver, and 
kidneys. After a first conversion by a cholesterol side chain cleavage enzyme 
complex, pregnenolone is fOimed. Pregnenolone is converted into progesterone by 
313-hydroxysteroid dehydrogenase or into 17a-hydroxypregnenolone by a 17a-
hydroxylase. Both compounds can be converted into 17a-hydroxyprogesterone, that 
is fmiher metabolized to androstenedione. Androstenedione can be convelied into 
estrone by an aromatase or by 1713-hydroxysteroid dehydrogenase into testosterone. 
In addition to the tissues mentioned above, aromatase activity is detected in placenta, 
fat tissue, fibroblasts, and brain tissue. Also in osteoblast and breast tumor cell lines 
aromatase activity is found (Purohit !992,PasauJlinj 1996, Tanaka !996,Jan~n 1999), 
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Figure 1.6. Formation of E,. Bolh lesloslerolle alld eslrolle are subslrales for E2 sYlllhesis. 
Testosterone is converted by an aroma/ase, whereas estrone is metabolized by 17jJ-hydro.,ysteroid 
dehydrogellase. 
More than 70% of E, secreted in the blood by the ovary is bound to albumin or sex 
hormone-binding globulin ,"",,, 19981. Metabolism of estrogens occurs mainly in the 
liver, but also in various other target tissues estrogen metabolism has been observed. 
Conjugated with glucuronic or sulfuric acid, the metabolites are secreted in the bile, 
reabsorbed into the blood and excreted in the urine as fl-glucuronides or sulfate esters. 
B.4.2. ESTROGEN RECEPTOR LIGAND BINDING 
An initial step in receptor activation is the ligand-induced confOlmational change of 
the ER (""'mao 19911. Ligand binding induces repositioning of the AF-2-containing helix 
12 of the ligand binding domain, resulting in closure ofthe ligand binding pocket like 
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a mouse trap. Because of the more compact folding of the receptor its sensitivity for 
proteases is lowered, which was confirmed by limited proteolytic digestion analysis 
(!l"km,m 19931, and Chapter 6. 
The cell sensitivity to estrogens is importantly influenced by ER levels in the cell. 
In a variety of cell lines a correlation was found between ER numbers and cellular 
responsiveness to estrogen (for references: see below). Modulation of ER levels is 
therefore an impOtiant mechanism to control target gene transcription. Like VDR and 
other nuclear receptors (See Section A.4.2., (Rt'.ad 19SB, Bellingham 1992, \ValeDA 1993), expression 
and/or stability of ER is under control of its ligand. During estrous cycle up-
regulation of uterine ER mRNA and protein level is observed in an E, plasma 
concentration-dependent manner ,"""no" 19921. E2 increased ER expression in 
endometrium of ovariectomized ewes by increasing the stability of ER mRNA ~. 
Zl>l!.Jm. R",,"59" 1998.!ng,l2221. On the other hand, in a pihlitary lactotrope cell line ER levels 
decreased after incubation with E, <AlMi<Ll2221, and in liver of ovariectomized ewes single 
and chronic administration of E, resulted in ER down-regulation @JLl221l1. Bodine ef al. 
demonstrated that the effect of E, on ER expression in rat calvarial-derived 
osteoblasts depended on cell differentiation stage. During the nodule-forming stage E, 
decreased ER mRNA, whereas during late mineralization stage E, up-regulated ER 
mRNA. As suggested by the investigators the developmental expression of ER 
mRNA might playa role in the observed osteoblast differentiation stage-dependent 
expression of bone cell genes like alkaline phosphatase, osteocalcin, and osteonectin 
lBodin< 19981. In the human breast cancer cell line T47D E, caused an increase in ER 
mRNA ~I, whereas in MCF-7 cells ER mRNA and protein levels were down-
regulated by E, tB<lJLl2!2. So"", 1998.A1Mi<ill22. El Khi&ii" 19991. The SERM L Y 117,018 itself was 
without effect but completely prevented E,-induced down-regulation ofER in MCF-7 
cells Ulo>!.ill2I. The synthetic ER ligand tamoxifen induced ER up-regulation in MCF-7 
cells, (J.'gN> 1997) and mimicked the effect of E, on ER mRNA and protein levels in 
endometrium of ewes (Roh<""," 19981. In women a single dose of tamoxifen induced an 
increase in ER levels in endometrium (Go"",," 19921, whereas c1n'onic administration of 
tamoxifen caused down-regulation of ER levels (P<re,.Lop" 19931. In breast cancer biopsies 
of postmenopausal women treated with tamoxifen increased ER levels were measured 
(Noguchi 1993) 
Also heterologous regulation of ER has been observed. It was found that 1,25-
(OH),D3 (B,m", 19931, triiodothyronine (Fuii"lQiQ 1997), and the antiprogestin RU486 (Smldi 19951, 
all increased ER mRNA stability and/or ER concentration in murine bone mal1'OW-
derived stromal cells, rat pituitalY cells, and human breast cancer cell lines, 
respectively, whereas TGFp (R"" 19891, the androgen 5a-dihydrotestosterone (j'o,lin 19891, 
the synthetic progestin R5020 GkiliLl2i2. S,,,Id; 19951, and 1,25-(OH),D3 (Sioi" 19991 had a 
decreasing effect on ER protein and mRNA levels in human breast cancer cell lines. 
A functional relevance for progestin-induced ER down-regulation in MCF-7 and 
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T47D breast cancer cells was found, as the decrease in ER levels was shown to 
conelate with decreased pS2 protein synthesis in response to E2 IS""",; 1995). Other 
studies also suggested that ER expression regulation has a functional role. For 
instance, ERa up-regulation in rabbit heatt and aorta after cardiac-aorta allograft 
transplantation might be related to the cardiovascular protective effect of E2 UmLJml, 
and the inverse relationship between circulating E2 levels and ER mRNA expression 
in the anteroventral periventricular nucleus of the preoptic region of the rat is 
suggestive for a functional role of ER levels in the responsiveness of neurons of the 
anteroventral periventricular nucleus to E2 IS;",,", 1996). However, the change in ER 
levels is not always related to the biological response of the compound that induces 
the change in ER levels. For instance, tamoxifen-induced up-regulation of ER in 
MCF-7 breast cancer cells was not related to the growth inhibitOty effect of 
tamoxifen on these cells (L,,,,,; 1991). All together these data indicate that ER level 
regulation is not an unequivocal process, but probably depends on the cell/tissue and 
its differentiation stage, the compound that induces the change in ER levels, and the 
way the compound is administered. 
Regarding receptor degradation, like the VDR, the ER is probably ubiquitinated 
and subsequently degraded by the proteosomc in a ligand-dependent maImer (N;m"l, 1995. 
Masuyama 1997, AlM:i.lill22. PI Khissjjn 1999 NawJZ 1999), sua 1, a cofactor involved in VDR turnover also 
binds to ER (VQm B,,<c 1996> and is probably also playing a role in ER degradation by the 
proteasome IMasuyama 1997), 
B.4.3. DISSOCIATION OF HEAT SHOCK PROTEINS 
When present in the cytoplasm ERs are associated with heat shock proteins. Heat 
shock proteins probably playa role in stabilizing the receptor during synthesis and 
transpOtt to the nucleus. FurthemlOre, the complex of receptor and heat shock 
proteins probably keeps the ER in a confonnation with high affinity for ligand and 
low affinity for DNA. Ligand binding induces dissociation of heat shock proteins iSmiJh 
j])21). However, removal of heat shock proteins is not sufficient to obtain a 
transcriptional active ER ~). 
B.4.4. ESTROGEN RECEPTOR PHOSPHORYLATION 
Like the VDR, the ER is phosphOtylated under influence of its ligand (An'O'hig 1987). Also 
other factors like epidemml gro\\1h factor, TOFa, and insulin-like growth factor I can 
activate ERs possibly by stimulating their phosphorylation at cel1ain sites (Amok, 1991. 
l,mr.Thmh",.> 1991, B"DO" 1996). It was shown that phosphOtylation of tyrosine within or near 
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the ligand binding domain increases ligand binding capacity fhHgH"oi, 19891, ER 
dimerization, and ERE binding (Arnold 1995). Phosphorylation by protein kinase A of 
serine 236 within the DNA binding domain of ERa also regulates ER dimerization 
(Chen 19991. Furthermore, serine 118 in the N-telminal AlB region is a specific 
phosphOlylation site linked to AF-I activity (A!ill2l.!oill22.\. fuloh..!222). Mitogen-activated 
protein kinase that is activated by Eo and certain growth factors (e.g. epidemlal 
growth factor) is involved in ER phosphOlylation at serine 118 (K;lliLl22.;. B"ooo< 1996. 'oo,h 
lm) 
B.4.S. ESTROGEN RECEPTOR DIMERIZATION 
After E2 binding ER dimerization is stimulated (W~g 1995) and DNA binding is 
facilitated (Koo" 1997). Both ERa and ERB homodimers as well as ERalERB 
heterodimers have been described ill vitro Ifu<l221.Cowley 1997''''"'0>9' 1997). 
B.4.6. ESTROGEN RECEPTOR TRANSLOCATION 
It was found that in the absence of ligand ERs are mainly located in the cytoplasm 
and that administration of E2 leads to an increase in nuclear ER levels ("",1m M,nd,; 1996). 
ER continuously shuttles between nucleus and cytoplasm (G'iochon.MMt<II9%). 
B.4.7. ESTROGEN RECEPTOR-DNA BINDING 
When looking at the numerous ER-regulated genes (ei"" 1995), relatively few ERE-
containing target genes have been identified (Table 1.4). It is conceivable that the 
ER regulates gene transcription of many genes not containing an ERE by 
modulating the activity of transcription factors like AP-l, NF kappa B, and Spl 
(~.~,~,~.~,~. Kleinert 1998. Ceri!!Q 1998, Kuiper 1999, Xi.U222. Borrelli 1999) 
Like the VDRE, ERE half-sites are (A)GGTCA or related motifs. The fact that the 
binding sites display almost perfect rotational symmetry suggests that ERs bind as 
dimers to these EREs (Kumar 1988, Klein-HiIN» 1989), However, exceptional ERE sequences 
have also been reported. For instance, the ERE found in the ovalbumine gene consists 
of four synergistically acting TGACC motifs separated from each other by more than 
100 bp (~) and EREs found in the rat prolactin gene have nonpalindromic sites 
IM,,"«h 1995). Similar to the VDRE, most EREs are located in the 5'-region upstream of 
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their promoter, although EREs were also identified in the 3' -untranslated region 
(mouse c-fos) and within the coding sequence of the target gene (rat c-jun, Xenopus 
laevis ER, Oreochromis aureus vitellogenin). Note that several genes contain multiple 
ERE-like sequences. These sequences are only slightly active as isolated EREs but 
activate gene transcription in a cooperative way. 
The presence of EREs within E,-responsive genes can be species-specific. For 
instance, in the rat calbindin D-9k gene an imperfect palindromic ERE sequence was 
revealed (Dm,," !99!1, whereas no such sequence was found in the human and porcine 
calbindin D-9k gene ~. Kri,;,,,, 199'). Similar species-dependent differences in ER 
binding were observed between the rat luteinizing hOiTIlOne P gene that contains an 
ERE (Sh,,";k 1991), and the bovine gene that lacks an ERE Oiliilm). 
The EREs reported to this date were characterized using ERa as the DNA binding 
protein. Based on the large homology in DNA binding domains between the two ER 
subtypes, it could be expected that ERa and ERJ3 bind to the same EREs. In more 
detailed ill vitro studies was found that the affinity of ERa for the vitellogenin ERE 
was higher than that ofERP (fumb1" 1997 OJ,,'" 1997), although others could not confirm this 
(P,"""" 1997). Also, gel mobility shift experiments pelfonned with the choline 
acetyltransferase ERE and the cathepsin D ERE demonstrated that ERP required 
higher DNA concentrations than ERa to form stable complexes ill vitro, indicating 
that the affinity of ERa for these EREs might be higher than that of ERP my'" 1999). 
Cowley et al. showed that ERa homodimers, ER/3 homodimers, as well as ERalERJ3 
heterodimers bound to the same ERE and that the affinity for the ERE depended on 
dimer composition: ERJ3 homodimer exhibited the lowest affinity and ERa 
homodimers the highest, while heterodimers demonstrated intermediate affinity. For 
the transcriptional activation potency the same pattern was observed (OJ"I., 19971. In 
addition, it is still possible that specific EREs for the ER subtypes exist. 
Some ill vivo studies indicated that ligand seems a requirement to observe ER 
binding to DNA (Ph,m 1991, Gilh<rt 1992), although other studies show the opposite 
(Truk,nIJon 1990). Also ill vitro the role of ligand in ER-ERE binding is not clear. In 
most gel mobility shift assays it was shown that ligand is not essential to observe 
ER binding to an ERE (Fawe1l1990, Murdoch 1990, Sabbah 1991,~, Murdoch 1991,~, Metzger 1995, 00 
1221. Tremblay 1998, Hyder 1999). However, smne ill vitro studies show ligand-dependent ER 
binding to DNA (Kumar 1999, Brown 1990, Beekman 1993, HansJein 1999\ possibly due to stringent 
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conditions in the gel mobility shift assay (e.g. magnesium concentration and 
temperature) (Drown 199m, 
Table 1.4 Estrogen receptor-regulated genes and nucleotide sequences of 
estrogen response elements identified in those genes 
GENE NUCLEOTIT>ESEQUENCE (Refs) 
Chicken vitellogenin A1 5'-GGTCA gcg TGACC-3' (Burch 1988) 
Chicken vitellogcnin A2 5' -GGTeA aea TAACC-3' (Burch 1988) 
Chicken apo VLDLU 5' -GGGeT eag TGACC-3' (\~ijDbQlds 1988) 
Chicken apc VLDLII 5' -GGTeA gae TGACC-3' OYijnhglds 1988) 
Human cathepsin D 5' -GGeCG gge TGACC-3' (Wang 1997) 
Human c-fos 5' -CGGCA geg TGACC-3' (Weisz 1990) 
Human Iactoferrin 5' -GGTeA agg CGATe-), (Teng 1992) 
Human oxytocin 5' -GGTGA eet TGACC-3' (Richard 1990) 
Human prolactin 5' -TGTCA eet TGGeC-)' (Bcrwacr 1991) 
Human pS2 5' -GGTeA egg TGGeC-), (Beny 1989) 
Mouse c-fos 5' -GGTCT agg AGACC-3' (Hyder 1992) 
Mouse choline acctyltransferase 5' -GGeeA ega TGACA-3' (Hyder 1999) 
Mouse lactoferrin 5' -GGTCA agg TAACC-3' (Teng 1992) 
Oreochromis aureus vitellogcnin 5' -GGGCA cae TGACA-3' (lli!..!.22ll) 
Oreochromis aureus vitellogenin 5' -CCAGT cca ACTTG-3' (Teo 1998) 
Rabbit uteroglobin 5' -GGTCA cca TGCCC-3' (L6~z d~ Haro 1220) 
Rat calbindin D-9k 5' -GGTCA ggg TGATC-3' (Darwish 1991) 
Rat creatine kinase B 5'-GGTCA gaa CACCC-3' (IVII-Peng 1222) 
Rat c-jun 5' -GCAGA gea TGACC-3' (Hyder 1995a) 
Rat luteinizing homlone J3 5' -GACAG atg GTGTC-3' (Shupnik 1991) 
Rat progesterone receptor 5' -GTTCA gtg TGAAC-3' (Kraus 1994) 
Rat progesterone receptor 5'-TGTCA aga TGTCC-3' (Kraus! 294) 
Rat progesterone receptor 5'-GGTCG tea TGACT-3' (Kraus 1994) 
Rat progesterone receptor 5' -GGACA gee TGCCC-3' (Kraus 1924) 
Rat progesterone receptor 5' -GGACA gee TGCCC-3' (Kralls 1924) 
Rat prolactin 5' -GGTCA eaa GCTGC-3 ' (MurdQ!,;;h 19~J.) 
Rat prolactin 5' -TGTCA eta TGTCC-3' (MurdQ!,;;h 122~) 
Salmon gonadotropin II beta 5' -TGTCA ate TGACC-3' (Li!L!22,i) 
Xenopus laevis ER 5' -GGTCA gtt TGACG-3' (Lee 1995) 
Xenopus laevis vitellogenin A I 5' -TGCCA cae TGAGC-3' (lValker 1984) 
Xenopus laevis vitcllogenin AI 5' -AGTeA ett TGACT-3' (lValker 1984) 
Xenopus laevis vitellogenin A I 5' -GGTCA eaa TGACC-3' (Walker 1984) 
Xenopus laevis vitellogenin A2 5' -GCCCA gag TGCCC-3 ' (Walker 1284) 
Xenopus laevis vitellogenin A2 5'-GGTCA cag TGACC-3' (Klein-Hitp:~ss 1986) 
Xenopus laevis viteliogenin BI 5' -GGCCA eag TGAAC-3' (Martinez 1987) 
Xenopus laevis vitellogenin BI 5'-AGTCA etg TGACC-3' (Martinez 1987) 
Xenopus laevis vitellogenin B I 5' -AGTTA tea TGACC-3' (Martinez 1987) 
Xenopus laevis vilelJogenin B2 5' -AGTCA ett TGACC-3' (Walker 19&4) 
Xenopus laevis vilellogenin B2 5' -AGTTA tea TGACC-3' (Walker 1984) 
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Despite these differences most researchers agree that addition of ligand changes 
the conformation of the ER-ERE complex. This might explain why in gel mobility 
shift assays the mobility of liganded ER-ERE complex is different from the 
mobility of l1nliganded ER -ERE complex (l&n.ill..2. Fawell 1990,~, Sabbah 1991, Tremblay 1998). 
The ligand-induced conformation is a prerequisite for interaction with basal 
transcription factors and cofactors and essential for full transcriptional activation. 
Furthelmore, presence of ligand seems to increase the stability of the ER-ERE 
complex (Dau\'ois 1992, McllW 1995,~). 
As mentioned above, besides via EREs, ERs regulate gene transcription via AP-I 
elements, Sp I binding sites, and NF kappa B response elements (lYri>L1.22.l.lJ>:<!<Llm. fubll 
l222. POrter 1997, ~,~, Ktriner! 1998, CerillQ 1998. Kuiocr 1999, Xk...Jm. Bonelli 1999), For instance, 
synthesis of chicken insulin-like growth factor I is controlled by E, via an AP-I 
motif located in its promoter region (IIm"'h'" 1994). Also transcription of the chicken 
ovalbumin gene is activated by interaction of fos, jun (AP-I) and the ER (Q®U99ID. 
Instead of DNA binding, protein-protein interactions seem to be involved in ER 
activation at AP-I sites since the DNA binding domain of the ER is not absolutely 
required (W,bb 1995). Interestingly, besides E2 also (pure) antiestrogens are able to 
activate the AP-I-mediated response by ER in the context of the collagenase 
promoter (l'illhl992I. 
B.4.8. ESTROGEN RECEPTOR-COFACTOR BINDING 
ER binding to an ERE results in DNA bending (Smbb3h 1992, Gilbert 1992, Narrln!lj 1991, Nardu!1i 1993a,Nill:illilli 
199.\). III vivo ER-induced alterations in chromatin structure are dependent upon the 
presence of E2 (Gilbe" 1992). However, ill vitro no difference in DNA bending was 
observed with liganded and unliganded ER, indicating that ER-induced DNA bending 
alone is not sufficient to activate gene transcription. However, it is still believed that 
DNA bending is essential for gene transcription: it might facilitate interaction 
between proteins bound to separate sites on DNA as was indicated by the finding of 
interaction between the AF-2 domain with certain factors (TFIIB, and TBP, a subunit 
ofTFIID) of the pre initiation complex at the TAT A box) (!ogi991). 
In addition to basal transcription factors also (prefOlmed complexes of) cofactors 
are essential for optimal regulation of gene transcription (I"",, 1998. ",K""" IW). The 
ligand-induced repositioning of the AF-2-containing helix 12 exposes specific amino 
acids critical for cofactor binding (See Sections A.2, AA.8., and B.2.) av,),"''' 1994). 
Binding of the nuclear protein RIP140, SRC-I, TIF I, TIF2/GRIPI, and estrogen 
receptor-associated protein ERAP 160 has been observed 1H,I"hmi 1994. c,,,i1111 1995. Qmk.l.99i. 
Mcinerney 1996, Le DouaDn 1996, V!X'gel 1996, ~ Cowley 1997, Tremblay 1997), E
2
, other steroids, estrogen 
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receptor agonists and phytoestrogens are able to stimulate interaction of ER with 
these cofactors, and may thereby detelmine their estrogenic activity (Ni,bik"" 1999). 
B.S. NONGENOMIC EFFECTS OF ESTROGENS 
Estrogens also exeli nongenomic effects <fulrill2ll.~. BmOOk" 1999). It was for instance 
shown that E2, estrone and estriol rapidly (i.e. within 5 seconds) increased the calcium 
ion concentration of chicken and pig granulosa cells. The transcription inhibitor 
actinomycin D and the protein synthesis inhibitor cycloheximide were not effective in 
blocking this rapid response. However, inhibitors of inositol phospholipid hydrolysis 
could abolish the effect of the estrogens, indicating that estrogens trigger the release 
of calcium from intracellular stores through induction of phosphoinositide breakdown 
"'Q!'''' 1992). Furthermore, it was shown that E2-induced activation of mitogen-activated 
protein kinase is preceded by mobilization of intracellular calcium, suggesting that 
nongenomic regulation of calcium homeostasis and mitogen-activated protein kinase 
signaling pathway are cOlmected by the action of E2 IImpro".O["" 1999). The rapid 
stimulation of alkaline phosphatase in chondrocytes by E2 appeares to be mediated by 
nongenomic stimulation of protein kinase C 1S,"i' 1998). FUlihelmore, Alarid ef al. 
attributed rapid E2-induced degradation ofER in pituitary lactotrope cells and MCF-7 
breast cancer cells to a nongenomic activity of estrogens (A!!li!!..lm). 
Similar to the VDR, a membrane version of the ER that could mediate these rapid 
responses of E2 was detected in a pituitmy tumor cell line and in MCF-7 human 
breast canccr cells (W""'" 1999. No",,,, 1999). Also in rabbit utems membrane estrogen binding 
proteins structurally related to intracellular ER were detected that could be impOliant 
in mediating nongenomic effects of E2 (Ml!I!iill22). Razandi ef al. demonstrated that both 
nuclear and membrane ERs are derived fi-om the same cDNA transcript. They also 
showed that membrane versions of both ERa and ERP exist (R~di 1999). However, the 
biological relevance of these membrane receptors and the mechanism of action by 
which these receptors might act are still to be resolved. 
B.6. SELECTIVE ESTROGEN RECEPTOR MODULATORS 
The side effects of estrogen replacement therapy and hormone replacement therapy: 
resumption of menses, breast tendemess, abdominal bloating (Uplo" 1982) and possible 
increased relative risk for breast and uterine cancer, have led to an intensified search 
for synthetic ER ligands with the beneficial effects of E;, (the effects on bone mass 
and the cardiovascular system), but with a diminished risk for development of breast 
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and uterus cancer. Because of their antagonistic effect on estrogen-dependent breast 
cancer growth, these compounds were originally named antiestrogens. The fact that 
these compounds exert their action via the ER and based on their tissue selective 
agonistic or antagonistic activity, makes the designation 'selective estrogen receptor 
modulators' (SERMs) more appropriate. Table 1.5 summarizes the 
agonistic/antagonistic action of E2 and several synthetic ER ligands in various target 
tissues. Between the two extremes- E2, as complete agonist, and N-n-butyl-ll-(3,l7P-
dihydroxyoestra-I ,3,5(1O)-trien-a-yl)n-methyl-undecanamide (lCI 164,384) and 7-a-
[9-(4,4,5,5 ,5-pentafluoro-pentylsulphiny l)nonyl]oestra-I,3 ,5( I O)-triene-3,17 beta-diol 
(lCI 182,780) known as pure antagonists- there is a range ofSERMs that exett tissue-
specific agonistic or antagonistic activity 0lwnl..l22S1. 
Table 1.5. Agonistic/antagonistic activities of E2 and several synthetic ER 
ligands in various target tissues 
Uterus Bone Breast Cardiovascular 
E, Agonist Agonist Agonist Agonist 
Diethylstilbestrol Agonist Agonist Agonist Agonist 
Raloxifene Antagonist Agonist Antagonist Agonist 
Tamoxifen Partial agonist Agonist Antagonist Agonist 
4-Hydroxytamoxifen Partial agonist Agonist Antagonist Agonist 
ICI164,384 Antagonist Antagonist Antagonist Antagonist 
ICI182,780 Antagonist Antagonist Antagonist Antagonist 
The activities of E2 and SERMs in the various target tissues are discussed in more 
detail in Section B.6.1. Pattial agonists mimic the action of Ez, albeit to a lesser 
extent, whereas an antagonist counteracts the action of E2. In Figure 1.7 the 
chemical stmctures of these compounds are presented. 
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Figure 1.7. Chemical structures of E, and a selection of synthetic ER ligands. 
These synthetic compollnds were de\'e/oped by successive chemical modifications at the 
triphelly!ethy!elle lIucleus, [omled by additioll o[ all extra phellY! rillg to the stilbelle lIucleus as 
present in for installce diethylstilbestrol. the most go/elll synthetic estrogen. The leI compoullds 
contain extellsiolls at C7 of E; (Grgfyger 1996 Wa/wling 19~. 
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B.6.1. BIOLOGICAL EFFECTS AND CLINICAL APPLICATIONS 
Uterus 
In the utems tamoxifen can be classified as an agonist of E,: It mimics the effect of 
estrogen on uterine weight iK<QMlm1. The risk of this stimulatory effect on the utems by 
tamoxifen is illustrated by the report of an increased number of patients with uterine 
carcinomas after breast cancer treatment with tamoxifen IFjilin 199'1. In most tissues 
raloxifene and tamoxifen have a similar profile. However, raloxifene is an antagonist 
in the uterus: Treatment of postmenopausal women with raloxifene did not result in 
uterine stimulation (D[,"" 1996'. In most studies, ICI 182,780 and ICI 164,384 lack any 
agonistic activity. However some studies demonstrated agonistic activity ill uterine 
cells (CIJ(trite 1991l, and endonletrial cancer cells (lm!lLl.22l. Castro-Rivera 1998), Therefore) although 
their selective effect is limited, the ICI compounds should perhaps also be considered 
as SERMs. The possible mechanism underlying the agonistic potency of the ICI 
compounds will be discussed in more detail in Chapter 7. 
BOlle 
III vitro experiments demonstrated that high concentrations (100 J.lM) of SERMs like 
tamoxifen and clomiphene inhibit bone resorption induced by PTH, prostaglandin E" 
and 1,25-(OH),D3 IS""," 19361. We showed that E, did not inhibit 1,25-(OH),D3-
stimulated ill vitro bone resorption, whereas ICI 164,384 and tamoxifen did IViok·V" 
Wijog,,['OO 19951. III vivo E, and tamoxifen decreased bone resorption in ovariectomized 
rats O:.mru2HJll. In addition, breast cancer patients treated with tamoxifen were protected 
against increased bone loss 1ill<.l2221. Raloxifene exetts also E,-like effects on bone. 
Both E, and raloxifene inhibited interleukin 6-induced bone resorption and stimulated 
the TGFp-inhibitoty effect on osteoclast differentiation and activity IBM", 1m} 
Postmenopausal osteoporotic women treated with raloxifene or E, had increased bone 
mineral density values, whereas women receiving placebo had decreased bone 
mineral density values compared to values at base-line. Futthennore, raloxifene 
reduced fracture incidence IDrJoer 1996, Delmas 1997 lJ.illlliJ...l2l, 
Cardiovascular system 
Beneficial effects of estrogens and SERMs on the cardiovascular system (e.g. on 
vascular smooth muscle proliferation, low density lipoproteins oxidation and effects 
on endothelial factors) are known. Administration of tamoxifen and raloxifene led to 
a decrease in cholesterol levels in ovariectomized rats and postmenopausal women 
11"",,[ 1996.illl!.>h..t.22l1. The number of cardiovascular events in breast cancer patients treated 
with tamoxifen was decreased (Rulq\ist 1993), 
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Breast tllll/ors 
E, is an impOitant regulator of normal and malignant cell growth. After estrogen 
replacement therapy increased risk for development of breast cancer is still a cause 
for concelll and as mentioned above was a stimulus to find new ER ligands with a 
more beneficial biological profile. Tamoxifen was onc of the first synthetic ER 
ligands evaluated for this purpose. III vitro, in the absence of E" tamoxifen and the 
tamoxifen metabolite 4-hydroxytamoxifen stimulate the growth of the human breast 
cancer cell line MCF-7 mjgnon 1988, Vink-Van Wiingaanlen 1993), However, in co-treatment 
expelilllents these synthetic ER ligands can be classified as antagonists: they inhibit 
E,-induced cell proliferation /yi,k·"" Wii,g~,d" 19911. In clinical studies, tamoxifen was very 
successful in the treatment of breast cancer. More than 50% of human breast cancers 
contain ERs and 70% of these ER-positive hi mol'S are inhibited in their growth by 
tallloxifen lIo,h, 19921. Nowadays tamoxifen is the most widely used endocrine therapy 
for breast cancer. However, during prolonged therapy tallloxifen resistance and 
relapse of breast hlluor growth is observed. As underlying mechanism of tamoxifen 
resistance several possibilities were proposed: e.g. the occunence of ER mutations 
and the accumulation of tamoxifen metabolites with less antagonistic or even 
agonistic activity ®<kl22l1, although others showed that these aspects are probably not 
playing a major role IWnl' DM 1991. K,",,,)I,,bo,,, 1997). Alternatively, altelllate ER activation 
pathways (alterations in ER phosphOlylation, changed interactions with AP-l-
mediated gene transcription) might be involved. See also B.6.2., pmt V. 
B.6.2. POSSIBLE MECHANISMS FOR THE SELECTIVE ACTION 
OF SELECTIVE ESTROGEN RECEPTOR MODULATORS 
The mechanism of action of a pure E, antagonist could, in theOlY, be velY simple: a 
ligand that lacks any estrogenic effect will compete with ~ for binding to the ER and 
in this way it prevents transcriptional activation. However, SERMs exelt partial 
agonistic/antagonistic activity. The fact that agonistic/antagonistic activities are 
species-, tissue-, cello, and target gene-specific makes the matter even more 
complicated. Fact is that the mechanism of action starts with competition of the 
SERM with the natural ligand ~ for the ER ligand binding site. After that, any 
defective interaction with an event in the cascade leading to activation of the ER (see 
Section AA.) will result in full or pmtial reduction of the potency of the SERM-ER 
complex to modulate target gene transcription. In thc section below several possible 
mechanisms of action to explain selective antagonistic/agonistic activity of SERMs 
are presented. 
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I. RECEPTOR NUMBER, AFFINITY, CONFORMATION AND HALF-LIFE 
As mentioned in Section BA.2. the biological response of ER ligands is importantly 
influenced by the level of ERs in target cells. It was reported that tamoxifen mimics 
E2 in increasing ER mRNA levels in endometrium ({)ml'''''i 1992. Rob<rt"'" 19981• In contrast, 
ICI 164,384 and ICI 182,780 induce rapid loss of ER in utelus and other cells, a 
feature that might underly the antagonistic propeliy of this compound 1Giim" 1991.Bmill'll. 
D""Qi, 1992, ,,,"" 19991. In addition, SERMs might have an ER subtype-selective up-
regulatOlY effect. In Chapter 6 lYe will show that the effect of ICI on ER stability is 
ER subtype-dependent. Also for RU 58668 strongly decreased ER levels in the 
human breast cancer cell line MCF7 was repOlied, indicating that this pure antagonist 
ofE2 might act via a similar mechanism as the ICI compounds (1ill.l22lI. 
ERa and ERp show around 60% homology in their ligand binding domain and, in 
general, both ER subtypes demonstrate similar binding affinity for a large number of 
ligands. However, some phytoestrogens (coumestrol, genistein) show increased 
binding affinity for ERI3 (",it'" 19971. Therefore, it might be feasible that ER subtype-
selective ligands exists or can be developed. However, one should note that, similar to 
the situation with the VDR, the binding affinity of a ligand for the ER probably does 
not reflect its biological potency =-1. 
Differences in effect on ER confOimation probably forms the basis of the selective 
action of SERMs. X-ray crystal stlUcture studies ,""""",ki 1991 ShiMLl22S1, patiial digestion 
analysis (8,,""'" 1993. M<J)ono,1l 19951, antibody detection (~I, and phage ELISA ~I 
revealed that E2 and SERMs induce distinct conformational changes of ER. Ligand-
induced changes in ER conformation will also interfere with subsequent steps in the 
transactivation cascade: ER dimerization, DNA binding and cofactor interaction. 
FUlihermore, a change in ER conformation can also result in a change in ER half-life, 
since the accessibility of protease cleavage sites of enzymes which take care of 
receptor processing can also be affected. 
E2 and synthetic agonists like diethylstilbestrol (see Figure 1.7 for chemical 
structure) induce a conformational change of the ER characterized by refolding of the 
ligand binding domain. In this process described in the so-called mouse trap model, 
helix 12 is positioned over the ligand binding pocket formed by helices 3, 5/6, and II. 
Raloxifene contacts the hydrofobic groove fOimed by helices 3 and 5, but in addition 
the alkylaminoethoxy side chain of raloxifene interacts with amino acid 351 in helix 3 
,"",,"m,Li 19911. This specific interaction prevents helix 12 from rotating and might affect 
interaction of the receptor with cofactors essential for full receptor activation. 
Interestingly, studying the effect of raloxifene on TOFa mRNA induction in MDA-
MB 231 human breast cancer cells this SERM is an antagonist with wild type ER, 
whereas raloxifene acquires agonistic potency when the cells were transfected with 
ERs with a mutation at position 351 (em'50' 1998). Likewise, the side chain of 4-
hydroxyiamoxifen prevents helix 12 from folding over the ligand binding pocket (Sh@y 
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l22.a1. Changed folding ofhelix 12 will influence presentation of certain residues (AF-
2) important for cofactor interaction. This will affect AF-2 function and might explain 
why raloxifene and 4-hydroxytamoxifen exert tissue-dependent partial 
agonistic/antagonistic activity. 
The conformational change of ERa induced by ICI 164,384 and ICI 182,780 might 
be an explanation for their antagonistic potency in many responses studied. ICI 
164,384 increases tumover of ERa, both ill vitro (P"";, 19921 and ill vitro (G.b,," 1991) and it 
is hypothesized that this is a direct consequence of the induced conformational 
change (see Chapter 6). 
II. RECEPTOR PHOSPHORYLATION 
Although little is known concerning SERM -specific effects on ER phosphorylation, 
some data indicate that this aspect might be involved in the selective effect of 
SERMs. For instance it was shown that tamoxifen inhibited E2-stimulated ER 
phosphorylation (A,ri,eb;Q 1987), and that in the absence of E2, ICI 164,384 and 4-
hydroxytamoxifen stimulated ER phosphorylation although not as effectively as the 
natural ligand (A!lffill. 
III. RECEPTOR DIMERIZATION 
Although ligand seems to be no prerequisite to observe ER dimerization ill vitro (~ 
-. !JJill..lm1, it was shown that E2 and 4-hydroxytamoxifen promoted ER dimerization 
(I}",.,;, 19931. In contrast, it was proposed that the antagonistic activity of ICI 164,384 is 
based on its inhibitory effect on ER dimerization, resulting in decreased ERE binding 
and diminished transcriptional activation (f;",,11 (990. A"'"", (9921. FurthernlOre, impaired 
dimerization might result in a shorter half-life of the receptor, as was observed in 
mouse utems, mouse testes cells, human breast cancer cells, and transfected COS-I 
cells (G;b,," 1991. Rru<l.22.l. P''''Q;, 19921. However, Metzger et af. and Lees et al. repOIted that 
ICI 164,384 did not impair ER dimerization tLttLill2. Meu'" 19951• Also, Wang et af. 
demonstrated, using the yeast two-hybrid system, that not only the partial 
agonist/antagonist tamoxifen but also the pure antagonist ICI 182,780 was able to 
induce ER dimerization, although to a lesser extent than E2. However, when E2 and 
the anti estrogens were added simultaneously, dimerization was pClturbed Q\'~, 1'91). 
IV. TRANSLOCATION OF THE RECEPTOR TO THE NUCLEUS 
As already mentioned, E2 induces translocation of ER to the nucleus (G"jochQo.M~I<I 19961• 
SERMS also intetfere with migration of ER to the nucleus. In addition, expOIt from 
the nucleus, nucleocytoplasmic shuttling, also takes place. The observed dismption of 
nucleocytoplasmic shuttling of ERs observed after treatment with ICI could also be a 
consequence of impaired ER dimerization. It was found that ICI 182,780 and ICI 
62 
164,384 were able to block nucleocytoplasmic shuttling of ERs and caused 
accumulation of ERs in the cytoplasm (Dauvois 1993, Ferrei@ Mendes 1996), Interestingly, 
treatment with tamoxifen also led to decreased nucleocytoplasmic shuttling, but 
instead of accumulation in the cytoplasm nuclear retention of ERs was observed 
(ferreira Mendes 1996) 
V. DNA INTERACTION 
Partial agonistic/antagonistic effect of SERMs is probably not a result of blocking 
ER-ERE binding. In most studies it was shown that binding of ill vitro synthesized 
ER to an ERE did not require ligand and that ER-ERE binding was not affected 
quantitatively by E2 or SERMs <L=.ill2.Illli<..1.22.l. "<I,m 19951• Also ill vivo ER binding to 
DNA was not prevented by SERMs (E"" 1991. "",'" 19951. However, for pure antagonists 
like ICI 164,384 and ICI 182,790 this matter seems more complicated. Some repOlis 
showed an impaired ill vitro DNA binding of ERs after treatment with the leI 
compounds (],,,,,II 199!). rub,,,,,, 19921. In contrast, others demonstrated ER binding to DNA 
when the receptor is occupied by leI (!..ru...1.2]2,Martinez 19S9,Ikm:..l29.Q, RruUm, Sabbab 1991. TrembJay 1998), 
Also ill vivo data are conflicting. Reese and Katzenellenbogen showed that ERs 
exposed to leI 164,384 ill vivo did not bind to DNA Ulli,'-.l22D. However, a report by 
Pham et al. demonstrated that leI 164,384 was able to induce ERE binding ill vivo 
(Phom 19911. Also, more recently leI-induced ill vivo ER-ERE binding was reported ~ 
-I 
Binding of the ER dimer to an ERE induces folding of DNA (S,bOOb 1222. N"",m 1223. 
",""II; 1293, N"',II; 19951. It is plausible that interaction of ERs with a SERM-induced 
conformation will result in folding of DNA distinct from the situation where the ER 
conformation is induced by E2. However, data from Pham et al. showed similar 
alterations of chromatin stl1lcture when ER is bound to E2 or the anti estrogen 
nafoxidene, although the DNAse I sensitivity assay used is not very sensitive (fllilm 
1221) 
Differences in DNA folding/conformation can be visualized to some extent 
in gel mobility shift assays. Several studies showed that an E2-ER-ERE complex 
had increased gel mobility compared to antiestrogen-ER-ERE complexes, indicating 
that distinct conformational differences between the agonistic- and antagonistic-ER-
ERE complexes exist (Kumar 198&,~.~,~,~, S3hbah 1991, Be.-i;!l1jlD 192}' ~l22.1). 
FUlihemlOre, work fi'om Klinge et al. provided ill1ll1unological data indicating that 
confOimations of E,-ER-ERE, tamoxifen-ER-ERE, and 4-hydroxytamoxifen-ER-
ERE are clearly distinct (K1inru.2'lQ.~I. 
In addition it was shown that stability and kinetics of ER-ERE complexes formed 
differed between ER ligands, IChdl; 19971 and also depended on flanking sequences of 
the ERE, as well as on cellular context (e.g. cell specific cofactors) (An2lik..122l. ~I. 
The stability of the ligand-induced ER-ERE complex may also differ among ER 
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subtypes. For instance, in gel mobility shift assays ICI 182,780 could not prevent loss 
of ERa binding to an ERE after temperature elevation, whereas ERP-DNA binding 
was not affected ID=l221). Furthennore, it was demonstrated that the agonistic activity 
of tamoxifen and nafoxidene depended on the ERE sequence itself a&nill2l) and on the 
promoter contcxt in which the ERE was studied /W"",b, (997). 
Homodimers of ERa or ER13, as well as ERalERB heterodimers have been described 
and it might be possible that each dimer interacts preferentially with a specific ERE. 
Differences in affinity between the three dimer forms (ERaIERa, ERaIERp, 
ERPfERP) for the same ERE is in this respect suggestive (eM/', (9971. Experiments with 
transfected COS-I cells showed that ERa has greater gene transcriptional activity via 
the luteinizing hOlTIlOne 13 ERE, whereas ERB preferentially activates vitellogenin 
ERE transcription (l'<nniill2i). Therefore, possible SERM-specific induction of a certain 
ER dimer form may lead to differential activation of ER target genes. 
Besides via EREs, ERs regulate gene transctiption via protein-protein interaction at 
AP-I elements (W''''' /995. ~). Webb et al. speculated that activation of AP-I-
mediated gene transcription by tamoxifen might underly tissue-specific agonistic 
effects of this SERM. This feature of tamoxifen might also underly tamoxifen-
stimulated growth of ER positive tumor cells (discussed in Section B.6.1.). In this 
respect, the observation of Johnston et al. is of interest. They observed increased AP-
I binding and c-jun NHrtelTIlinal kinase activity (an AP-I activating enzyme) in 
tamoxifen-treated ER positive breast tumors with acquired tamoxifen resistance 
compared to untreated tumors or tumors that were arrested in their growth by 
tamoxifen (IQh"wQ (999) Paech et al. repOlted differential activation of ERa and ERJ3 by 
E2 and SERMs at an AP-I element: With ERa, both E2 and SERMs stimulated gene 
transcription, whereas with ERB, E2 inhibited and the SERMs stimulated gene 
transcription ®«1Ll991). Interestingly, the ICI compounds were also able to activate AP-
I responsive genes via ERa and ERP 0I'<lllLl99.l.l\W..l221). 
Another example of ligand-specific interaction with regulatory elements in DNA is 
the strong ill vitro activation of the bone matrix protein TGF133 gene by raloxifene, 
tamoxifen, and ICI 164,384, but only weak activation by E2 via a sequence in the 
promoter region of the TGF133 gene, called the raloxifene response element ~). 
Interestingly, binding of the ER to this response element was not dependent on the 
DNA binding domain of the ER, indicating that an adaptor protein might interact ffing 
199O) 
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VI. COFACTOR INTERACTION AND CELLULAR CONTEXT 
III vitro studies revealed that identical repOlter constructs in different cell types gave 
contrasting results. In some cells SERMs acted as agonists, whereas in other cell 
types antagonistic propetties were observed (!km'-l22Q, \V,",oh< 1997). The ER contains two 
AFs (see Section B.2. and Figure 1.5) (IDeo 1989) and in some tissues full agonistic 
activity is only achieved when both AF-l and AF-2 are active, whereas in other 
tissues AF-I is sufficient to obtain maximal transcriptional activity of the ER tKlliJl<r 
]222). SERMs like tamoxifen and its metabolite 4-hydroxytamoxifen block AF-2 
activity, whereas AF-l activity is only pat1ially decreased 1\V"me' 198. !lm:lL!m). TIllS 
might explain the pattial agonistic/antagorllstic activity of these compounds in utents 
where the AF-I activity is high. In breast tissue, both AF-I and AF-2 are required for 
maximal transcriptional activity of the ER and here tamoxifen acts antagonistic t!km< 
m!I). However, cell- or tissue-specific differences in AF-I activity do not provide a 
complete explanation for the tissue-specific agonistic/antagonistic activity of 
tamoxifen, since tamoxifen also exetts agonistic activity in cells with low AF-I 
activity (e.g. endometrial and cervical cells), As already mentioned in Section V on 
DNA interaction, the activation of AP-I-mediated genes as suggested by Webb et al. 
{\v.bb 1995) as well as other transcription factor-mediated gene transcription processes 
might be involved. 
The cell-, and tissue-dependent activity of AF-l and AF-2 indicates that the 
cellular and nuclear context is an important detenninator in this respect. Therefore, 
presence and relative distribution of cofactors (both activators and suppressors), 
combined with the potency of the ER ligand to induce their interaction with the ER 
are likely important factors in deciding whether a SERM acts agorllstic or 
antagonistic in a specific cell type. Here, prevention of interaction of ERa and ERJl 
with the coactivators SRC-I, GRIPI, TIF2, ERAPI60 and RIPI40 by synthetic ER 
ligands like ICI 164,384, ICI 182,780, 4-hydroxytamoxifen and EM-800 is of interest 
(OwaiHh 1995, Halachmi 1994, Voege1I996. Schwartz 1998, Tremb!av 1998', Work of Shiau et al. demonstrated dear 
differences in ER folding and subsequent cofactor binding when an estrogen 
(diethylstilbestrol) or a SERM (4-hydroxytamoxifen) is bound. Binding of 
diethylstilbestrol to the ligand binding domain of ERa results in exposition of a 
hydrofobic groove fOlmed by residues from helix 3, 4, 5, and 12, and the tum 
between helixes 3 and 4. Within this groove interaction sites for cofactor GRIP I are 
located. In contrast, with 4-hydroxytamoxifen these sites are occluded by helix 12 
and, as a consequence, GRIP I binding is prevented ~). Also work of Nonis et 
al. using phage display indicated that E2- and SERM-mediated interaction with 
cofactors is distinct ~). 
A different distribution of ER subtypes in target tissues might be involved in 
tissue-selective agonistic or antagonistic activities of tamoxifen and other SERMs. 
Although both ERs are highly homologous (see Section B.2.), the NB domain 
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containing the AF- I function is poorly conserved (about 20%). It was shown that AF-
I of ERIl was not sufficient to activate ERIl bound to tamoxifen IW,,,,,'" 1997). However, 
tamoxifen regained agonistic activity with ERIl when its AlB domain was replaced 
with the NB domain of ERa IM,/"m" (998). Observations by Kobori et al. indicate that 
the cell-, and tissue-specific distribution of ER subtypes and cofactors might explain 
cell type-specific effect of ER ligands. They found that transactivation by E2 of ERE-
containing reporter gene constructs was much higher with ERIl than with ERa in 
osteoblast cell lines, whereas in non-osteoblast cell lines the transactivation activity of 
both receptors was reversed IK""," (998). 
In a rat prostate cDNA library an ERP splice variant (ERP2) was found with a 18 
amino acids inseliion within the hormone binding domain (11m>!," 1999). In contrast to the 
original ERP and ERa, ERP2 did not interact with the cofactor SRC-l and its 
sensitivity for E2 was 1000-fold lower (1/""", (999). Recently, ER subtype-selective 
interaction with cofactors was also described by Endoh et al. (Erufuh..Jm). They found 
that coactivator p68 specifically interacted with the AF-I region of ERa and not with 
ERp. In addition, Tremblay et al. showed that SRC-I and Ras enhanced the 
transcriptional activity of ERa only in the presence of E2, while the activity of ERP 
was enhanced by these cofactors both in the absence and presence of E2 (Tn'mbl,y (998). 
Fmihennore, celiain ligands and distinct DNA interaction sites (ERE, AP-l, SP I) 
might have a preference to bind one of the two ER subtypes (","per /997.K"", /998.!b:JkLl992). 
Therefore, more abundant expression of either ERa or ERP might influence the 
tissue- or cell-specific response. In this respect the report of Pujol et al. of a shift in 
the ratio ofERalERIl dUl'ing carcinogenesis of the OVaIY in favor of ERa is of interest 
(I'l!iillm) 
VII. LIGAND METABOLISM 
The efficacy of SERM delivelY via the blood stream and entrance of the SERM into 
the target cell will detelmine its local concentration in the target cell. Binding of the 
SERM to albumin, sex hormone-binding globulin, or other caITier proteins are 
impOliant aspects in this respect. In addition, SERMs might have a regulatory effect 
on the production of these sel1lm binding proteins. It was for instance shown that 
tamoxifen or droloxifene therapy of postmenopausal breast cancer patients increased 
the sel1lm sex hormone-binding globulin concentration (l!Q;'-.l'l'll.G,'>i" (995), whereas ICI 
182,780 had no effect moo,,!! 19961• FUlihemlOre, SERMs might interfere in the 
percentage free and protein bound E2. Tamoxifen therapy reduced the percentage of 
non-protein bound E, and albumin-bound E2, whereas it increased sex hormone-
binding globulin-bound E, (R2l<.l99l). Also, metabolic stability of the SERM, as well as 
the biological activity of the metabolites fonned might determine the eventual 
potency. These processes could be cell- or tissue-specific. However, for two major 
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metabolites of raloxifene (raloxifene-4' -Il-glucuronide and raloxifene-6-1l-
glucuronide) no target tissue-differential conversion to raloxifene was observed, 
indicating that the tissue-specific effect of raloxifene (agonistic in bone and 
antagonistic in ute11ls), does not result from tissue-selective deconjugation of these 
metabolites (Dodge 1997), 
VIII. NONGENOMIC EFFECTS 
Although little data on this topic are repOlied, it is known that SERMs also exeti 
nongenomic effects ~). It was found that tamoxifen had an inhibitOlY effect on 
protein kinase activity «(yBo" (985) and possibly induces apoptosis of a hypothalamic 
neuronal cell line via a nongenomic pathway (H""""" (991). 
C. SCOPE OF THE THESIS 
Several of the synthetic ligands of VDR (1,25-(OH)2D3 analogs) and ER (SERMs) 
have improved therapeutic characteristics compared to the natural ligands. For 1,25-
(OH)2D3 analogs, these include the increased divergence between effects on cell 
proliferation/differentiation and calcemic effects. For the SERMs, clinical relevance 
lies in an enlarged separation between beneficial effects on bone and the 
cardiovascular system on the one hand and effects on development and growth of 
breast and ute11lS cancer on the other hand. 
The mechanism(s) of action by which the synthetic ligands of VDR and ER 
determine the rate of gene transcription, often in a gene-, cell-, or tissue-dependent 
manner are largely unknown. Gene transcription is regulated by a complex cascade 
of events including ligand-receptor binding, receptor phosphOlylation, and 
receptor-DNA interaction. The aim of the studies presented in this thesis is to 
provide more insight into the processes playing a role in gene transcription 
regulation and to investigate the relevance of these processes to the altered 
biological profiles of synthetic VDR and ER ligands. 
Several aspects of interaction of 1,25-(OH)2D3 analogs and SERMs with their 
receptors were studied. In Chapter 2, the effects of 1,25-(OH)2D3 analogs on the 
growth and differentiation of osteoblast-like cells and the effect on ill vitJ'O bone 
resOlption were evaluated. A possible explanation for the observed increased 
biological activity of one of the most potent 1,25-(OHhD3 analogs, KHlO60 was 
fmiher investigated. We have studied its effect on the confonnational change and 
stabilization of the VDR (Chapter 3). The effect of nucleotide sequences of VDREs 
on 1,25-(OH)2D3- and KH 1060-induced VDRIRXR binding and transactivation was 
examined in Chapter 4. The contribution of metabolites to the biological potency of 
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the parent compound KHI060 is described in Chapter 5. In Chapter 6 we have 
studied the effect on ERa and ERG conformation by the SERMs tamoxifen, ICI 
164,384, and ICI 182,780. Finally, in Chapter 7, the results are discussed and 
summarized and suggestions for fmiher research are made. 
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CHAPTER 2 
DIFFERENTIAL EFFECTS OF 1,25-DIHYDROXYVITAMIN D3 
ANALOGS ON OSTEOBLAST-LIKE CELLS 
AND ON IN VITRO BONE RESORPTION 
Van den Bemd GJCM, Pols HAP, Birkenhiiger JC, Kieineko0l1 WMC, Van Leeuwen JPTM 
J Steroid Biochem Molec Bioi 55, 337-346,1995 
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2.1. ABSTRACT 
Although numerous studies have shown potent antiproliferative and 
differentiation-inducing effects of 1,25-(OH),D3 and its analogs on cells not 
directly related to bone metabolism, only few reports focussed on the effects of 
these analogs on bone. We compared the action of several recently developed 
analogs with that of 1,25-(OH),D3 on human (MG-63) and rat (ROS 17/2.8) 
osteoblast-like cells and on ill vitro bone resorption. In MG-63 cells the analogs 
EBI089 and KHI060 were about 166,000 and 14,000 times more potent than 
1,25-(OH),D3 in stimulating type I procollagen and 100 and 6,000 times more 
potent in stimulating osteocalcin production, respectively. Also in ROS 17/2.8 
cells EBI089 and KHI060 were most potent in inducing osteocalcin synthesis. 
III vitro bone resorption was 2.3 and 17.5 times more potently stimulated by 
EBI089 and KH1060, respectively. In MG-63 cells, 1,25-(OH),D3 and the 
analogs inhibited cell proliferation, whereas both 1,25-(OH),D3 and the analogs 
stimulated the growth of ROS 17/2.8 cells. Differences in potency could neither 
be explained by affinity for the VDR nor by a differential involvement of protein 
kinase C in the action of the analogs. Together, these data show that also in bone 
the analogs EBI089 and KHI060 are more potent than 1,25-(OH),D3' but that 
the potency of the analogs compared to 1,25-(OH),D3 is dependent on the 
biological response. On basis of these observations it can be concluded that the 
reported reduced calcemic effect in vivo is not the result of a decreased 
responsiveness of bone to these analogs. Lastly, in view of eventual clinical 
application of 1,25-(OH),D3 analogs, the observed stimulation of in vitro bone 
resorption and growth of an osteosarcoma cell line warrant ill vivo studies to 
further examine these effects. 
2.2. INTRODUCTION 
The central role of vitamin D in the regulation of calcium and bone metabolism 
is well established (R,k"<1 (950'. In addition, in 1981, Abe e/ al. (Ab< (n(, demonstrated 
that 1,25-(OH),D3 inhibited the proliferation and stimulated the differentiation of 
mouse myeloid leukemia cells. This finding was promising for the use of 1,25-
(OH),D3 in the treatment of hyperproliferative diseases and immunological 
disorders 0"'"'' (99". However, the high doses of 1,25-(OH),D3 needed to achieve 
these nonclassic effects may lead to undesirable side effects on calcium 
metabolism (hypercalcemia, hypercalciuria). This has prompted the development 
of 1,25-(OH),D3 analogs with potent cell growth regulating properties but 
relative low calcemic activity (CQb-to."'Il 1992, MathiMen 199), B~np In8. A~ )989, Bin&np 1991), Hithelto the 
ill vitro effects of these analogs were mostly studied in cells not directly related 
to bone and calcium metabolism. Therefore, knowledge on their effects on bone 
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and bone cells is limited and mainly restricted to the analogs MC903 and OCT 
!Marie 1990, Vahil 1990,~, P~mlkte 1991, Pol> 19911, In the present study, we have analyzed the 
effects of 1,25-(OH),D3 and several of its analogs with side chain modifications 
on osteoblast-like cells and on il/ vitro bone resorption and compared their 
potencies. These analysis may provide insights whether the il/ vivo observed 
reduced calcemic activity reflects a decreased responsiveness of the skeleton to 
these analogs. 
2.3. MATERIALS AND METHODS 
Reagel/ls 
Non-radioactive 1,25-(OH),D3 and the 1,25-(OH),D3 analogs MC903, CB966, 
EB1089, KHI049 and KHI060 were provided by dr. L. Bindemp, Leo 
Pharmaceuticals, Ballemp, Denmark. OCT was a gift from dr. N. Kubodera, 
Chugai Pharmaceutical Co., Ltd, Tokyo, Japan. Chemical stJuctures are depicted 
in Figure 1.3 The sterols were dissolved in absolute ethanol and stored at -20°C 
at a concentration of 10-4 M. [23,24-3H]-1,25-(OH),D3 (120 Ci/mmol) and "Ca 
were obtained fi'om Amersham International, Amersham, U.K .. Alpha minimal 
essential medium (aMEM) and neutral red were from Sigma Chemical Co., St. 
Louis, MO, USA. The rat osteocalcin antisemm was a gift of Prof. R. Bouillon, 
Katholieke Universiteit Leuven, Lem'en, Belgium. Penicillin, streptomycin, and 
L-glutamine were fi'om Gibco Life Technologies Ltd., Paisley, Scotland. Fetal 
bovine selUm was from Sera-Tech, St. Salvator, Germany. Biggers Gwatkin-
Judah medium was made using reagents fi'om Merck, Darmstadt, Germany. 1-0-
hexadecyl-2-0-methyl-rac-glycerol was purchased from Bachem AG, 
Bubendorf, Switzerland. All other reagents were of the best grade commercially 
available. 
Cells 
The human osteoblast-like MG-63 cells were provided by Prof. R. Bouillon, 
Katholieke Universiteit Leuven, Leuven, Belgium. The rat osteoblast-like 
osteosarcoma cell line ROS 17/2.8 and the non-osteoblast-like osteosarcoma cell 
line ROS 25.1 were a gift from dr. S.B. Rodan, Merck, Sharp & Dohme Research 
Laboratories, West Point, USA. The cells were cultured in aMEM supplemented 
with 2 mM L-glutamine, 100 units/ml penicillin, 100 flg/ml streptomycin, 0.1% 
D-glucose plus the indicated concentration fetal bovine semm or charcoal-treated 
fetal bovine semm. 
Osteocalcil/ measl/I'emellfs 
The cells were seeded in 24 wells culture plates at a density of 40,000 cells/em' 
72 
and cultured for 24 hours (MG-63) or 48 hours (ROS 1712.8) in aMEM plus 
10% fetal bovine serum. Next, the medium was replaced by aMEM with 2% 
charcoal-treated fetal bovine serum and the cells were cultured in the absence or 
presence of various concentrations of I,2S-(OH),DJ or its analogs. After 24 hours 
medium was collected and osteoca1cin content was determined. Osteoca1cin 
measurements in medium of ROS 17/2.8 cells were perfOimed according to the 
method described by Verhaeghe et al. {\'"'"",,I9S91. Osteocalcin measurements in the 
medium of MG-63 cells were perfOimed by radioimmunoassay (Incstar, 
Stillwater, MN, USA). 
Type I pI"ocollagellmeaslII"emellts 
MG-63 cells in aMEM plus 10% fetal bovine serum were seeded in 24 wells 
culture plates at a density of 40,000 cells/em'. After 24 hours medium was 
replaced by aMEM with 2% charcoal-treated fetal bovine serum and the various 
concentrations of 1,2S-(OH),DJ or its analogs. After 24 and 48 hours media were 
collected and analyzed for type I procollagen by radioimmunoassay (Orion 
Diagnostica, Espoo, Finland). 
Proliferatioll assay 
Cell proliferation was studied using the neutral red assay described by L6wik et 
al. I"'" 19931. The absorbance of neutral red is proportional to the number of viable 
cells. In short, 1,000 MG-63 cells/em' and 3,000 ROS 17/2.8 or ROS 2S.1 
cells/em' were seeded in a 96 wells plate and cultured for 24 hours in aMEM 
plus 10% fetal bovine serum. After 24 hours the medium was replaced by 
aMEM with 2% charcoal-treated fetal bovine serum with or without various 
concentrations of 1,2S-(OH),D3 or 1,2S-(OH),OJ analogs. After 3 days medium 
was replaced by new medium with or without the adition of the various analogs. 
After 6 days SO III of a neutral red solution (0.5 mg/ml in 0.9% NaCl) was added 
to each well for a 90 minutes incubation. Next, the medium was removed, the 
wells were washed twice with 100 [II phosphate-buffered saline and the neutral 
red was extracted from the cells with 100 [II 0.05 M NaH,P04 in 50% ethanol. 
The absorbtion was measured at 540 nm (630 nm reference filter) in a microplate 
reader (Bio-Rad 450). All measurements were performed in quadruplicate and 
expressed as the percentage of control optical density (00) values. 
BOlle I"esOIptioll assay 
TIle ill vitro bone resorption assay was perfOimed with 17-day-old fetal mouse 
radii/ulnae, using a method based on the fetal rat limb explant assay described by 
Raisz I","' 1%51. By injecting the mother on day 16 of gestation with 30 IlCi of 4'Ca, 
the fetal radii/ulnae were labeled ill utero. After explantation on day 17 the 
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radii/ulnae were precultured for 24 hours in 400 /11 of Biggers Gwatkin-Judah 
medium with 5% charcoal-treated fetal bovine serum at 37°C, to reduce free 
exchangeable calcium. Next, the medium was changed to Biggers Gwatkin-
Judah medium supplemented with 5% charcoal-treated fetal bovine serum with 
or without various concentrations of 1,25-(OH),D3 or analogs. After 3 days the 
medium was replaced by fi'esh medium, i.e. with or without 1,25-(OH),D3 or the 
analogs. The 4lCa content of the medium at 3 and 6 days of culture and of the 5% 
fOlmic acid extracts of the bones was measured by liquid scintillation counting 
and used to calculate the total 'lCa and the cumulative percentage 45Ca released. 
VDR billdillg studies 
The competitive receptor binding assays were performed as previously described 
(po' 1'8S). Receptor protein was prepared by cytosolic extraction on ice of MG-63 
and ROS 1712.8 cells with a hypertonic buffer consisting of 10 mM Tris-HCl, 
300 mM KCl, I mM EDTA, 5 mM dithiothreitol, 10 mM sodiummolybdate and 
0.1 % Triton X-I 00 (PH 7.4). After centrifugation at 100,000 g for I hour at 4°C, 
the cytosolic extracts (250 /11, ± I mg protein/ml) were incubated at 0 °C with 0.5 
nM [23,24-3H]-1,25-(OH),D3 and increasing concentrations of non-radioactive 
1,25-(OH),D3 or 1,25-(OH),D3 analogs. After 3 hours the bound and fi'ee [23,24-
3H]-1,25-(OH),D3 were separated by charcoal adsorption. Concentrations of 
1,25-(OH),D3 or the analogs at which half-maximal displacement of [23,24-3H]-
1,25-(OH),D3 was achieved were calculated. 
DNA measuremellfs 
DNA measurements were performed according to the method of Karsten and 
Wollenberger (Kmko 1977). 
Statistical allalysis 
The data shown are the mean of at least two independent experiments each 
consisting of two-four separate cultures. For clarity purposes standard deviations 
were not depicted in the figures. In all cases standard deviations were smaller 
than 10%. 
2.4. RESULTS 
Effect of 1,25-(OH}!J3 alld 1,25-(OH)!J3 allalogs 011 osteocalcill productioll by 
MG-63 aud ROS 1712.8 cells 
In both cell lines 1,25-(OH),D3 and the analogs stimulated osteocalcin 
production in a dose-dependent manner (Figure 2.1). Besides differences in 
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median effective dose (ED,o), in MG-63 cells but not in ROS 1712.8 cells, also a 
difference in maximal response was detected. 
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Figure 2.1. Effect of 1,25-(OH),D3 and 1,25-(OH),D3 analogs on osteocalcin 
production in MG-63 (A) and ROS 1712.8 cells (B). The cells were stimulated with 
1,25·(OH}]D3 or tlze 1,25-(OH)2D3 allalogs Jar 24 hOIll~ alld osteoealcill was measured as 
described ill Materials alld Methods, Sectioll 2.3. 
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The maximal stimulation of osteoca1cin production by the compounds with the 
lowest ED,o (KHI060, EB1089, KHI049) was about twice that of 1,25-(OH),D1, 
OCT, and CB966 (Figure 2.1A: 1,25-(OH),D3' OCT, EB1089, KHI060). Except 
for KHI060 and KHI049, the ROS 17/2.8 cells appeared to be more sensitive for 
I ,2S-(OH),D1 and the analogs than the MG-63 cells (Table 2.1). 
Effect of J,25-(OH),D] alld J,25-(OH),D] allalogs 011 type I procollage/l 
productio/l by MG-63 cells 
The effect on type I collagen synthesis was assessed by measuring the 
concentration of carboxy terminal propeptide of type I procollagen ~I,!llo '990) in the 
medium ofMG-63 cells after 24 and 48 hours treatment with 1,2S-(OH),D3 or its 
analogs. Figure 2.2 shows the dose-response curves after 48 hours of incubation 
with 1,2S-(OH),D3 and the most potent analogs. 
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Figure 2.2. Effect of 1,25-(OH),D3 and 1,25-(OH),D3 analogs on the 
production of type I pro collagen by MG-63 cells after 48 hours of 
incubation. Medfllm was evaluated for type I procolfagell content by radioimmunoassay as 
described in Materials alld }vlethods. SectioJ12.3. 
KHlO60 and EBlO89 were about 14,000 and 166,000 times respectively more 
potent than 1,2S-(OH),D3' The ED,o's were 7xlO·J3 M and 6xlO·14 MfaI' KHlO60 
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and EB1089, respectively, and lxlO-' M for 1,25-(OH),DJ• Only a slight effect of 
the sterols could be detected after 24 hours of culture (data not shown). 
TABLE 2.1. Effects of 1,25-(OH),D3 and 1,25-(OH),D3 analogs on 
osteocalcin production and cell proliferation and their affinity for the VDR 
---
MG-63 Cells 
Compound Osteocalcin Growth Relative affinity for 
production inhibition the VDR 
ED" (M)(') ED,,(M) 
1,25-(OH)2D, 6xJO-IO (I)~) IxJO·' (I) 1 (c) 
OCT 6xJO- IO (I) 3x10-' (3) 0.15 
MC903 ND IxIO-' (I) 0.21 
CB966 2x10-IO (3) 2x10·9 (5) 0.70 
EBJ089 6XJO-12 (100) 5xJO· ll (200) 0.71 
KHJ049 2XJO-12 (300) 6XJO-12 (1,660) 0.22 
KHI060 IxlO-13 (6,000) 4xJO-I' (250,000) 0.29 
ROS 17/2.8 Cells 
Compound Osteocalcin Growth Relative affinity for 
production inhibition the VDR 
ED" (M)(') ED" (M) 
r-
1,25-(OH)2D, 4XJO-12 (I) 2x10-IO (I) 1 
OCT 5x 1 0-12 (0.8) 6xl 0-10 (0.3) 0.08 
MC903 4x10-12 (I) ND 0.33 
CB966 2xI0-12 (2) ND 0.80 
--
EBI089 IxIO-14 (400) Ix10-14 (20,000) 0.80 
-----
KHI049 IxJO-12 (4) ND 0.19 
KHI060 IxIO-I' (40) Ix 1 0.12 (200) 0.20 
-~ 
The effect of 1,25-(OH),D3 and the analogs on the production of osteocalcin 
was measured by radioimmunoassay. Cell proliferation was determined by the 
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neutral red assay after 6 days of culture in the presence of 1,25-(OH)lD3 or the 
analogs. Binding to the VDR was measured in cytosolic extracts by 
displacement of [23,24-3H]-1,25-(OH)lDJ. ('jThe concentration needed to 
achieve the half-maximal effect of 1,25-(OH)P3 is designated as ED,o' (bjThe 
potency of the analogs (at ED,o) was calculated in relation to that of 1,25-
(OH)lDJ. (ojResults are expressed as relative affinity (at half-maximal 
displacement) in comparison with 1,25-(OH)lD3' The data are the mean of three 
independent experiments. ND: Not detennined. 
Effect 011 tile pro/ij'eratioll of MG-63 cells alld ROS 17/2.8 cells 
The proliferation of the human osteoblast-like cell line MG-63 was inhibited by 
1,25-(OH)lD3 and the analogs tested. No significant difference in maximum 
inhibitory effect (approximately 45%) between 1,25-(OH)lD3 and the analogs 
was found. Figure 2.3A shows dose-response curves of 1,25-(OH)PJ, OCT, 
EB1089, and KHlO60 after 7 days of culture. The ED,o's and the potencies 
relative to 1,25-(OH)lDJ (at ED,o) for these and the other analogs are sununaIized 
in Table 2.1. 
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Figure 2.3. Effect of 1,2S-(OH),D3 and 1,2S-(OH),D3 analogs on the 
proliferation of MG-63 (A) and ROS 1712.8 cells (B). The effects 01/ cell 
proliferation were studied using the neutral red assay. See ~Materials alld A1etllOds, Section 2.3. 
I7w data represent the mean percelltage of control OD values. 
KHlO60 was the most effective analog (ED5o was 4xlO·14 M compared to IxlO-8 
M for 1,25-(OH},DJ). KHlO49 and EB 1 089 also were more potent than 1,25-
(OH),DJ; 25 and 200 times respectively, whereas the other analogs were 
equipotent or only slightly more potent (Table 2.1). 
In contrast to MG-63 cells, the growth of the rat osteoblast-like cells ROS 
17/2.8 was not inhibited but stimulated by 1,25-(OH},DJ and the analogs tested. 
The proliferation was stimulated in a dose-dependent manner and no significant 
difference in maximum effect between 1,25-(OH),D3 and the analogs was 
observed (Figure 2.3B). EBlO89 and KHlO60 were most potent, reaching 50% 
growth stimulation at IxlO-14 M and Ix 10-1' M, respectively, compared to 2xlO-IO 
M for 1,25-(OH),DJ (Table 2.1). Changing culture conditions (serum free and 
serum containing medium) and seeding density did not change the effect of 1,25-
(OH},DJ and the analogs (data not shown). The observed stimulation of the 
proliferation by 1,25-(OH},D3 and the analogs was confirmed by cell counts 
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using a Coulter counter (Sysmex-Toa, model F-300, Kobe, Japan). 
Effect of 1,25-(OH)1>3 alllll,25-(OH)1>3 allalogs 011 ill vitro bOlle resorptioll 
1 ,25-(OH),D3 and all analogs tested stimulated ill vitro bone resorption in a dose-
dependent manner, both after 3 and 6 days of culture. Figure 2.4 shows the ill 
vitro bone resorption activity of 1,25-(OH),D3 and the analogs OCT, EB 1089, 
KH 1049 and KH 1060 after 6 days of culture. In Table 2.2 the concentrations of 
the sterols leading to a half-maximal "Ca release after 6 days of culture and the 
relative potency compared to the EDso of J ,25-(OH),DJ are presented. There was 
no difference in EDso-values between 3 and 6 days of culture (data not shown). 
KHI049, KH1060, and EBI089, analogs with a far more potent effect on 
extracellular matrix synthesis and cell proliferation, were also more potent than 
J,25-(OH),D3 in inducing ill vit/'o bone resorption (35, 17.5, and 2.3 times more 
potent, respectively), whereas CB966 and OCT were as potent as 1,25-(OH),D3• 
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Figure 2.4. Effect of 1,25-(OH),D3 and 1,25-(OH),D3 analogs on 4SCa release 
from fetal mouse radii and ulnae after 6 days of culture. For details see Materials 
alld Methods. Sectioll 2.3. 
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TABLE 2.2. Stimulation of ill vitro bone resorption by 1,25-(OH),D3 and the 
analogs after 6 days of culture 
COMPOUND EDso (MY') Potency 
relative to 1,25-(OH),D3 
1,25-(OH),03 7xlO-11 
CB966 7x1O- 11 
OCT 6x 10-11 1.2 
EBI089 3xIO-11 2.3 
KHI060 4xIO-12 17.5 
KHI049 2xlO-12 35 
The ill vitro bone resorptive activity of 1,2S-(OH),OJ and the analogs was 
determined by measuring 45Ca release from pre-labeled radii/ulnae from fetal 
mice. (')The concentration needed to achieve the half-maximal effect of 1,25-
(OH),DJ is designated as EOso' The E050 values are the mean of three 
independent experiments. 
Ability of tile 1,25-(OH),DJ allalogs to compete witll 1,25-(OH),DJ fo/' billdillg 
to tile VDR 
In view of the potent effects of some analogs the ability to bind to the VDR fium 
MG-63 and ROS 17/2.8 cells was examined. Displacement studies performed 
with cytosolic extracts demonstrated that all analogs exhibited lower affinity for 
the VDR compared to 1,25-(OH),OJ (Figure 2.5). In both cell types similar 
results were obtained (Table 2.1). 
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Figure 2,5. VDR affinity of 1,2S-(OH),D3 aud the 1,2S-(OH),D3 analogs. High 
salt cytosolic extracts of MG-63 cells were incubated with 0.5 nM 3H-l,25-(OHJ2D3 alld 
increasing concentrations of 1,25-(OH)2D3 or 1,25-(OHhD3 analogs as described in 
Materials and Methods, Sectioll 2.3. 
Effect of 1,25-(OH)J>3 amI KH1060 011 tlte pl'olijeratioll of ROS 25.1 cells 
Regarding the very potent effects of some analogs and their reduced affinity for 
the VDR we further examined the role of the VDR. The ROS 25.1 cell line is a 
non-osteoblast-like rat osteosarcoma cell line with no detectable VDR 
expression. The growth of ROS 25.1 cells was not affected by neither 1,25-
(OH),D3 nor by the potent regulator of proliferation in both MG-63 and ROS 
17/2.8 cells, KHI060. In addition, as expected, also no effects on osteocalcin 
production by 1,25-(OH),D3 or the analogs OCT, KH1049, EB 1089, and 
KH1060 were observed (data not shown). 
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Role o/proteill killase C iIl1,25-(OH))), alld 1,25-(0H),D, alia logs stimulated 
osteocalcill productioll 
Considering the dissociation between VDR binding and biological activity and 
the fact that protein kinase C has been shown to playa role in 1,25-(OH),D3 
action in bone CVm l~""" ''''') an attempt was made to investigate a differential 
involvement of protein kinase C in the action of 1,25-(OH),D3 and the analogs. 
To examine the role of protein kinase C in the stimulation of osteocalcin 
production we cultured the ROS 17/2.8 cells with various concentrations of 1,25-
(OH),D3 01' analogs, in combination with I-O-hexadecyl-2-0-methyl-rac-
glycerol (25 11M), a specific inhibitor of protein kinase C. In both the 1,25-
(OH),D,- and analogs-incubated cells I -O-hexadecyl-2-0-methyl-rac-glycerol 
decreased the maximal osteocalcin production to similar extent (± 40% 
inhibition). I-O-hexadecyl-2-0-methyl-rac-glycerol did not cause a shift in EDso 
values (data not shown). 
2.5. DISCUSSION 
The present study demonstrates that in bone the same analogs are more potent 
compared to 1,25-(OH),o3 than, as has been reported before, in cells not directly 
related to bone and calcium metabolism. However, the potency of the analogs 
compared to 1,25-(OH),D3 is dependent on the biological response. For example, 
the analogs KH I 060 and EB I 089 are far more potent stimulators of type I 
procollagen and osteocalcin synthesis than 1,25-(OH),D3' whereas the 
di fferences in EDso for the stimulation of bone resorption are less marked. This 
observation indicates that, at least in an ill Vi/I'O situation, for these analogs the 
balance between stimulation of bone matrix proteins synthesis and bone 
resorption is in favor of bone f0ll113tion (Table 2.3). One may hypothesize that 
both analogs may direct the osteoblast to a more mature phenotype with higher 
bone formation capabilities without affecting bone resorption in a similar way. 
The shift in the balance between bone resorption and bone fonnation in favor of 
bone formation is an interesting charactetistic for a possible application in 
metabolic bone diseases. Although the use of 1,25-(OH),D,Iderivatives is still 
controversial (l'.ru" I9SS. ""', ,,,,. F"r" 1992" several studies have shown positive effects of 
vitamin D metabolites, e.g. 1,25-(OH),D3, in the treatment of metabolic bone 
diseases (G,II"ho 1982. Riw '98". Treatment with vitamin D compounds has been shown 
to reduce bone mineral loss (A'",. 1988. G".,h" '."') and to reduce vertebral fracture rates 
1TI1rard 1992) 
III vivo studies have demonstrated that some of these analogs have a 
reduced ca1cenlic activity (C()I;\On I99UIlt11i1.$\'n 1993, Bin&nm ]988. At.: 1%9, BinOOup 1991, Vmun 1993). However, 
despite a favorable balance between bone resorption and bone fOlmation, both 
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EBI089 and KH1060 still exert an increased ill vitro bone resorptive activity 
compared to 1,25-(OH),D3• Therefore, the present data show that the reduced 
calcemic activity of the analogs ill vivo is not the result of a decreased 
responsiveness of bone to these analogs. Considering ill vivo application of 1,25-
(OH),D3 analogs to inhibit tumor cell growth the present observations are 
important in view of the relationship between stimulated bone resorption and 
increased risk for bone metastases (Orr 1993,. Also, in patients with malignant tnmors 
and active Paget's disease the first metastases were found in the page tic bone 
lesions with high bone resorption and fOimation (A,", 1976. "'"'u '''''. 
In relation to the use of 1,25-(OH),D3 analogs as antitnmor agents the 
observed stimulation of ROS 17/2.8 cell growth by 1,25-(OH),D3 and the 
analogs is also significant. The more so, since Yamaoka et al. O'~o'" 19i6) reported 
that 1,25-(OH),D3 promoted the growth of tnmors arising from intracutaneous 
inoculations of athymic nude mice with ROS 1712.8 cells. Furthennore, 1,25-
(OH),D3 also stimulated the fOimation of skin tnmors in mice treated chronically 
with 7, l2-dimethylbenz[alanthracene (\\'ood '''''. 
TABLE 2.3. Ratio of the EDso's for stimulatiou of ill vitro bone resorption 
aud stimulation of extracellular matrix synthesis 
Compound Bone Bone Bone 
resorption / resorption / resorption / 
Osteocalcin Osteocalcin Type! 
MG-63 Cells ROS 1712.8 procollagen 
Cells MG-63 Cells 
1,25-(OH),D, 0.1 17.5 0.007 
-
OCT 0.1 12 ND 
EB1089 5 3,000 500 
KH1060 40 40 5.7 
A ratio> I indicates stimulation of the synthesis of the extracellular matrix 
proteins at lower concentrations than stimulation of bone resorption whereas a 
ratio <I indicates the opposite situation. ND: Not determined. 
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With low concentrations of 1,25-(OHl,D3 stimulation of ill vitro cell proliferation 
has been described before (~hksb. 19$2, FreJi;e 1981, MangeL<dorf 1934, Dol;clI 19&4J, Although at higher 
1,25-(OHl,D3 concentrations usually a growth inhibition is observed some 
studies reported also at these concentrations a stimulation of cell proliferation ~ 
!22>l. v," AWc" 19". hh'ru 1993). It has been argued that the observation of growth stimulation 
is due to culture conditions or cell density IR"""I9S4.E;;mml9S". However, in our hands, 
experiments performed in seium free conditions and in 2% charcoal-treated fetal 
bovine semm containing medium resulted in similar effects and no relationship 
between seeding density and the 1,25-(OHl,D3 effects on proliferation could be 
demonstrated. Another explanation for the differential actions of 1,25-(OHl,D3 
on cell proliferation might be the large heterogeneity within the ROS 17/2.8 cell 
line {Van Aukm 1994, GrigQriadisl955, Spiess 19S6,Maie;b.1982l, In contrast to ROS 17/2.8 cells, with MG~ 
63 cells a growth inhibition was observed. Interestingly, in both cells the same 
analogs were, although opposite, the most potent growth regulators. This 
different growth regulation does not reflect a general difference between these 
cell lines because in both cell lines 1,25-(OHl,D3 and the analogs stimulated the 
osteoca1cin production. 
All analogs examined have a lower affinity for the VDR in comparison 
with the natural ligand. Despite a decreased VDR affinity, the analogs were 
equipotent or far more potent in their biological responses. Other studies also 
reported a dissociation between receptor affinity and biological activity {ll"'-'"" 1991. 
Pmllkte 1991, Calmley 1994, P~r 1992, Vink-VaIl Wiing<!J.fd,;n 1994, A~ 19871, Therefore, it can be concluded that 
VDR affinity is not predictive for the biological activity of the 1,25-(OHl,D3 
analogs. Posner et al. (po;oc, (992) suggested that the biological action of the analogs 
they tested is not regulated via binding to the VDR. However, the findings of 
others 0'=010 1986. ""''''' 1984. '"- 1987) and our own results obtained with VDR deficient 
ROS 25.1 cells underline that presence of the VDR is essential for biological 
activity of 1,25-(OHl,D3 and the analogs. In addition, Carlberg et al. IC"lbm 19''') 
recently demonstrated that the analogs studied in the present paper are able to 
activate gene reporter systems both via the VDR homodimer and the VDRlRXR 
heterodimer pathway. In this respect it is tempting to speculate about a 1,25-
(OHl,D3- or analog-specific induction of homo- or heterodimer fonnation. A 
possible higher sensitivity of the VDR target genes for one of these signalling 
pathways might then explain the observed differences in potency between 1,25-
(OHl,D3 and the analogs. 
Although the exact role of DBP is not clear, its presence can affect 1,25-
(OHl,D3 action. On the one hand it is known that DBP decreases the free 
concentration of 1,25-(OHl,D3 in the circulation. In both il/ vivo (Em"n 1992. """ (991) 
and il/ vitro studies IV"""m 1988. BOk 1989) DBP was shown to limit the access of 1,25-
(OHl,D3 to the target cells. Therefore, analogs with low affinity for DBP, and 
thus a high free concentration, may have more potent cellular effects. On the 
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other hand, the unbound sterol is less protected against degradation and cleared 
more rapidly. For OCT the low DBP affinity has been put forward as an 
explanation for the decreased calcemic effect ill vivo (Oboo (9&9,). However, the 
differences in potency between 1,25-(OH),DJ and the analogs we observed 
cannot solely be explained by a lower affinity for DBP, since both equipotent 
(OCT) and much more potent analogs (EB1089 and KH1060) exhibit diminished 
affinity for DBP compared to I 25-(OH) D (C"Ct<" (99( Oboo 19&9') Also studies 
, 2 3 ., 
performed with different cellular conditions, e.g. in the absence or presence of 
serum, resulted in similar differences in potency between 1,25-(OH),DJ and the 
analogs (our unpublished observations). 
Since the observed increased potency in biological responses could not be 
explained by a stronger affinity for the VDR and probably not by a lower affinity 
for DBP, other nonclassic mechanisms of action might playa role. As we have 
repOited earlier (Vm L<,~tt 1992'" protein kinase C is involved in the action of 1,25-
(OH),DJ in bone and bone cells. I-O-hexadecyl-2-0-methyl-rac-glycerol, a 
specific inhibitor of protein kinase C, inhibited the 1,25-(OH),DJ stimulated 
osteocalcin production in ROS 17/2.8 cells and in non-transformed isolated fetal 
rat osteoblasts. In the cunent study we investigated the role of protein kinase C in 
the action of 1,25-(OH),DJ analogs on osteocalcin production in ROS 17/2.8 
cells. The finding that I-O-hexadecyl-2-0-methyl-rac-glycerol inhibited the 
1,25-(OH),DJ and 1,25-(OH),oJ analogs stimulated osteocalcin production to the 
same extent without a shift in ED50, suggests that the protein kinase C sigualling 
pathway is not differently regulated by 1,25-(OH),DJ and the analogs. In other 
words, activation of protein kinase C by the 1,25-(OH),DJ analogs can not 
account for the large difference in potency compared to 1,25-(OH),DJ in the 
stimulation of osteocalcin production. 
Although the mechanism(s) underlying the differential changes in 
biological potencies remains unknown, the present data show that modifications 
in the side chain of the 1,25-(OH),DJ molecule can lead to analogs with 
enhanced potential in osteoblast-like cells and on ill vitro bone resorption. 
Lengthening of the side chain, especially in combination with the introduction of 
double bonds (EB 1089) or an altered stereochemistry at position C-20 and 
substitution of an oxygen atom at C-22 (KHI060, KHI049) results in 1,25-
(OH),DJ analogs with enhanced biological activity within osteoblast-like cells. 
Furthennore, the analogs EB 1089 and KH 1060 exhibit characteristics that might 
be promising for the application of 1,25-(OH),DJ analogs in case of metabolic 
bone diseases. The increase in bone resorption induced by these analogs and the 
observed stimulation of the proliferation of an osteosarcoma cell line by 1,25-
(OH),DJ and the analogs urges caution in the systemic application of these 
compounds in the treatment ofhypetproliferative disorders like cancer and points 
out that further investigations on longterm ill vivo and ill vitro responses are 
required. 
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CHAPTER 3 
CONFORMATIONAL CHANGE AND ENHANCED 
STABILIZATION OF THE VITAMIN D RECEPTOR BY 
THE 1,2S-DIHYDROXYVITAMIN D3 ANALOG KHI060 
Van den Bemd GJCM, Pols HAP, Birkenhiiger JC, Van Leeuwen JPTM 
Proe Nat! Aead Sci USA 93, 10685-10690, 1996 
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3.1. ABSTRACT 
The 1,25-(OH)2D3 analog KHl 060 exerts velY potent effects on cell proliferation 
and cell differentiation via the VDR. However, the activities of KH1060 are not 
associated with an increased affinity for the VDR. We now show that increased 
stabilization of the VDR-KH1060 complex could be an explanation for its high 
potencies. VDR half-life studies performed with cycloheximide-translational 
blocked rat osteoblast-like ROS 1712.S cells demonstrated that, in the absence of 
ligand, VDR levels rapidly decreased. After 2 hours less than 10% of the initial 
VDR level could be measured. In the presence of 1,25-(OH)2D3' the VDR half-
life was 15 hours. After 24 hours less than 20% of the initial VDR content was 
detectable, whereas, at this time-point, still SO% of the VDR was present when 
the cells were incubated with KH1060. Differences in 1,25-(OH)2DJ- and 
KHI060-induced conformational changes of the VDR could underlie the 
increased VDR stability. As assessed by limited proteolytic digestion analysis, 
both 1,25-(OH)2DJ and KH1060 caused a specific conformational change of the 
VDR. Compared to 1,25-(OH),o3' KH1060 induced a conformational change 
which led to a far more dramatic protection of the VDR against proteolytic 
degradation. In conclusion, the altered VDR stability and the possibly underlying 
change in VDR conformation caused by KHI060 could be an explanation for its 
enhanced bioactivity. 
3.2. INTRODUCTION 
Besides the traditional effects on calcium and phosphate metabolism 'R<i"<II9&9', the 
effects of 1,25-(OH)2DJ on cellular differentiation and proliferation and on 
immunological processes (Dikl, 1992) might have relevance for the treatment of 
hyperproliferative and autoimmune diseases. However, the side effects 
(hypercalcemia and hypercalciuria) induced by the high doses needed to achieve 
these effects limit the use of 1 ,25-(OH)2D3 in clinical practice. This has prompted 
the development of new 1,25-(OH),o3 analogs with reduced calcemic activity. 
Previous studies have shown that modifications in the side chain of the 
1,25-(OH)2D3 molecule can lead to far more potent analogs. One of the most 
potent analogs until now, KH 1 060 ""W"" '9951, is a strong inhibitor of tumor cell 
growth ffiin&rup 1991, Vink.van Wijngwokn 1994) and an inducer of cell differentiation rnin.krup 1991. BnmTl 
199'. y~ d" 8,," 19951. KH 1 060 also exhibits strong immunosuppressive activity in both 
ill vitro and ill vivo studies fBind<np 1991,Vmon 199J, 1>hthieu 19951, Furthermore, KHI060 is more 
potent than 1,25-(OH)2DJ in stimulating ill vivo and ill vitro bone resorption and 
osteoclast recruitment in murine bone ma11'OW cultures (ll~rupl991, Van den Btmd 1995, Wiberg 1995), 
The differences in biological activity between 1,25-(OH)2DJ and KHI060 
could not be explained by an increased affinity for the VDR rum&", 1991. yrnt,Y" "ij"g'''''''' 
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l22J. V,,"', B,,", '99". However, the presence of a (functional) VDR is essential for the 
biological responses of 1,25-(OH),D3 and KHI060 0'm"',B,mJ 1995.Eu_19S1. EC,"""". It is 
known that, through binding to the VDR, 1,25-(OH),D3 stabilizes the receptor 
celli" 1986.lVi,re '991.~). Since VDR stabilization might influence biological activity 
of the ligand, we studied the effect of KH 1060 on the VDR half-life in ROS 
17/2.8 osteoblastic cells. We examined the effect of KHI060 on the 
confomlation of the VDR. A 1,25-(OH),D3 analog with normal stereochemisoy 
at C-20 but, like KH1060, with an oxygen atom at the C-22 position, OCT was 
used as a reference compound in this study. 
3.3. MATERIALS AND METHODS 
Reagents 
1,25-(OH),D3 and the analog KHI060 were generously provided by dr L. 
BindeIUp (Leo Pharmaceutical Products, Ballerup, Denmark). OCT was a gift 
from dr N. Kubodera, Chugai Phann3ceutical Co., Ltd., Tokyo, Japan. The 
chemical structures of 1,25-(OH),D3' OCT, and KHI060 are depicted in Figure 
1.3. rRNasin ribonuclease inhibitor, luciferase DNA, brome mosaic virus RNA, 
and the coupled ill vitro o'anscription and o'anslation rabbit reticulocyte lysate 
system (TNT lysate assay) were purchased from Promega, Madison, WI, USA. 
[23,24-3H]-1,25-(OH),D3 (120 Cilmmol), L-[35 S]methionine (> I ,000 Ci/mmol), 
and Enhanced Chemiluminescence Western blotting reagents were obtained fi'om 
Amersham International, Bnckinghamshire, UK. aMEM, cycloheximide, 
oypsin, and chymohypsin were from Sigma Chemical Co., St. Louis, MO, USA. 
Proteinase K was obtained from Boehringer Mannheim, Germany. N,N,N',N'-
tetramethylethylenediamine and ammonium pC/'sulfate were obtained from 
BioRad Laboratories, Richmond, CA, USA. AClylamide and 
methylenebisacrylamidc were purchased from Pharmacia Biotech, Uppsala, 
Sweden. The human VDR cDNA was a generous gift fi'om dr M.R. Haussler 
(University of Arizona, Tucson, AZ, USA). Nitrocellulose was ii-om Schleicher 
& Schuell, Dassel, GClmany. Penicillin, streptomycin, and L-glutamine were 
fi'om Gibco Life Technologies Ltd., Paisley, Scotland. Fetal bovine seIUm was 
purchased fi'om Sera-Tech, St. SalvatoI', Gennany. 
Cells 
The rat osteoblast-like osteosarcoma cell line ROS 1712.8 (kindly provided by dr 
S.B. Rodan, Merck, Sharp & Dolnne Research Laboratories, West Point, PA, 
USA) was cultured in aMEM supplemented with 2mM L-glutamine, 100 
unitslml penicillin, 100 ).Ig/ml sO'eptomycin, 0.1% D-glucose, and 10% fetal 
bovine serum. Incubations with 1,25-(OH),D3, OCT, KH1060, or vehicle were 
performed in the presence of2% charcoal-o'cated fetal bovine SCIUm. 
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VDR stability study 
ROS 1712.S cells (2.0x I 06) were seeded in 100x IS mm tissue culture dishes and 
cultured for 2 days. Then, at SO% confluency, medium was changed to 2% 
charcoal-treated fetal bovine semm aMEM containing 10 11M cycloheximide to 
block translational activity and thereby new synthesis of VDR. Next, vehicle, 
1,2S-(OH),D3' OCT, or KHI060 (lxlO,8 M) was added and, after vmying 
incubation periods, cell exh'acts were prepared by Dounce homogenization in 
SOO ~ll TED buffer (SO mM Tris-HCI, pH 7.4, I.S mM EDTA, SmM 
dithiothreitol) and an equal volume of TED buffer with 600 mM NaCI according 
to the method described by Wiese et al. ov;,~ ""'. The supematants were liozen in 
liquid N, and stored at -SO°C until they were assayed for VDR content using the 
immunoradiometric assay described by Sandgren and DeLuca '''''''''" ,m,. 
III vitro trallscriptioll alld trallslatioll 
Human VDR cDNA (lllg) inserted into the EcaRI site of pOem 4 ,""" 1985) was in 
vitro transcribed with Sp6 RNA polymerase and translated in the presence of 
[31Sjmethionine and ribonuclease inhibitor rRNasin, using Promega's TNT lysate 
assay according to the manufacturer's instmctions. Brome mosaic vims RNA and 
luciferase DNA were used as templates in the TNT lysate assay for the 
production of molecular mass markers. 
Limited proteolytic digestioll o/ill vitro sYlltltesized VDR proteill 
The ill vitro synthesized VDR protein was treated for 20 minutes at room 
temperature with various concentrations of 1,2S-(OH),D3' OCT, KH 1060, the 
noncognate ligands all-trans retinoic acid, 9-cis retinoic acid, E" thyroid 
hormone, progesterone, or with vehicle (0.0 I % ethanol). Protease solution (2 Ill) 
was added to hormone/vehicle-h'eated VDR (2 Ill). Trypsin, chymotrypsin, and 
proteinase K were used at concentrations of S to SOO Ilg/ml. After a digestion 
period of 10 minutes at room temperature, 20 ~tl of denaturing SDS-sample 
buffer was added and the samples wcre heatcd for S minutes at 9S DC. TIle 
samples were loaded on a 12.5% (w/v) SDS polyaclylamide gel for 
electrophoresis (SDS-PAOE) and the labeled fragments were visualized by 
ovemight exposure to Fuji RX medical X-ray film at -SO°C. 
blllllUlloblottillg 
The ill vitro synthesized VDR proteins wcre incubated for 20 minutes at room 
temperature with vehicle, 1,2S-(OH)P3' OCT, or KHI060 and subsequently 
h'eated for 10 minutes at room temperature with vehicle or trypsin (2S ~lg/ml). 
After SDS-PAOE (12.S% gel), the protein fragments were h'ansfened 
elech'ophoretically to nitrocellulose. Westem blotting was perfOlmed using the 
IVOSCII monoclonal antibody to the porcine intestinal VDR (D,m, 19&6, 
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Immunoreactive proteins were visualized using Enhanced Chemiluminescence 
Westem blotting detection reagents. 
3.4. RESULTS 
Differellces ill VDR affillity alld ill vitro effects betweell 1,25-(OH),Dp OCT, 
ami KHI060 
To emphasize the differences in biological potencies between 1,25-(OH),D3 and 
the analogs a summary of two biological responses is presented in Table 3.1. In 
addition, the relative affinity of the analogs for the VDR is shown. The effects of 
OCT, KH1060, and 1,25-(OH),D3 on the production of the bone matrix protein 
osteocalcin by the ROS 1712.S osteoblastic cells and on ill vitro bone resorption 
are shown as examples, but KHlO60 was also more potent than 1,25-(OH),D3 in 
other responses, whereas OCT was equipotent (V~ "" 8m" "'5). Despite these 
increased potencies, KHlO60 displayed reduced affinity for the VDR extracted 
from ROS 17/2.S cells. 
Table 3.1. VDR affinity and ill vitro biological effects of 1,25-(OH),DJ , 
OCT, and KHI060' 
-
Ligand Osteocalcin III vitro bone Relative 
production ED50 resorption ED,o affinity for 
(M)t (M) theVDR 
--
1,25-(OH),D3 4x10-1l (1)1 7xlO- li (I) I 
OCT 5xlO-12 (O.S) 6xlO- 11 (1.2) O.OS 
KHI060 IxlO-13 (40) 4xlO-12 (17.5) 0.20 
These data are presented in extended fOim in Chapter 2. In short, osteocalcin 
production by ROS 17/2.S cells was measured by radioimmunoassay. III vitro 
bone resorption was assayed by measuring "Ca release from pre-labeled 
radii/ulnae fi-om fetal mice. Data after 6 days of culture are presented. VDR 
affinity was determined in the cytosolic extract of ROS 17/2.8 cells by 
competitive receptor binding assays with [23,24-3H]-1,25-(OH),D3. tThe 
concentration needed to achieve the half-maximal effect of 1,25-(OH),D3 is 
designated as ED,o' IThe potency of OCT and KH 1060 (at ED,o) was calculated 
in relation to that of 1,25-(OH),DJ• 
In other osteoblastic cells (human osteosarcoma MG-63 cells) (\'" "" 8,"" <"5) and in 
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cells not directly related to bone metabolism (e.g. the human breast cancer cell 
line MCF-7) CYrnk·V~ "ie,"- 19'141, a reduced VDR affinity of KH1060 compared with 
1,25-(OH),D3 was observed. 
VDR Half-life ill rat osteoblast-like cells 
When no ligand was present, the VDR in ROS 17/2.8 cells was almost 
completely degraded within 4 hours (half-life = 1.5 hours) (Figure 3.\). 
However, when the cells were incubated with 1,25-(OHhD3, the VDR half-life 
was prolonged by 13.5 hoUt's. Less than 20% of the initial VDR level could be 
detected after 24 hoUt's. A comparable result was obtained when the cells were 
treated with OCT. KH1060 had a much stronger stabilizing effect on the VDR. 
After 24 hours, sti1l80% of the initial VDR level was detectable. 
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Figure 3,1. Effect of vehicle, 1,25-(OH),D3, OCT, and KHI060 on the VDR 
half-life in ROS 17/2.S cells, Extracts oj cycloheximide-treated ROS 1712.8 cells were 
prepared afler differellt lime periods ojillcubatiollwith vehicle 0, 1,25-(OIf)2D3 ., OCT A, 
or KIf1060 • as described ill Materials alld Methods (Sectioll 3.3), alld assayed jor VDR 
cOlltell1 by imlJlltlloradiometric assay. Each pOint represents mean ± standard errol' of duplicate 
cultures that were measured ill triplicate. Significance of the differellces between 1,25-
(OIfJ2D 3- alld KIf1060-ilicubated cells was calculated usillg the paired Studellt's t test. 
*P<O.005, **P<O.0005. 
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Figure 3.2. Effect of 1,25-(OH),D3, OCT, and KHI060 on VDR 
conformation. (A) III vitro sYllthesized hlllllall VDR was illcllbated with vehicle, 10 11M 1,25-
(OH)2D3, 10 11M OCT, or 10 11M KHI060 alld sllbseqllently treated \Vith illcreasillg 
COllcentrations of trypsin. The }lumbers above the lanes indicate the amouII! of protease added 
(0-75,1511111), Thefraglllems were allalyzed by SDS-PAGE. 11,e sizes of the lIIoleclllar \Veight 
markers are indicated. (B) Computerized scan of the 32 kDa resistant fragment at increasing 
tf)ljJsill concentrations. X-rays of experiments similar to the e'periment presented ill Figure 
3,2A were scalllled, alld the OD of the 32 kDa fraglllellt was expressed as percelltage of illtact 
VDR OD vailles, Figllre 3.2B was cOllstructed with data of 6 (OCT) to 13 (vehicle, 1,25-
(OH)2D3, KHI060) difJerem experilllellts, The sallie sYlllbols as ill Figllre 3,1 \Vere IIsed, 
After 48 hours of incubation, a rebound effect was observed: The conh'ol-, 1,25-
(OH),D3-, and OCT-incubated cells regained their VDR synthesis, but the VDR 
content was still lower than the starting level. At this time point, KH I 060-
incubated cells contained VDR levels comparable to the starting point levels 
(data not shown), 
Limited jJroteolytic digestioll of ill vitro syllfltesized VDR jJroteill 
The increased VDR half-life could be the result of a conformational change of 
the VDR. We used partial enzymatic digestion of ill vitro synthesized human 
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VDR as a means to gain insight into ligand-induced conformational changes of 
the VDR. The rationale behind this technique is that a changed VDR 
confOlmation will lead to a changed accessibility of cleavage sites within the 
VDR molecule. So, changes in VDR confOlmation will lead to an altered VDR 
digestion. III vitro synthesized [35SJmethionine-labeled VDR protein was 
separated by SDS-PAGE into three bands of Sl, 48, and 4S kDa (Figure 3.2A), 
probably representing different forms (e.g. phosphOlylated) of the VDR. 
Immunoblot analysis revealed that all tlu'ee proteins were immunoreactive with 
the IVG8Cli antibody to the VDR (Figure 3.6). When hypsin was added, two 
distinct fi'agments of 32 and 27 kDa appeared (Figure 3.2A). Increasing the 
hypsin concentration to SO ~lg/ml led to a complete degradation of the VDR. 
When VDR was incubated with 1,2S-(OH),D3 before hypsin h'eatment, 
degradation was retarded, resulting in more persistent fi'agments (Figure 3.2A). 
Compared with 1,2S-(OH),D3, VDR treatment with OCT resulted in a similar 
protection against proteolysis (Figures 3.2A and B), whereas incubation of VDR 
with KH I 060 resulted in a dramatic increase in the resistance against protease 
activity (Figures 3.2A and B). To further illush'ate the large difference in potency 
to protect the VDR against protease activity between 1,2S-(OH),D3 and KH1060, 
we extended the hypsin concenh'ation range and found that, at a hypsin 
concentration of SOO ~lglml, fi'agments were still detectable when the VDR was 
incubated with KH1060, whereas 1,2S-(OH),D,-incubated VDR was already 
completely degraded at a hypsin concentration of ISO /lglml (Figure 3.3). 
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Figure 3.3. Comparison of the effects of 1,25-(OH),D3 (Upper) and KHI060 
(Lower) on the conformational change of the VDR. 111 vitro sYllthesized hlllllall 
VDR was illcllbated with 100 11M 0/ Iigalld alld thell treated/or 10 lIIilllltes with 0-500 ;15/1111 0/ 
I1ypsill. The numbers above the lanes indicate the amollnt of protease added. The degradation 
fragments were separated by SDS-PAGE alld visualized by autoradiography. The arrowhead 
lIIarks the 24 kDa /raglllellf. 
Notice that in the KHI060-incubated VDR, a third fragment of approximately 24 
kDa is present that could not be detected when VDR was incubated with 1,25-
(OH),D3 or OCT (Figures 3.2A and 3.3). This 24 kDa fragment could be the 
result of processing of the larger fragments_ 
The observed protection was not due to direct blockade of specific 
cleavage sites of trypsin, since with chymotrypsin (Figure 3.4) or with the 
broadband protease proteinase K (data not shown) virtually the same 
observations were made: 1,25-(OH),D3, OCT, and KH1060 protected the VDR 
against proteolytic breakdown, resulting in more preserved fi'agments with 
KH1060 being far more effective than 1,25-(OH),D3 or OCT. 
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Figure 3.4. 1,25-(OH),D,-, OCT-, and KHI060-induced conformational 
changes of the VDR.lll vitro synthesized humall VDR was incubated with vehicle, 10 nAi 
1.25-(OH)2D3. 10 I/M OCT, or 10 I/M KH1060 al/d suhsequel/tly treated with il/creasil/g 
COllcentrations of c/zymollJ'Psin. 111e numbers above the {alles indicate the amoullI of protease 
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added (0-75 flJlm/). 77le VDR fragmellts were separated by SDS-PAGE. 77le sizes of the 
molecular weight markers are indicated. 
The ligand-induced conformational change of the VDR was ligand-concentration 
dependent (Figure 3.5). Furthelmore, the conformational change was ligand-
specific. Incubating the VDR with the noncognate ligands all-trailS retinoic acid, 
progesterone, E" thyroid hormone, and 9-cis retinoic acid did not result in an 
increased preservation of distinct VDR fragments (data not shown). 
To exclude the possibility that the observed protection was due to direct 
inactivation of the protease by 1,25-(OH),D3 or the analogs we perfOimed time 
course studies. Adding KH 1060 and trypsin simultaneously did not result in an 
increased protection against proteolytic degradation, whereas a 10 minutes 
preincubation with KHI060 was effective (data not shown). 
The observed differences in protective effect between 1,25-(OH),D3' OCT, 
and KH I 060 was not specific for the incubation temperature routinely used in 
this study (room temperature). When the temperature dUling the ligand and the 
trypsin incubation period was raised to 37°C, KHI060 was still much more 
potent than 1,25-(OH)2D3 in protecting the VDR against proteolytic breakdown 
(data not shown). 
[mmlmoblot analysis of proteolytic VDRjragments 
To gain insight whether the proteolytic VDR fragments and the 32 kDa product 
in particular contain at least part of the DNA binding site, we performed 
immunoblot analysis with the IVG8CII monoclonal antibody directed to the 
DNA binding site of the porcine intestinal VDR. Incubation with 1,25-(OH),D3, 
OCT, or KH I 060 did not affect the immunological signal of the three main bands 
around 50 kDa. Incubation with trypsin (25 flg/ml) resulted in a loss of 
immunoreactivity, both in the presence and absence of 1,25-(OH),D3' OCT, or 
KH 1060. With all three ligands, none of the proteolytic fragments were 
immunoreactive (Figure 3.6). 
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Figure 3.5. Effect of ligand concentration on the presence of the 32 kDa VDR 
fragment. II/ vitro syl/thesized hUlllal/ VDR was il/cubated with vehicle (shaded bar) or 
il/creasil/g cOl/cel/tratiol/s oj 1.25-(OH}]D3 (opel/ bars) or KH1060 (solid bars) (10-10-10-7 
M) al/d subsequel/tiy treated with 5 ,e/llli oj lIypsill. After SDS-PAGE. the Faglllellts were 
scanned from the altloradiograph and OD were expressed as percelltage of the intact VDR OD 
milies. 
3.5. DISCUSSION 
It is known that modifications in the side chain of the 1,25-(OH),D3 molecule can 
result in analogs with increased biological activity. One of these interesting 1,25-
(OH),D3 analogs, KHI060, is a much more potent regulator of cell proliferation 
and differentiation lBiOOerup 1991. "ink·Vom Wijngaankn 1!194, Van d<n [Iemd 1995). However, the 
mechanism(s) underlying the differences in potency remain unclear. The 
increased potency of KI-Il 060 is not associated with an increased affinity for the 
VDR (Vffik,VMWii",""'" (99'.VMdm",ml !99", although the presence of the receptor is essential 
for the effects on cell proliferation and differentiation (VM""",md!99". 
The present study demonstrates that, compared with I ,25-(OH),D3' 
KH 1060 increases the half-life of the VDR, which could provide an explanation 
for the increased biological potencies of KH 1060. Binding of KH 1060 to the 
VDR causes an almost complete stabilization of the VDR, whereas with 1,25-
(OH),D3 after 24 hours only 20% of the initial amount ofVDR was present. 
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Figure 3.6. Immunoblot analysis of ill vitro synthesized human VnR and 
protease degradation prodncts. Humall VDR was illcubated with vehicle, 100 11M of 
i,25-(OH}]D3, 100 11M OCT, or 100 11M KH1060 alld subsequelltly treated with vehicle (-j or 
with 25 JiJlml ofOypsill (+j. 17" samples were separated by SDS-PAGE alld thell trallsferred 
/0 a nitrocellulose membralle. Immunological detection was peifarmed with the 1 VGBe)] 
monoe/ollal antibody alld Enhanced Chemiluminescence Western blotting detection reagents. 
Earlier studies showed that 1,25-(OH),D3 or naturally occurring 1,25-(OH),D3 
metabolites stabilized the VDR in LLC-PK I pig kidney cells (Co," 1986', mouse 
fibroblasts, rat intestinal epithelial cells lWi'~ 1992', and ROS 1712.8 cells (A""~ 1993'. 
Our data are consistent with the VDR half-life of 2 hours in the absence of 1,25-
(OH),D3 reported by Arbour et al. ("""~ 19))). They also observed a VDR 
stabilization when the ROS 17/2.8 cells were treated with 1,25-(OH),D3' 
However, they were not able to determine a VDR half-life, since the VDR 
content was unchanged within the 6 hours studied. The present paper is, to our 
knowledge, the first report concerning the effect of 1,25-(OI-I),D3 analogs on 
VDR stability. 
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Besides VDR stabilization, the effect of 1,25-(OH)2DJ' OCT, and KH1060 
on the VDR conformation was examined. As suggested by Allan et al. (Allm "92', 
hOlmone-induced conformational changes might be crucial for DNA binding, 
dimerization, and transcriptional activation, but in addition it could also playa 
role in receptor stability. We used partial enzymatic digestion of in vitro 
synthesized human VDR protein as a means to gain insight into ligand-induced 
conformational changes of the VDR. Partial enzymatic digestion has proven to 
be a useful method for studying conformational changes of the VDR iN"," "". rilis 
1995. K"""I9", and other members of the steroid receptor superfamily (Allm 1991. K,Id" 199'. "" 
1993. S'""co 19.0. Kwl ''''. B~_ 199". As we show here, incubation of the VDR with ligand 
leads to a conformational change of the receptor. Incubation with 1,25-(OH)2DJ' 
KH1060, or OCT resulted in the protection against proteolytic breakdown of 
specific fi'agments of the VDR. This protection was not due to a direct effect of 
the ligand on the enzymes. In contrast to a 10 or 20 minutes preincubation with 
ligand, simultaneous addition of ligand and protease did not cause enhanced 
protection against degradation of the VDR. Also, it was not the result of blockade 
of specific cleavage sites by the ligands because with tlu'ee different proteases 
similar results were obtained. In this respect, it is noteworthy that the ligand 
binding domain of the VDR contains over 20 evenly distribnted cleavage sites 
for trypsin. Therefore, it seems unlikely that a relatively small molecule like 
1,25-(OH)2DJ is able to protect a 32 kDa fragment fi'om proteolytic degradation 
via direct blockade of these cleavage sites. The protection against protease 
activity could only be achieved when the receptor was incubated with its cognate 
ligand: VDR was not protected by E2, progesterone, all-trans retinoic acid, 
thyroid honnone, and 9-cis retinoic acid. 
In an attempt to identifY the VDR fragments that are protected by ligand 
incubation, we performed immunoblot analysis. None of the fragments were 
inununoreactive with the IVG8CII antibody which epitope has been mapped to 
amino acids 57 to 164 (Hro"n 19"', encompassing the second Zinc finger of the DNA 
binding domain (amino acids 21-87) and most of the hinge region (amino acids 
88-188) (Figure 3.6). Furthermore, the theoretically calculated molecular weight 
of the ligand binding domain of the VDR is about 30 kDa, which is indeed 
comparable to the size of the major VDR degradation product. This suggests that 
the protected fi'agments are predominantly part of the ligand binding domain. As 
we do not possess specific antibodies against this region of the VDR, we cannot 
provide proof of this. For the progesterone receptor, a progesterone-induced 30 
kDa fragment and for the estrogen receptor an estrogen-induced 32 kDa, both 
corresponding to their ligand binding domains, were reported (All" 199". 
The observation that 1,25-(OH)2DJ' OCT, and KH1060 induce a 
confol1113tional change of ill vitro synthesized VDR, leading to enhanced 
resistance against protease activity, makes it tempting to speculate about the role 
ofVDR confOlmation in its stabilization. As shown in Figures 3.2A, 3.3, and 3.4, 
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KHI060 is much more potent than 1,25-(OH),DJ and OCT in the protection 
against proteolytic degradation. This is further illustrated when the major 
degradation product, a 32 kDa fragment, was quantified and plotted against the 
protease concentration (Figure 3.2B). At high protease concentrations with 
KHI060, a 24 kDa VDR fragment was found that was not observed after 
incubation with 1,25-(OH),DJ or OCT (Figure 3.3). Most of the conformational 
analysis were performed at room temperature, but, at 37°C, the difference 
between KHI060 and 1,25-(OH),DJ was present, indicating that the observed 
phenomenon also holds at a physiological more relevant temperature. Together 
these data indicate a different VDR confOlmation after binding KH 1060, which 
can be involved in the increased VDR stabilization observed in cells. This is even 
more likely when the background of the receptor confonnational analysis is 
taken into account: protection against proteolytic breakdown due to reduced 
accessibility of cleavage sites in the receptor by ligand binding. Moreover, in the 
VDR conformational studies 1,25-(OH),DJ and OCT showed similar effects and 
induced a comparable increase in VDR half-life (Figures 3.1, 3.2A, 3.2B, and 
3.4). 
Based on the observed different effects between OCT and KHI060 on 
VDR half-life and VDR conformation, we conclude that only specific alterations 
in the side chain structure of the 1,25-(OH),DJ molecule result in more potent 
analogs. The reported ill vitro (Table 3.1) and ill vivo biological effects of OCT 
<Van&n B~rnJ 1995, Abe 19£9, Du;so 1991, P(ml.kte 1991, Bro"Tl 1993) and the data presented here with respect to 
its effect on VDR half-life and VDR conformation (Figures 3.1, 3.2, and 3.4) 
show that substitution of the C-22 by an oxygen atom results in an analog that 
mimics most of the activities of 1,25-(OH),DJ. TIlerefore, we conclude that the 
potent effect ofKHI060 is not the result of the substituted oxygen atom at C-22, 
but is probably due to (combinations with) other modifications in the side chain. 
In view of the fact that stabilization and conformational change of the 
VDR could be responsible for increased receptor-mediated responses in target 
cells (A.oow 1993. AIm, 19921, the present study provides a means by which KH I 060 can 
exert biological responses more potently than 1,25-(OH),DJ' In this respect, the 
report by Sasaki ef al. (""" 19951 is of interest. TIley speculated that the higher 
biological activity of the analog 1,2S-(OH),-F6-D3 could (partly) be due to a 
structural change of the VDR induced by this analog, leading to enhanced 
binding affinity of the VDR for the VDRE and subsequently to enhanced 
transcriptional activity. It should, however, be taken into account that in addition 
also pharmacokinetic aspects (e.g. in relation to DBP affinity or altered 
metabolism) may conllibute to the increased bioactivity of KH 1060 (K;~"d995' and 
other 20-epi-analogs (011,,,"'(99',. 
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CHAPTER 4 
VITAMIN D RECEPTOR-DNA BINDING AND 
TRANSACTIV A TION IS DIRECTED BY SPECIFIC 
NUCLEOTIDES IN VITAMIN D RESPONSE ELEMENTS 
AND BY CELLULAR CONTEXT 
Van den Bernd GJCM, TIlamai P, Staal A, Van Wijnen N, Lian JB, Stein GS, Pols HAP, Van 
Leeuwen JPTM. In preparation. 
Part of the data presented in tllis paper was already published in: 
Van den Bernd GJCM, Pols HAP, Staal A, Van Wijnen AJ, Lian JB, Stein GS, Van Leeuwen 
JPTM. Specific nucleotides in the proximal half-site ofDR3-type vitanlin D response elements 
direct vitamin D receptor-retinoid X receptor binding. In: Vitamin D, Chemistry, Biology and 
Clinical Applications of the Steroid Hormone. Nonnan A W, Bouillon R, Thomasset M 
(Eds.).Walter de Gmyter, Berlin, p 284-285, 1997 
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4.1. ABSTRACT 
The 1,25-(OH),D3 20-epi-analog KHI060 exerts its strong biological activity via 
the VDR. As we reported earlier, changes in VDR conformation and enhanced 
VDR stability induced by KHI060 and some of its metabolites are part of the 
mechanism that underlies the increased potency. In the present study we 
elaborated further on the mechanism of action and investigated 1,25-(OH),D,-
and KH I 060-induced VDR binding to VDREs of three different target genes: rat 
osteocalcin, human osteocalcin, and mouse osteopontin. 
To study VDR-VDRE binding, gel mobility shift assays were performed 
with ill vitro synthesized VDR and its dimer partner RXRa, or with nuclear 
extracts from rat osteoblast-like ROS 17/2.8 cells. 32P-Iabeled oligonucleotides 
encoding the rat osteocalcin, human osteocalcin, or mouse osteopontin VDRE 
were used as probes. To study the impact of differences in nucleotide sequences 
in more detail, hybrid VDREs were used in which mouse osteopontin VDRE 
half-sites or single nucleotides were substituted in the rat osteocalcin VDRE 
context. Transcriptional activity via these VDREs was tested by transient 
transfection ofa luciferase repOlier construct into ROS 17/2.8 cells. 
We found that both 1,25-(OH)2D3 and KHI060 dose-dependently 
increased binding of ill vitro synthesized VDRlRXRa to the VDREs. KH 1060 
was only slightly more potent than 1,25-(OH)2D3 in stimulating VDRlRXRa 
binding to the mouse osteopontin VDRE. Surprisingly, despite of its increased 
biological potency, KHI060-stimulated VDRlRXRa binding to human 
osteocalcin VDRE equally effective as 1,25-(OH)2D3 and to the rat osteocalcin 
VDRE even less active than 1 ,25-(OH),D3. When gel mobility shift assays were 
perfonned with nuclear extracts ofROS 17/2.8 cells, KHl060 was clearly more 
potent than 1,25-(OH),D3 with all three VDREs. Furthermore, we observed for 
both 1,25-(OH),D3 and KH 1060 considerable differences between the tlu'ee 
VDRE types in intensity of the ligand-induced retarded bands. Binding to the 
rat osteocalcin VDRE was less compared to binding to the human osteocalcin 
VDRE and binding was even stronger when mouse osteopontin VDRE was 
used as probe. Studies with a series of substitution mutations demonstrated that 
the third and/or fourth nucleotide (both thymidines) in the proximal half-site of 
the mouse osteopontin VDRE determined this stronger VDR binding. 
Transfection studies with a VDRE-Iuciferase reporter constlUct in ROS 1712.8 
cells showed that introduction of these thymidines into the proximal half-site of 
the rat osteocalcin VDRE resulted in a two-fold enhancement of 1,25-(OH)2D3-
induced transcriptional activation compared to the native rat osteocalcin 
VDRE. 
Based on these findings we conclude that the extent of both 1,25-
(OH),D,- and KHlO60-induced VDRlRXR-VDRE binding and transactivation 
activity depends on specific nucleotide sequences of VDREs and that the 
nuclear context is a prerequisite to obtain an analog-enhanced magnitude of 
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VDRlRXR-VDRE binding that reflects the increased biological activity of that 
analog. 
4.2. INTRODUCTION 
The classic role of 1,2S-(OH),D3 includes regulation of calcium and bone 
metabolism <P<L~, '99". In addition, the homlOne is an important mediator of cell 
growth and differentiation (lV."," '992. Vm d," ",m" 2(lOO,'. The 20-epi-analog KHI060 
mimics these biological activities of 1,2S-(OH),D3, albeit with considerably 
increased potency (Bind~nrp 1991, Vand~n Bernd ]995, P~Je-g [995), KH 1 060 is more potent than 1,25-
(OH),D3 in stimulating genes encoding for bone matrix proteins (e.g. human 
collagen type I, rat osteocalcin, human osteocalcin, and mouse osteopontin), 
both at the level of transcription and translation (VM den Bum 1995, R>h!nen 1996, Dil\\-onh 19971, 
The search for an underlying mechanism to explain the increased 
biological activity still continues and focuses on studying the cascade of events 
that leads to modulation of gene transcIiption (See Chapter I, Section AA.). 
According to this classic model, ligand (I ,2S-(OH),D3 or an analog) binds to the 
VDR and induces a conformational change (Ym drn Ikml 1996. p"" 199". As a consequence, 
the VDR can foml dimers with anodler nuclear receptor, usually RXR <Y!c.12W, 
although homodimerization has been described as well (0""",, '993. F<=Imm 'm. """'" '99'. f£lIJ: 
-. Next, the VDRIRXR dimer binds to specific DNA sequences, so· called 
VDREs in the promoter region of 1,2S-(OH),D3 target genes after which the 
preinitiation complex is fOlmed and gene transcription is initialized or suppressed. 
Earlier we showed that KH 1060 changed the three-dimensional folding of 
the VDR in such a way that its sensitivity for proteases was diminished (Ym.JrnIkmlI99". 
We also found that the KHlO60-induced increase in protease resistance was 
reflected by a KHlO60-induced increased VDR half-life in cells (Ym "'" Ikml '996,. In 
addition, specific metabolites ofKHI060 were found to be biologically active and 
shared the VDR stabilizing property of their parent compound (ym do" Bm" 200". In the 
present study we elaborated on the potential mechanism of action and investigated 
whether the KHlO60-induced change in VDR conformation affects binding of the 
VDRIRXR dimer to a selection of natural occurIing VDREs. Using gel mobility 
shift assays we studied the binding of ill vitro synthesized VDR and RXRa, as well 
as the binding of nuclear extracts (containing VDR and RXR (Sm' 199") ofROS 17/2.8 
cells to the rat osteocalcin (S'-GGGTGA atg AGGACA-3') """., 1992', mouse 
osteopontin (S'-GGIT!:.:A cga QGTTCA-3') (Ii"'" '99", and human osteocalcin 
VDRE (S'-GGGTGA acg QGGQCA-3') "'Om"" '95". These VDREs are of the 
DR3-type (U~;,"" '99" to which the VDRlRXR complex binds with a defined 
polarity: the distal half-site is occupied by RXR, while VDR binds to the 
proximal half-site """" '996. n" '996. ~'. The human osteocalcin VDRE and mouse 
osteopontin VDRE differ within their half-sites by the underlined nucleotides 
from the rat osteocalcin VDRE. TIle impact of differences in nucleotide 
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sequences was further unraveled using hybrid YDREs in which the rat 
osteocalcin VDRE half-sites were replaced by mouse osteopontin VDRE half-
sites and by introducing a series of substitution mutations in the rat osteocalcin 
YORE half-site. Finally, we transfected ROS 1712.8 cells with VDRE-driven 
luciferase reporter constructs to study the influence of distinct nncleotides in 
the YDRE half-sites on the transcriptional activation by 1,2S-(OH),03 and 
KH1060. 
4.3. MATERIALS AND METHODS 
Reagellts 
1,2S-(OH),03 and KHI060 were a gift Ji"om dr. L. Binderup, Leo Pharmaceuticals, 
Ballerup, Denmark. Chemical strnctures are depicted in Figure 1.3. aMEM was 
from Sigma Chemical Co., St. Louis, MO, USA. VDRE-encoding 
oligonucleotides, fetal bovine serum, penicillin, streptomycin, and L-glutamine 
were purchased from Gibco Life Technologies Ltd., Paisley, Scotland. The TNT 
lysate assay, NheI, Bglll, Tfx-SO, the pGL3 control and reporter plasmids, and 
luciferase assay reagent were from Promega, Madison, WI, USA. 
Cells 
The rat osteoblast-like osteosarcoma cell line ROS 1712.8 was cultured in 
aMEM supplemented with 2 mM L-glutamine, 100 units/ml penicillin, 100 
flg/ml streptomycin, 0.1% O-glucose plus 10% fetal bovine selUm. When the 
cells reached subconfluence medium was replaced by aMEM containing 2% 
charcoal-treated fetal bovine serum. After 24 hours of culture ligand 
incubations or transfections were perfOimed for the indicated period of time. 
Itl vitro synthesis o/VDR alld RXRaalld preparatioll o/III/clear extracts 
Human recombinant VDR and RXRa were ill vitro synthesized with Promega' s 
TNT lysate assay according the instructions of the manufacturer using cDNA 
encoding for human VDR (in pGem4; a gift from dr M.R. Haussler, University of 
Arizona, Tucson, AZ, USA) and RXRa (in pSGS; a gift from dr P. Chambon, 
INSERM, Str·asbourg, France). For preparation of nuclear extracts, rat 
osteoblastic ROS 17/2.8 cells were incubated for I hour with 1,2S-(OH),D3 or 
KHI060. Next, nuclear extracts were prepared in 20 mM HEPES, pH 7.S, 420 mM 
KC1, 2S% glycerol and 0.2 111M EOTA, according to the method described 
previously "mll99". 
Gel mobility shift assay 
Gel mobility shift assays were perfOimed as desclibed earlier """' '990'. In brief: 1 0 fll 
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of a mixture of ill vitro synthesized VDR and RXRa treated for 15 minutes at 37 
°C with ligand (I,25-(OH),D3 or KH I 060); or 10 III of diluted nuclear extract (5 
Ilg protein) was incubated for 15 minutes at room temperature with 10 III of 3'P_ 
labeled oligonucleotides (10 finol). The oligonucleotides used in this study are 
presented in Table 4.1. TIle proteinlDNA complexes formed were separated on a 
5% polyacrylamide gel (acrylamide:bisacrylamide = 80: I) in 0.5 x TBE buffer. In 
the competition expeliments, 32P-labeled oligonucleotides and different 
concentrations of unlabeled oligonucleotides were mixed and subsequently 
incubated with nuclear extract. The VDR ligand-responsive complex was 
visualized by exposure to Fuji RX medical X-ray film. All gel mobility shift 
expeliments were performed with excess probe, but for reasons of clarity only the 
shifted bands are shown. 
Table 4.1. DRJ-type VDREs used in this study 
ROC 5'-etgeaet GGGTGA atg AGGACA ttaetga-3' 
MOP S'-acaa GG~T£A ega ~GTTCA cgtct-3' 
HOC 5 I -qactcacc GGGTGA aeg ~GG~CA ttgega-3' 
OP/OC S'-ctgcact GG~T£A a tg AGGACA ttactga-3' 
OC/OP S'-ctgcact GGGTGA atg ~GTTCA ttactga-3' 
Op/Op 5'-ctgcact GG~T£A atg ~GTTCA ttaetga-3' 
PM 3T 5 1 -ctgcact GGGTGA atg AG~ACA ttactga-3' 
PM 4T 5'-ctgcact GGGTGA atg AGG~CA ttactga-3' 
PM 3T4T 5'-ctgcact GGGTGA atg AG~CA ttaetga-3' 
PM lG3T 5'-ctqcact GGGTGA atg ~G~ACA ttactga-3' 
PM lG4T S'-ctgcact GGGTGA atg ~GG~CA ttactga-3' 
ROC = rat osteocalcin, MOP = mouse osteopontin, HOC = human osteocalcin. 
The oligonucleotides OP/OC, OC/OP, OP/OP, PM 3T, PM 4T, PM 3T4T, PM 
IG3T, and PM IG4T contain substitution mutations within the rat osteocalcin 
VDRE context. The underlined nucleotides are distinct from the cOlTesponding 
nucleotides within the rat osteocalcin VDRE half-sites. 
Trallsactivatioll assays 
Oligonucleotides with Bg/lI - and NlleI -compatible ends containing the rat 
osteocalcin: 5' -CTAGCTGCACTGGGTGAatgAGGACA TT ACTGA -3', or 
OC/OP VDRE: 5'-CTAGCTGCACTGGGTGAatgGGTTCATTACTGA-3' 
(VDREs are shown in bold. The underlined nucleotides are distinct from the 
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cOlTesponding nucleotides within the proximal rat osteocalcin VDRE half-site) 
were cloned into the multiple cloning site of the pOL3 vector containing luciferase 
cDNA as the repOlier gene. Sequences were confirmed by dideoxysequencing 
using a 310 genetic analyzer (Perkin Elmer). ROS 17/2.8 cells cultured in 10 cm' 
dishes were transfected with 5 f.lg of reporter plasmid/well using TfX-50 reagent 
(I :3). The pOL3 control plasmid was used as the normalization vector. Cells 
recovered for 4 hours, and were then treated with vehicle (0.1 % ethanol) or 10-8 M 
1,25-(OH),DJ. Luciferase activity was measured after 24 hours of ligand 
incubation using luciferase assay reagent and the Lumac Biocounter M2500. 
4.4. RESULTS 
Oel mobility shift assays revealed that ligand-induced binding of ill vitro 
synthesized VDRlRXRa to the VDREs was ligand-dependent. In the absence of 
1,25-(OH),DJ, only minor VDRlRXRa binding was observed. 1,25-(OH),DJ and 
KHl060 dose-dependently enhanced VDRlRXRa binding (Figure 4.1). With the 
mouse osteopontin VDRE KH1060 was only slightly more potent than 1,25-
(OH),DJ. 
1,25-(OHhD3 KH1060 
ROC 
HOC ~ ••• 
MOP 
0-10 -9 -8 -7 -10 -9 -8 -7 
Log [Ligand) (M) 
Figure 4.1. Binding of ill vitro synthesized VDR and RXRa to rat 
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osteocalcin, human osteocalcin, or mouse osteopontin VDREs. III vitro 
synthesized VDR alld RXRa were incubated for 10 minutes with vehicle (0.1% ethanol) or 
illcreasillg amoullis of 1,25-(OHJ2D3 or KHI060 (10- 10_10- 7 M) alld subsequently 
incubated with 10 fillol of 32P-labeled rat as/eoca/dll, human as/eoca/Gin, or mouse 
osteopontin VDREs and protein/DNA complexes were separated by gel electrophoresis. 
However, unexpectedly in view of its potent induction of osteocalcin production 
IVM~" B<mJ 1995', KHlO60 and 1,25-(OH),DJ had a comparable stimulatOlY effect on 
VDRlRXRa binding to the hnman osteocalcin VDRE and the potency ofKHlO60 
to induce VDRlRXRa binding to the rat osteocalcin VDRE was even lower than 
that of I ,25-(OH),D3 (Figure 4.1). 
In the present study we also perfOimed gel mobility shift assays using 
nuclear extracts of ROS 17/2.8 cells, in which we already demonstrated the 
presence of VDR and RXR using monoclonal antibodies (Sm' 1990'. When nuclear 
extracts of 1,25-(OH)Pr or KHlO60-treated ROS 1712.8 cells were used, ligand 
dose-dependent binding of nuclear proteins to all three VDREs was observed 
(Figure 4.2). In contrast to the studies perfonned with ill vitro synthesized VDR 
and RXRa, the experiments with nuclear exh'acts demonstrated a sh'onger effect of 
KH 1060 than of 1,25-(OH),DJ, not only on the binding to the mouse osteopontin 
and human osteocalcin VDRE, bnt also to the rat osteocalcin VDRE (compare 
Figures 4.1 and 4.2). 
ROC HOC MOP 
1,25·(OHhD3 KH1060 1,25-(OHhDJ KH1060 1,25-(OHhDJ KH1060 
.VDRlRXR 
0-12 -10 -8 -12 -10 -8 0-12-10 -8-12 -10-8 o -12 -10 -8 -12 -10-8 
Log [Ligand] (M) 
Figure 4.2. Binding of nuclear proteins of ROS 1712.8 cells to rat 
osteocalcin, human osteocalcin, and mouse osteopontin VDREs. Gel mobility 
shift assays were peJformed with nuclear extracts/rom l'elzic!e-, 1,25-(OH)2D3-, or KH1060-
treated (10-/2_10-10_10-8 Al, 1 hOIll) ROS 1712.8 ce/ls. £rtmcts were illcubated with 10 filial of 
32P-labeled rat osteocalcin, human osteocalcin and mouse osteopolIHn VDREs and protein/DNA 
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complexes were separated by gel electrophoresis. Ligand-responsive comple:res for the various 
VDREs are indicated by the arrowhead. 
Figure 4.1 also shows that, when compared with the rat osteoca1cin VDRE the 
Jiganded (either 1,25-(OH),D3 or KH1060) VDRJRXRa complex exhibits a 
preference for binding the mouse osteopontin VDRE, while with the human 
osteocalcin VDRE intennediate VDR!RXRa-VDRE binding was observed. 
Likewise, the intensity of the shifted complex with nuclear extracts was strongest 
for the mouse osteopontin VDRE, followed by the human osteoca1cin and rat 
osteocalcin VDRE (Figure 4.2). 
To study the conttibution of the vmious hexamer motifs in this differential 
preference for DNA we introduced substitution mutations, replacing rat osteocalcin 
VDRE half-sites by mouse osteopontin VDRE half-sites (Table 4.1). 
ROC OP/OC 
1,25-(OH),o3 KH1060 1,25-(OH),D3 KH1060 
••••••••••• 
• 
-9 -8 -7 -9 -8 -7 -9 -8 -7 -9 -8 -7 
OC/OP OP/OP MOP 
1,25-(OH),o3 KH1060 1,25-(OH),o3 KH1060 1,25-(OH),D3 KH1060 
-9 -8 -7 -9 -8 -7 -9 -8 -7 -9 -8 -7 -9 -8 -7 -9 -8 -7 
Log [Ligand] (M) 
Figure 4.3. Binding of ill vitro synthesized VDR and RXRa to hybrid rat 
osteocalcin and mouse osteopontin VDREs. III vitro sYllthesized VDR alld RXRa 
were incubated for 10 minutes with vehicle (0.1% ethanol) or iI/creasing amollnts of 1,25-
(OH)2D3 01' KH1060 (10-9-10-8-10-7 M) alld subsequelltly il/cubated with 10 fil/ol of 32p_ 
labeled oligollucleotides encodingfor wild-type and substitution mutation VDREs as presellfed ill 
Table 4.1. Protein/DNA compleres were separated by gel electrophoresis. 
113 
With both ill vitro synthesized VDR and RXRa (Figure 4.3) and nuclear extracts 
(Figure 4.4) replacement of the distal rat osteocalcin VDRE half-element by the 
corresponding mouse osteopontin VDRE half-site (OP/OC) only slightly increased 
the intensity of the 1,25-(OH),Dr and KH1060-induced shifted band. Substitution 
of the proximal half-site alone (Oe/oP), or in combination with the distal half-site 
(OP/OP), led to further increased DNA binding to levels comparable to that of the 
intact mouse osteopontin VDRE (MOP). 
This was observed with both ill vitro synthesized VDRlRXRa and nuclear 
extracts and with 1,25-(OH),D3 as well as KH1060 (Figures 4.3 and 4.4). So far 
these findings clearly indicate that the proximal VDRE half-site, i.e. the VDR 
binding-site, has the largest impact on the extent ofVDRIRXR binding to DNA. 
ROC OP/OC 
1,25·(OH),D3 KH1060 1,25·(OH),D3 KH1060 
-12 -10 -8 -12 -10 -8 -12 -10 -8 -12 -10 -8 
OC/OP OP/OP 
1,25·(OH),o3 KH1060 1,25·(OH),D3 KH1060 , , 
-12 -10 -8 -12 -10-8 -12 -10 -8 -12 -10-8 
MOP 
1,25·(OH),D3 KH1060 
• , 
-12 -10 -8 -12 -10 -8 
Log [Ligand] (M) 
Figure 4.4, Binding of nuclear proteins of ROS 17/2,8 cells to hybrid rat 
osteocalcin and mouse osteopontin VDREs. Gel mobility shif! assays were 
pel/armed with nuclear extmcts from vehicle·, 1,25·(OH)2D3·, or KHI060·treated (1O·12-lrr 
1O_lrr8 M, 1 hOllr) ROS /712.8 cells. Nuclear exlmcls were incubaled wilh 10 final of 32p_ 
labeled oligonllcleolides encoding for wild·/)pe and sllbslillliion mlliation VDREs (Table 4.1). 
Protein/DNA complexes were separated by gel electrophoresis. 
Using single substitution mutations we fuliher investigated which nucleotide(s) in 
114 
the proximal half-site islare significant in determining the observed differences in 
VORE binding. The significance of the 3T and 4T nucleotides in the proximal 
half-site of the mouse osteopontin VDRE was already notified if-= 1m SWl ""'. Here, 
we show that introduction of one (PM 3T, PM 4T) or both of these nucleotides 
(PM 3T4T) strongly enhanced 1,25-(OH),Dr induced VDRlRXR-VORE-binding. 
Additional substitution of 10 (PM IG3T and PM 104T) had no clear 
supplementary effect (Figure 4.5). 
ROC HOC pm3T pm1G3T pm4T 
-12 -10 -8 -12 -10 -8 -12 -10 -8 -12 -10 -8 -12 -10 -8 
pm1G4T pm3T4T oeloP OPIOP MOP 
-12 -10 -8 -12 -10 -8 -12 -10 -8 -12 -10 -8 -12 -10 -8 
Log [1 ,25-(OH),D,] (M) 
Figure 4.5. Binding of nuclear proteins of ROS 17/2.8 cells to rat osteocalcin 
VDREs containing specific point mutations. Gel mobility s"if! assays were 
pel/armed wilh III/clear e.ttractsj'oml,25-(OH)2D3-trealed (lrr12-1rrJO-lrrB Nf, 1 hOIll~ ROS 
1712.8 cells and poinl mutated VDREs as presented ill Table 4.1. 
We also studied whether differences in binding to VOREs are reflected by 
differences in affinity for these VDREs, Competition analysis using 32P-Iabeled rat 
osteocalcin VDRE and increasing amounts (10-1,000 finol) of unlabeled 
competitor oligonuceotides (rat osteocalcin or mouse osteopontin VDRE) showed 
that ill vitro synthesized VDRlRXRa displayed increased affinity for mouse 
osteopontin VORE (Figure 4.6). 
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Figure 4.6. Competition gel mobility shift analysis with ill vitro synthesized 
VDRfRXRa and rat osteocalcin VDRE. III pallel A. ill vilro sYlllhesized VDRlRXRa 
illcllbaled with 1,25-(OH)2D3 (10-8 M, 10 millllles) was illcllbaled with a mixlllre oj 10 filial 
of 32 P-labeled rat osteocalcill VDRE-colltailling oligollucleotides and increasing amounts of 
unlabeled rat osteocalcill (ROC) 01' mouse osteopolltill (MOP) competitor oligollucleotides 
(10-1000 filial). III pallel B, a complllerized oplical dellsily scali oj Ihe shifted complex is 
shown. Data represent the mentiS of Iwo illtiependelit e.tperimellls +/- standard deviations. The 
OD vallie oJlhe shifted complex ill Ihe absellce oj compelilor was sella 1. 
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Figure 4.7. Competition gel mobility shift analysis with nuclear extracts of 
ROS 1712.8 cells and OCIOP VDRE. 111 pallel A, lIuclear extract of ROS 17/2.8 cells 
il/cubated with l,25-(OH) 2D3 (10-8 M, 1 hour) was iI/cuba ted with a mixture of 10 jillol of 32p_ 
labeled aC/DP VDRE-colltainillg oligollucleotides and increasing amounts of till/abeled 
competitor rat osteocaldll (ROC) or OC/OP oligol/ucleotides (10-1000 jillol). 11/ pallel D, a 
computerized optical density Scali of lite shifted complex is shown. Data represent the means of 
three independent eJ.perimen/s +/- standard deviations, TI,e OD mlue of the shifted complex ill the 
absence of competitor was set /0 1. 
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We further investigated the impact of differences in nucleotide sequences on the 
affinity of nuclear exu'acts for the wild type rat osteocalcin VDRE and the OC/OP 
VDRE. Competition assays revealed that nuclear proteins of ROS 1712.8 cells 
displayed an increased binding affinity for OC/OP VDRE (Figure 4.7). 
Finally, we investigated whether the differences in VDRIRXR binding to 
DNA observed in the gel mobility shift assays are reflected by differences in 
transactivation activity. ROS 17/2.8 cells were transfected with a pOL3 luciferase 
reporter vector containing rat osteocalcin or OC/OP VDRE sequences. As can be 
seen in Table 4.1 these VDREs differ only by 3 nucleotides in the proximal half-
site. We found that the transactivation activity of 1,25-(OH),DJ was enhanced two-
fold when the first, third, and fOUlih nucleotide of the proximal half-site of the rat 
osteocalcin VDRE were replaced by con'esponding nucleotides of the mouse 
osteopontin VDRE (Figure 4.8). 
4.5. DISCUSSION 
The present paper shows that the increased biological potency of KH1060 is 
not reflected by an increased binding of ill vitro synthesized VDR and RXRa to 
various VDREs. KHI060-induced binding of ill vitro synthesized VDRlRXRa 
to the mouse osteopontin VDRE was slightly increased, while binding to 
human osteocalcin and rat osteocalcin VDREs was comparable to or even less 
than with 1,25-(OH),DJ. Studies by Imai et al. with RO 24-2637 and RO 23-
7553 also demonstrated a lack of parallelism between the potency of these 
analogs to induce binding of recombinant human VDR and RXRa to the 
human osteocalcin VDRE and the capacity of these analogs to activate a human 
osteocalcin VDRE-driven reporter gene Ihrui "'''. However, when we performed 
the gel mobility shift assays with nuclear extracts of osteoblast-like cells, the 
biological potency of KH I 060 was paralleled by an increased binding of 
nuclear factors to the different VDREs studied. These observations underline 
the absolute importance of the cellular context, i.e. absence or presence of 
(nuclear) cofactors for the interaction between VDRlRXR and VDRE and to 
observe KHI060-induced VDRlRXR-DNA binding that reflects its biological 
potency. Also Zhao et al. showed that the ability of KHI060 and other 1,25-
(OH),DJ analogs (RO 24-5531, MC903, ED-71) to enhance binding of VDR 
expressed in COS-7 cells and RXRa from yeast extract to the human 
osteocalcin VDRE con-elated with their potency to transactivate a human 
osteocalcin VDRE-driven reporter gene 1&0 1991). The importance of a 
nuclear/cellular context is also illustrated by cell type-dependent repression of 
gene h'anscription via the human PTH VDRE. In bovine parathyroids and in rat 
pituitaty OH4Cl cells, but not in ROS 17/2.8 cells the human PTH VDRE 
tnediates transcriptional repression (MacKey 1996). 
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Figure 4.8. Transactivation assay with ROS 17/2.8 cells transiently transfected 
with a luciferase reporter gene driven by either the rat osteocalcin VDRE or 
OC/OP hybrid YORE. The rat osteocalcill (ROC) VDRE alld OC/OP VDRE were 
transiently transfected illto ROS 1712.8 cells as described in Materials and Ale/hods, Section 4.3. 
Luciferase activity was measured after 24 hours of ligand incubatioll. TIle luef/erase activity 
measured ill the ~'ehicle-treated ROS 1712.8 cells t!'al/sleeted 'with the 'wild type rat osleocalcill 
(ROC) VDRE was set to 1. 
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This cell type-specific difference was paralleled by distinct protein-DNA 
binding: in the extracts of bovine parathyroids and GH4CI cells VDR 
homodimer binding to the human PTH VDRE was observed, whereas the 
complex formed with extracts of ROS 1712.8 cells contained VDRlRXR 
heterodimers. Transcriptional repression of the human PTH gene seems, 
therefore, dependent on the ability of the cell (i.e. dependent on the presence or 
absence of certain cofactors) to induce VDR-VDRE binding without 
interference of RXR (;\lad:ey 1996). 
Several processes might be involved in the increased potency of KH I 060 to 
induce VDRlRXR-DNA binding. Incubation ofROS 17/2.8 cells with KHI060 
might have a different effect than 1,25-(OH),Dj on the amount and/or 
distribution of VDR, RXR, and/or cofactors in the nucleus leading to changed 
formation and/or affinity of DNA-binding complexes. Although the ligand 
incubation period used was relatively short (I hour) it is not unlikely that de 
novo synthesis of receptors or cofactors has taken place (C",d,li,~ '09". In addition, 
during the incubation period migration of receptors/cofactors from the 
cytoplasm to the nucleus might occur. It was for instance shown that the VDR 
migrates from the cytoplasm to the nucleus within several minutes after 
addition of 1,25-(OH),Dj rom'" (997). In addition, compared to 1,25-(OH),Dj 
KHI060 might induce the formation of a more stable VDRlRXR-DNA 
complex. Cheskis et al. demonstrated, by using surface plasmon resonance, that 
certain analogs with stronger transcriptional activation activity than 1,25-
(OH),DJ induced increased stability of the VDRlRXR-mouse osteopontin 
VDRE complex eCh.;," ""'. 
Another important observation in the present study is the difference in 
intensity in the DNA-bound complexes between the three VDRE types tested. 
Over 30 different genes have been identified that contain a responsive element 
for 1,25-(OH),DJ (See Table 1.2). The various VDREs show higher or lower 
resemblance to the consensus sequence GI AGGTCA ttg AGTTCA eNi;h;"'", ""'. 
Variations in flanking and half-site sequences may be important discriminators 
involved in specific gene regulation. Earlier, our laboratOlY showed the impact 
of differences in nucleotide sequences within VDREs on the immunoreactivity 
of the VDRlRXR complex (Su,' 19%', indicating that specific conformational 
changes occur upon VDRlRXR-VDRE binding. These conformational changes 
will affect subsequent interaction with cofactors and basal transcription factors 
and eventually will result in altered gene transcription. Here we show that 
ligand-induced binding ofVDRIRXR complexes to rat osteoca1cin VDRE was less 
pronounced compared to the binding to human osteoca1cin and mouse osteopontin 
VDREs. This confirms our previous work (S"" "'fu" and is supported by work fi'om 
others (K~ ''''. - "'~'. Our observation that VDREs containing the mouse 
osteopontin proximal half-site have a higher affmity for VDRIRXR and osteoblast 
nuclear extracts than wild type rat osteocalcin VDREs is consistent with findings 
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of Mackey et al. showing that VDRIRXR complexes /i'om GH4C I cells bound 
with higher affinity to the mouse osteopontin VDRE than to the rat osteocalcin 
VDRE Q,hd..ey 19%). 
In addition, we show that the intensity of ligand-induced VDRlRXR 
binding to functional VDREs can mainly be attributed to the VDR half-site, the 3 
and/or 4 T in particular. The impact on the extent of VDRlRXR-DNA binding 
by minor changes in nucleotide sequences is also illustrated by work of others 
CJu<l..tllincn 1995, Ko;zellski 1999, Ozono 1998), Ozona et al. showed that a non-VDR binding 
accessOlY element within the rat 24-hydroxylase gene was converted to a VDR-
binding site when the fourth nucleotide within its proximal half-site was 
substituted by adenine or thymidine 10"00 "'''. Koszewski et al. demonstrated that 
two mutations in the proximal half-site of the avian PTH VDRE converted the 
negative activity of this VDRE into a positive one ""m"" 1m,. The large impact 
of only small changes in nucleotide sequences on receptor-DNA binding is not 
restricted to VDR-VDRE interaction. For instance, within EREs a change of 
one base pair in the proximal half-site (the vitellogenin A2 ERE versus the 
human pS2 ERE; see Table 1.4) resulted in a tlu'ee-fold lower ER affinity I£!!!!i! 
12W, and introduction of two mutations converted the vitellogenin A2 ERE into 
a glucocorticoid responsive element IM.",~, 1981,. 
In summaty, the present data demonstrate that for the 1,25-(OH),D3 
analog KH 1060 a cellular/nuclear context (i.e. absence or presence of nuclear 
cofactors) is crucial to observe ligand-induced VDR-VDRE binding that 
reflects its increased biological potency (Van den Bemd 1995, RyMr.en 1996. Dilworth 1997l, Thereby, 
this study implicates the significance of these nuclear co factors for detelmining 
the extent of transcriptional activity. Finally, the present data emphasize that 
VDRlRXR binding is directed by specific nucleotides in VDRE sequences. 
This might form part of a mechanism to achieve response selectivity in the 
action of 1,25-(OH),D3 and 1,25-(OH),D3 analogs. 
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CHAPTERS 
CONTRIBUTION OF SEVERAL METABOLITES 
OF THE VITAMIN D ANALOG KHI060 
TO THE OVERALL BIOLOGICAL ACTIVITY OF KHI060 
BY A SHARED MECHANISM OF ACTION 
Van den Bemd GJCM, Dilworth FJ, Makin HLJ, Prahl JM, DeLuca HF, Jones G, Pols HAP, 
Van Leeuwen JPTM 
Biochem Phannacol, 59, 621-627, 2000 
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5.1. ABSTRACT 
The synthetic 1,25-(OH),D3 analog KHI060 is considerably more potent than its 
cognate hOlIDone. The mechanism of action ofKHI060 includes interaction with 
the VDR. We previously showed that KHI060 increases VDR stability in ROS 
1712.8 osteoblastic cells by inducing a specific conformational change in the 
VDR. KHI060 is metabolized, both ill vivo and ill vitro, into several stable 
products. In the present study, we investigated whether these metabolites might 
contribute to the increased biological activity of KH1060. We found that the 
potencies of two of these metabolites, 24a-OH-KHI060 and 26-0H-KHI060 
were similar to that of 1,25-(OH),D3 in inducing osteocalcin production by the 
osteoblast cell line ROS 17/2.8. This report further showed that these metabolites 
had the same effect as KHI060 on VDR: they increased VDR stability in ROS 
1712.8 cells, while limited proteolytic analysis revealed that they caused a 
confol1national change in the VDR, resulting in an increased resistance against 
proteolytic cleavage. Furthermore, as shown in gel mobility shift assays, both 
compounds clearly induced VDR binding to VDREs. Together, these results 
show that the potent ill vitro activity of KHI060 is not only directed by the 
effects on the VDR conformation/stabilization of the analog itself, but also by 
celiain of its long-lived metabolites, and emphasizes the importance of detailed 
knowledge of the metabolism of synthetic hormonal analogs. 
5.2. INTRODUCTION 
The clinical usefulness of 1,25-(OH)2D3 in the treatment of cancer and 
immunological disorders is limited by its calcemic activity IVI,. (990). In an attempt 
to obtain agents with a more favorable therapeutic profile, numerous 1,25-
(OH)2D3 analogs have been developed (BooliM 1995'. Some of these analogs exert 
increased ill vivo and ill vitro activity compared to 1,25-(OH),D3' One of the 
most potent, KH1060, has velY strong effects on ill vitro cell growth and 
differentiation and has high immunosuppressive activity (Dillokrup 1991. modo"" 1992. ~ 
"'jog",,", 199'. Vm ,", B,,", 1995'. TIle mechanism(s) underlying the increased potency of 
KH I 060 are not completely clear. Interaction with the VDR is crucial for the 
action ofKHI060 IVm""B,rnJ 1995). In a previous study, we showed that, compared to 
1,25-(OH)2D3' KHI060 potently increased VDR stability in ROS 17/2.8 
osteoblastic cells. KH 1060 also induced a different conformation of the VDR, 
resulting in an increased protease resistance which is in line with the VDR 
stability data lV .. , .. n,"" 1996). Besides these VDR localized mechanisms, the 
metabolic characteristics of the analogs might also be impOliant. 
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Figure 5,1. Chemical structure of the side chain of 1,25-(OH),DJ and the 
modifications in the side chain of the synthetic analog KHI060 and its 
metabolites 24a-OH-KHI060, 24-0H-KHI060, 26-0H-KHI060, and 26a-
OH-KHI060 
[/I vitro KHI060 is metabolized into at least 22 different compounds, including 
several stable and biologically active ones (l>!"oM 1997). The fOlmation of these 
metabolites might contribute to the increased biological activity of KH 1060. In 
the present study, the 4 most abundant metabolites (24a-OH-KHI060, 24-0H-
KH1060, 26a-OH-KHI060, and 26-0H-KHI060) were examined as to their 
capability to stimulate osteocalcin synthesis in the osteoblast cell line ROS 
1712.8. Furthermore, the effects of these metabolites on VDR stability, VDR 
conformation, and VDR binding to VDREs were investigated. 
5.3. MATERIALS AND METHODS 
Reagel/ls 
aMEM and cycloheximide were from Sigma Chemical Co. L-Glutamine, 
penicillin, and sh'eptomycin were fi'om Gibco Life Technologies Inc. Fetal 
bovine serum was purchased from BioWhittaker. 32p_ATP and [35S]methionine 
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were from Amersham. Ribonuclease inhibitor recombinant RNasin and the TNT 
lysate assay were from Promega. Trypsin was fi'om Boehringer Mannheim. 
Poly[ dr-dC] was purchased from Pharmacia. 
Generation, Extraction alld Purificatioll of Metabolites o/KHI060 
HPKlA-ras cells (a gift from R. Kremer, Royal Victoria Hospital, McGill 
University, Montreal, Canada) were incubated with KH I 060 (provided by L. 
Bindemp and A.-M. Kissmeyer, Leo Phmmaceutical Products) to generate 
KH I 060 metabolites as described earlier (0;\"",," 1991'. The most abundant 
metabolites, i.e. 24a-OH-KHI060, 24-0H-KHI060, 26-0H-KHI060, and 26a-
OH-KHI060, were further examined in this study. Their identities were 
confirmed by GC-MS and their chemical structures are depicted in Figure 5.1. 
Osteocalcin Production Measurements 
TIle rat osteoblast-like cell line ROS 17/2.8 (provided by S.B. Rodan, Merck, 
Sharp & Dohme) was cultured for 24 hours with vehicle, or with 1,25-(OH)lDj, 
KHI060, or the metabolites (10. 14_10.8 M) as described earlier {\''" "'" "oro 1995,. 
Osteocalcin production was measured by radioil11l11unoassay cy,"""" 195". 
VDR Stability Study 
As described earlier (V,,'mB,,'" (9ge, the ROS 17/2.S cells were seeded in 100xlS mm 
tissue culture dishes and cultured for 2 days in o:MEM supplemented with 2 mM 
L-glutamine, 100 unitslml penicillin, 100 flg/ml streptomycin, 0.1 % D-glucose, 
and 10% fetal bovine semm. At SO% confluency, the medium was changed to 
o:MEM containing 2% charcoal-treated fetal bovine semm and 10 flM 
cycloheximide to block translation and thereby new synthesis of VDR. Next, 
vehicle, 1,25-(OH)lDJ, KH1060, or its metabolites (I nM) were added and after 4 
and 24 hours cell extracts were prepared (Wi'" 1991'. In the exh'acts, VDR content 
was measured using an enzyme-linked immunoassay (Uh1",,-$mifu(996). 
III vitro Transcriptioll and Translatioll 
Human VDR cDNA (M" 1988', a gift from M. R. Haussler of the University of 
Arizona, was ill vitro transcribed and translated in the presence of 
[ 35S]methionine (specific activity 1000 Ci/mmol) and ribonuclease inhibitor 
recombinant RNasin, using the TNT lysate assay according to the manufacturer's 
instructions. 
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Limited Proteolytic Digestioll of ill vitro Sylllhesized VDR 
11/ vitro synthesized VDR was incubated with 1,25-(OH),D3, KHI060, or the 
metabolites (10'''-10.9 M, 20 minutes, room temperature) and subsequently 
treated with trypsin (25 J.lg/ml) for 10 minutes at room temperature. Trypsin 
concentration-dependent (0-500 J.lg/ml) resistance was tested at 10 nM ligand. 
The labeled fi'agments were separated on a 12.5% (w/v) polyacrylamide gel and 
visualized by exposure to Fuji RX medical x-ray film. 
Gel Mobility Shift Assay 
Gel mobility shift assays with nuclear extracts fi'om ROS 1712.8 cells treated for 
I hour with vehicle, 1,25-(OH),D3, KHI060, or the metabolites (I nM) were 
perfonned as described earlier "u,1 1996'. The 32P-labeled rat osteocalcin (5'-
CTGCACTGGGTGAATGAGGACAITACTGA-3') and rat cytochrome P450 
(CYP24) VDRE oligo (5'-CGCGAGGTGAGTGAGGGCGCCGC-3') were 
incubated with 5 J.lg of nuclear protein in a final KCI concentration of 50 mM 
and in the presence of 0.1 J.lg/J.ll of poly[dI-dC] non-specific competitor DNA. 
The protein-DNA complexes were electrophoretically separated on a 5% non-
denatuting polyaclylamide gel in 0.5 x TBE (0.045 M Tris-borate; 0.001 M 
EDT A) buffer and visualized by autoradiography. The shifted probe was scanned 
fi'om the autoradiograph, and OD values were expressed relative to the OD of the 
shifted probe after vehicle treatment. For reasons of clarity standard deviations 
(always smaller than 10%) were not depicted in most of the figures. 
5.4. RESULTS 
Effect of 1,25-(OH),D" KHI060, alld the Metabolites Oil Osteocalcill 
Productioll by ROS 1712.8 Cells 
Figure 5.2 shows that 1,25-(OH),D3' KH1060, and the KH1060 metabolites 
induced osteocalcin production in a dose-dependent manner. On the basis of 
ED,o, KHI060 was the most potent analog (4.5xI0·13 M) followed by 24a-OH-
KHl060 (1.3xlO·11 M), 1,25-(OH),D3 (7.2xI0·1I M), 26a-OH-KHI060 (1.2xI0·1O 
M), 26-0H-KHI060 (2.5xlO·1O M), and 24-0H-KHI060 (1.4xI0·9 M). All 
metabolites and 1,25-(OH),D3 induced osteocalcin production with a similar 
maximum, whereas KH 1060 had a somewhat lower maximal response. 
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Figure 5.2. Effect of 1,25-(OH),D" KH1060, and its metabolites 24a-OH-
KH1060, 24-0H-KH1060, 26-0H-KH1060, and 26a-OH-KH1060 on the 
synthesis of osteocalcin by ROS 1712.8 cells. Cells were treated for 24 hOllrs with 
!'e!tiele or with 1.25-(OHhD3. KHI060. or its metabolites 24a-OH-KHl060, 24-0H-KHI060, 
26-0H-KH/060, alld 26a-OH-KHI060 (Irr14-lrr8 M) alld osteoca/cill secreted illto the 
medium lvas determined as described ill Materials and Aletlzods (Sectioll 5.3). Each point 
represellts the mean of two indepel1dent cultures ill duplicate. 
VDR Half-Life ill ROS 17/2.8 Cells 
Figure 5.3 shows the ligand-induced stabilization of the VDR in ROS 17/2.8 
cells. In the absence of ligand, VDR was rapidly degraded. At I nM, 1,25-
(OH),DJ' KHI 060, and its metabolites increased the VDR half-life in ROS 17/2.8 
cells, although there was a marked difference in potency. Incubation with 
KH1060 and 24a-OH-KH1060 resulted in the most potent stabilization of the 
VDR. After 24 hours incubation, still about 60% (KH1060) and 45% (24a-OH-
KH1060) of the initial VDR content was present. The other metabolites 
stabilized the VDR comparably to 1,25-(OH),DJ, while only 24-0H-KHI060 
seemed less effective. 
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Figure 5.3. Effect of 1,25-(OH},D" KHI060, and its metabolites 24a-OH-
KHI060, 24-0H-KHI060, 26-0H-KHI060, and 26a-OH-KHI060 on VDR 
half-life in ROS 17/2.8 cells. Cycloheximide-treated ROS 1712.S cells were illcllbated fol' 
4 01' 24 hOlll's with vehicle or with 1.25-(OH}2D3, KH1060, 01' its metabolites 24a-OH-
KHl060, 24-0H-KHJ060, 26-0lJ-KH1060, alld 26a-OH-KH1060 (I 11M). 17,en, extracts were 
prepared and assayed for VDR cOlltellt by enzyme-linked immunoassay. Data represent the 
means afthree independent experiments alld were e.\pressed as VDR contellt relative to T=O. 
Limited Proteolytic Digestioll of ill Vitro SYllthesized VDR 
As shown in Figures 5AA and B, 1,25-(OH},DJ, KH1060, and its metabolites 
24a-OH-KHl060, 26-0H-KHl060, and 26a-OH-KHl060 all protected, in a 
dose-dependent manner, ill vitro synthesized VDR against trypsin activity. There 
was a conservation of distinct fi'agments of 32, 30, and 27 kDa (Figures 5AA and 
C). We found that VDR incubated with KHlO60 or its metabolites 24a-OH-
KHl060 and 26-0H-KHI060 was less sensitive to trypsin than VDR incubated 
with 1,25-(OH},DJ or 26a-OH-KHI060. The metabolite 24-0H-KHI060 was 
virtually ineffective in protecting VDR against protease action. The effects on 
VDR conformation were further studied by taking a fixed ligand concentration 
(l0 uM) and a dose range of trypsin (Figures 5AC and D). In this set-up, the 
same order of potency of the ligands to protect the 32 kDa product was observed. 
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Figure 5.4. Effect of 1,25-(OH),D" KHI060, aud its metabolites 24a-OH-
KH1060, 24-0H-KHI060, 26-0H-KHI060, and 26a-OH-KHI060 on VDR 
conformation. /11 panel A, in vitro synthesized human VDR was incubated with increasing 
cOllcelltratiolls of 1,25-(OH)2D3. KH1060, or its metabolites 24a-OH-KH1060, 24-0H-
KIll060, 26-0H-KH1060, alld 26a-OH-KIlJ060. nell, VDRproteill was treated with fI)psbt 
(25 Jlg/JII/), alld tlte protease-resistallt jhlgmellts (32, 30, alld 27 kDa, marked a, b alld c, 
respectil'el)~ were allalyzed by SDS-PAGE. Tlte Iigalld cOllcelltratiolls testet/, 10.12_10-9 M, 
are indicated by 1-4. III pallel B, a computerized OD scan (mean of two experiments) of the 32 
kDa fragmellt (marked 'a' ill pallel A) at increasing ligand concentrations is shown, The ODs of 
tlte 32 kDa product were 1I0rmalized to tlte effect of 111M 1,25-(OH)2D3. A represelltative gel 
of a tl)psin concentration-dependent degradation of ill vitro syl1lhesized VDR treated with 10 
11M 1,25-(OH)2D3, 10 11M KH1060, or 10 11M of its metabolites is SltowlI ill pallel C. Tlte 
tlJpsin cOllcentrations tested, 0-5-25-100-500 pg/mf, are indicated by 1-5. Pallel D represents a 
computerized OD scan (mean of two e.\perimellls) of the 32 kDa product (marked by the 
arrowlteads ill pallel C) 1I0rmalized to tlte 1,25-(OH) 2D3 eflect at 5 Jlg/ml tl)psill. 
Gel Mobility Shift Assays 
In order to assess whether the KH1060 metabolites induce binding of the VDR to 
DNA, gel mobility shift analysis were perfonned. As shown in Figure 5.5, 1,25-
(OH),DJ' KH1060, and its metabolites induced binding of the VDR to the rat 
osteocalcin VDRE, with KH1060 and 24a-OH-KH1060 the most active, 26-0H-
KH1060 and 26a-OH-KH1060 were also more active than 1,25-(OH),DJ in 
stimulating VDR binding to the osteocalcin VDRE, while 24-0H-KH1060 was 
least effective. With the CYP24 VDRE, KHI 060 metabolite-induced VDR 
binding was also observed, and again 24-0H-KH1060 was least effective (data 
not shown), The shifted band (marked by the arrowhead) could be dislUpted by 
adding the anti-VDR monoclonal antibody IVG8CI I (Uhl~d·Smi. ""'J (data not 
shown). 
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Figure 5.5. Gel mobility shift assay with the rat osteocalcin VDRE probe and 
nuclear extracts of ROS 17/2.S cells. Results from a gel mobility shifl assay with 
Ill/clear extracts ji"Olll ROS 1712.8 cells treated for 1 hOl/r with vehicle (lalle I). 1 11M 1.25-
(OH}]D3 (lalle 2). 111M KH1060 (lalle 3). or 111M of its metabolites 24a-OH-KHl060 (lalle 4). 
24-0H-KH1060 (lalle 5). 26-0H-KH1060 (lalle 6). or 26a-OH-KH1060 (lalle 7) are presellted 
ill pallet A. A computerized OD scan (mean +/- standard deviations of two e.\perimell(s) of the 
shifled probe is presellted ill pallel B. The OD of the shifled probe ajier vehicle treatmelll was 
set to 1. 
5.5. DISCUSSION 
The present study addresses the important issue of the metabolism of synthetic 
hormone analogs and the biological activity and mechanism of action of the 
metabolites formed. Previously, we showed that part of the increased biological 
potency of the 1,25-(OH),D3 analog KHl060 probably lies in a specific 
interaction with the VDR. KHI060 enhanced the VDR half-life in ROS 1712.8 
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cells (VM d" B<ml 1996) and induced an altered conformational change in the VDR (VM "'" 
""ill 1996, P<I" 1"5, 'mri 1996), Besides these VDR-based mechanisms, metabolic aspects 
(e,g, increased metabolic stability or fOimation of biologically active 
metabolites) might also contribute to the increased potency ofKH1060, For other 
potent analogs of i,25-(OH)2D3' such as EB1089, MC1288, and 1,25-(OH)2-F6-
D3, ill vivo and ill vitro metabolic stability could playa role in their increased 
potency (l1I.lN.I99J,~,Ki>sm~wrl995,Sh.mkarI997). However, for KHI 060, the stability of the 
compound itself is not likely to be an important factor, since both ill vivo and ill 
vitro KHlO60 is metabolized at a rate comparable to or faster than that of 1,25-
(OH)lD
3 
(DilIHlM 1997,Ki»mew 1995). 
In addition to the metabolic stability of the analogs, the metabolites 
generated can also contribute to the biological potency of an analog, Both 
biological activity and stability detemline the impact of metabolites on the 
eventual biological potency of a parent compound, The biological activity of a 
metabolite does not necessmily have to surpass the activity of the parent 
compound to contribute to the overall effect. A metabolite with modest activity 
but increased stability will also add to the eventual effect (I~ "97, ~), An 
example of generation of metabolites with increased stability and significant 
biological activity is 1,23,25-(OH),-F6-D3' the major metabolite of 1,25-(OH)2-
F,-D3, which demonstrated distinct transcriptional activity in a reporter gene 
expression system (S"w,i 1995), Another example is the target tissue specific 313-
hydroxy epimerization of 1,25-(OH)2D3 (RolJy 1"7) and potentially its analogs, 
However, for the metabolites of the I ,25-(OH),D3 analogs EB I 089 (Sh,rn", I"q~""",,, 
1997), OCT OV,I.uub< 19%), and MC903 (Ki;,~", 1.>1), no contribution of the metabolites to 
the biological potency of the parent compound could be assessed, 
The supposition that metabolites of KHI060 might also add to the 
biological potency of the parent compound is underscored by the finding that 
several of its ill vitro generated metabolites (e,g, 24a-OH-KHI060 and 26-0H-
KH1060) retained trails-activating and mRNA inducing activity (Dil"" I."', In 
addition, the metabolites ofKHI060 might contribute to the biological activity of 
the analog ill vivo: in serum and in liver tissue taken from rats injected with 
KH1060, both 24a-OH-KHI060 and 26-0H-KHI060 could be identified (Dih,,,," 
l22D, and 24a-OH-KHI060 was detected in pig liver incubations I.,."",.A",,~' 1992), 
Here, we extend the observation that KHlO60 metabolites are biologically active 
and elucidate mechanisms involved in their action, Some of the metabolites were 
as potent as 1,25-(OH)2D3 while others were somewhat less potent but still able 
to induce osteocalcin production by ROS 17/2,8 cells, An interesting aspect of 
these metabolites is that they are stable, Even after 72 hours, they could be 
detected in cells treated with KH 1060 (Oil"" 199'1, This is in marked contrast to the 
metabolites of 1,25-(OH)2D3' which disappear very rapidly ~i>;"" 199<), 
Analysis of the possible mechanism(s) involved in the action of these 
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metabolites demonstrated that, like the parent compound IV~d<.B,"" ""', they affect 
VDR stability. The metabolites 24a-OH-KHI060, 26-0H-KH1060, and 26a-OH-
KHI060 enhance VDR stability comparably to or more than 1,25-(OH),D,. The 
metabolites 24a-OH-KHI060 and 26-0H-KH1060 also induce conformational 
changes in the VDR that result in an increased resistance to proteolytic cleavage 
compared to I ,25-(OH),DJ' while 26a-OH-KHI 060 exerts similar effects as 1,25-
(OH),D,. Gel mobility shift analysis with nuclear extracts fi'om ROS 17/2.8 cells 
revealed that KHI 060 metabolites also induce binding of the VDR to VDREs of 
vitamin D responsive genes. The low activity of 24-0H-KH1060 on the 
biological processes presented here underscores the significance of 
hydroxylation at C-24 in the 1,25-(OH),D, side chain in the inactivation of the 
hormone. In contrast, hydroxylation at C-24a only leads to marginal reduction in 
biological activity. 
From a conceptual point of view the present data are interesting. Not only 
the parent molecule itself but also its (long-lived) metabolites may exeti effects 
and act via similar receptor-mediated mechanisms. In so doing metabolites can 
significantly contribute to the eventual biological effect of an analog. Therefore, 
knowledge of both the metabolism of synthetic analogs and of the mechanism of 
action of the metabolites formed is of utmost importance. It is conceivable that 
this is not only applicable to vitamin D analogs, but also to other hormone 
analogs such as estrogen-like compounds, which have been the object of much 
recent attention ''''''~F'''', 1990. o,,,~ "". ow" 1997,. An additional aspect in the concept of 
the metabolism of synthetic analogs is target tissue-specific metabolism. Not 
only may synthetic analogs be metabolized to different, more active metabolites 
than the natural occurring counterpart, but this metabolism may also be target 
cell-It issue-specific IB,"', 1991'. This latter aspect may also be part of the clinically 
interesting target tissue-specific effects of vitamin D analogs as well as estrogen 
antagonists. 
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CHAPTER 6 
DISTINCT EFFECTS ON THE CONFORMATION OF 
ESTROGEN RECEPTOR ex AND ~ BY BOTH THE 
ANTIESTROGENS ICI 164,384 AND ICI 182,780 LEADING TO 
OPPOSITE EFFECTS ON RECEPTOR STABILITY 
Van den Bemd GJCM, Kuiper GGJM, Pols HAP, Van Leeuwen JPTM 
Biochem Biophys Res Commun 261, 1-5, 1999 
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6.1. ABSTRACT 
Tissue-specific effects of E, and synthetic ER ligands on target gene regulation 
might at least partly be explained by a selective ligand-induced conformational 
change of their receptors (ERa and EM), In this study, the effects of E, and the 
synthetic ER ligands tamoxifen, leI 164,384 and leI 182,780 on the 
conformation of ERa and EM were examined using limited proteolytic 
digestion analysis, We found that E, induced a conformational change of ERa 
resulting in the protection of a 30 kDa product whereas tamoxifen protected a 
28 kDa fi'agment. Strikingly, the ERa confonnational change induced by both 
leI 164,384 and leI 182,780 did not result in protection but rather seems to 
induce a ligand concentration-dependent increase in proteolytic degradation of 
the 30 and 28 kDa products, Incubation of ER~ with E, resulted in an increased 
protection of a 30 kDa fi'agment whereas with tamoxifen protection of a 29 kDa 
fragment was observed, In contrast to the situation with ERa, leI 164,384 and 
leI 182,780 incubation induced the protection of a similar 30 kDa fi'agment as 
E" In addition the leI compounds also induced in a dose-dependent manner the 
preservation of a 32 kDa fragment. Our observations demonstrate that leI 
164,384 and leI 182,780 have distinct effects on the conformation of ERa and 
ER~, resulting in receptor subtype-selective opposite effects on receptor 
stability ill vitro, 
6.2. INTRODUCTION 
The ER is expressed in two distinct [onns, ERa (Gr.:en (986) and ER13 (Kuiper (996, ~ 
!2W. Both ER subtypes bind estrogens and SERMs (Kui!l<T 1996, M05SelTlUn 1996, Co\\ky 19971, 
form dimers (Co.I,y 1997, Pm 19971, interact with basal transcription factors and 
coactivators /C<.m[ey (997, T~mbhy 199&), and bind to EREs in the DNA (CoI,-ley (997, Pa • .: (991) 
eventually leading to modulation of target gene transcription (Mo."Lruo 1996, C""y 1997, 
P,~h 19971, The distribution of both ER types varies among cells and tissues, Some 
tissues express predominantly one type of ER, while others express ERa and 
EM at more equal levels (Klip" 19971, Furthelmore, the ER subtypes can be 
differentially expressed during cell differentiation (Am 1997), It is tempting to 
speculate that the tissue-specific effect of estrogens and SERMs is at least partly 
based on the differential distribution of ER subtypes and selective interactions of 
the various ligands with these receptor subtypes, 
In view of the fact that the cascade of events resulting in target gene 
modulation is initialized by a conformational change of the receptor after ligand 
binding @O",'"'"1997', we investigated whether the conformation of ERa and ER~ is 
changed differently by the estrogen E, and the synthetic ER ligands tamoxifen, 
leI 164,384 and leI 182,780, Tamoxifen is a partial estrogen agonist/antagonist 
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and considered a SERM, whereas the ICI compounds are generally denoted as 
pure antiestrogens, although some agonistic effects have been reported (P'~h "97, "mil 
~,~, BJ~m 1993, Sibongl 1993. Ca;tr\}.Ri\-era 1998). 
6.3. MATERIALS AND METHODS 
Chemimls 
E2 and tamoxifen were purchased from Sigma Chemical Co, St.Louis, MO, USA. 
ICI 164,384 and ICI 182,780 were supplied by Zeneca Phmmaceuticals, 
Macclesfield, UK. Chemical structures are depicted in Figure 1.7. 
III vitro Trallscl'iptioll alld Trallslatioll 
Human ERa cDNA (T~ 195'" and ERJl cDNA (P,«h 19971 were ill vitro transcribed and 
translated for 2 hours at 30°C using the TNT lysate assay (Promega). Translation 
was performed in the presence of e5Sjmethionine (Amersham) to produce 
radioactive receptor protein. 
COllformatiollal studies 
Confonnational studies were perfOlmed as desclibed by Beekman et al. (B~kmm 1993'. 
ShOltly, ill vitro synthesized ERs were incubated with ligand (E" tamoxifen, ICI 
164,384, or ICI 182,780) for up to 30 minutes at 37°C in the presence of 10 mM 
Mg2+. The co-incubation studies were perfOlmed with 10,8 M E2 and increasing 
concentrations of either ICI 164,384 or ICI 182,780 added simultaneously to the 
ERs. After treatment with trypsin for 10 minutes at room temperature loading 
buffer was added. The samples were stored at -20°C or were directly analysed by 
SDS-PAGE (\2.5% w/v). The gel was dried and after radiography the bands 
were quantified by densitomelly. 
6.4. RESULTS 
In general, ERJl was less sensitive to trypsin than ERa (Figure 6.IA). Detailed 
analysis of the digestion products showed that Ilypsin Il'eatment (5 Jlg/mi) of 
ERa resulted in the formation of a distinct 28 kDa fi'agment and a faint 30 kDa 
fi'agment. Increasing the Ilypsin concenll'ation resulted in complete degradation 
of these fragments. Both E2 and tamoxi fen enhanced the hypsin resistance of 
ERa., However, the size and intensity of the preserved fi'agments vmied among 
the ligands studied. Incubation of ERa with E2 had a preserving effect on the 30 
kDa fi'agment, whereas incubation with tamoxifen resulted in an increased 
protection of the 28 kDa fi'agment (Figure 6.1). 
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Vehicle Estradiol Tamoxifen IC1164.384 
A 
o 5 25 100 250 0 5 25 100250 0 5 25100 250 0 5 25 100 250 
B 
1.0 1.0 T 
09 09 ERP 
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07 07 
06 .6 
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03 .3 
Q2 0.2 
01 01 
00' 0.0 
30 28kDa 32 30 29 kDa 
Figure 6.1. Trypsin resistance of ERa and EM after incubation with 
vehicle, E,. tamoxifen, or leI 164,384. In vitro synthesized ER was incubated with 
vehicle (-) (0.01% ethanol) or ligand: E2 (0). leI 164.384 (0), or tamoxijell (B) (1IJ-6 M), and 
subsequently treated with iI/creasing tl)psill cOllcelltrations (0-250 pg/Ill/). 17,e arrowhead 
illdicales the illtact ERs (Panel A). Computerized OD scans of the degradation products of ERa 
(at 5 Ilglml tl)PSill) and ERjJ (at 25 Ilglmlll)psin) are presented ill panel B. 17 .. maximal OD 
value measured in the E2 scans was set at olle wul was llsed as a reference for the other OD 
values. Each scan represents the mean affive illdepelldellt experiments. 
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In contrast, incubation of ERa with both ICI compounds did not result in 
increased protection of distinct fi"agments, but rather led to a slightly enhanced 
degradation of the receptor (Figure 6.2). The E,- and synthetic ligands-induced 
effects on ERa confonnation were ligand concentration-dependent (Figure 6.2). 
Trypsin h'eatment of vehicle-incubated EM resulted in the formation ofa 29 kDa 
fi'agment (Figure 6.1). E, protected a 30 kDa fragment, whereas tamoxifen 
mainly had an effect on a 29 kDa fragment. In conh'ast to the situation with ERa, 
both ICI 164,384 and ICI 182,780 induced a confOlmationa1 change of EM 
resulting in a stabilization demonstrated by the increased protection of a similar 
30 kDa fi'agment as seen with E,. Again these effects were ligand dose-dependent 
(Figure 6.2). 
Estradiol Tamoxifen IC1164,384 IC1182,780 
ERa ~30 
t'-"j ~ ·-32 
ER~ Ji~B 
0-11 ~ ·6 -11 ~ ·6 ·11 ~ ·6 -11 ~ ·6 
Figure 6.2. E,- and SERM-induced conformational changes of ERa and 
EM. III vitro sYllthesized ERa alld ERjJ 'were incubated with increasing COJlcentrations of E2, 
tamoxi[ell. ICII64.384 or IC1182,780 ([()·l LlfF6 M) as described ill Materia!s alld Methods 
(Sectioll 6.3) alld subsequelltly treated with 5 (ERa! or 25 fig/III! (ERJ3) ojtl)'Psill. 
Furthennore, the ICI compounds had a marked protective effect on an additional 
32 kDa fi"agment. At higher tamoxifen concenh'ations the 32 kDa fragment is 
also observed, whereas E, had hardly an effect on this fi'agment (Figure 6.2). Co-
incubation studies in which a fixed concenh'ation of E, and increasing 
concenh'ations ofthe lCI compounds were added simultaneously to the receptors 
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demonstrated that the E, effect on ER conformation can be overruled by the leI 
compounds (Figure 6.3). 
IC1164,384 IC1182,780 
ERa 
ER~ 
+++++++- - + + + + + + + -E, 
o 0 -11 ·6 ·6 o 0 -11 ~ ·6 ·61CI 
Figure 6.3. The effect of co-incubation of E, (10"8 M) and increasing 
concentrations of ICI 164,384 or ICI 182,780 (10-"-10-6 M) added 
simultaneously to in vitro synthesized ERa or ERIl. After treatmelll with 5 (ERa) 
or 25 pg/m/ (ERjJ) of 11)'Psill, the protease resistallt fragmellts were separated 011 a SDS-
polyacly/amide gel alld visualised by radiography. 
6.5. DISCUSSION 
Ligand-induced changes III receptor confonnation are a common feature in 
steroid honnone action fBe.:\aTl.ln 1993,~,~. Vanden Bern;! 1996, M~Do~!ll995) and it is believed 
that this event initiates a cascade of processes, eventually resulting in modulation 
of target gene transcription. Therefore, ligand-specific-induced changes in 
receptor confOlmation might underly the cell- and tissue-specific effects of 
estrogens and SERMs "V,,,,, 1995. Gre;, 1997. "om""'''. In addition, another aspect that could 
contribute to this was the identification of a second ER and the finding of a cell 
differentiation-dependent (Art; 1997) and tissue-specific distribution of ER subtypes 
(K";p" 1997). The current study shows distinct effects of the antiestrogens leI 
164,384 and leI 182,780 on the confomlation of the ER subtypes, resulting in 
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opposite effects on the stability of ERa and ERp. 
In general, we found that ERJl is more stable than ERa as exemplified by 
the increased protease resistance. This is not due to a diminished number of 
potential trypsin cleavage sites within the entire receptor molecule (about 60 in 
both receptor types) or ligand binding domain (about 20 in both receptor types), 
but is probably a direct consequence of its different conformation and resulting 
accessibility of trypsin cleavage sites. Whether the increased protease resistance 
of ERJl can also be observed in cells and tissues in terms of an increased receptor 
stability needs to be examined, but our previous conformational studies with the 
vitamin D receptor showed a close pal'allel between protease resistance of the 
receptor and its half-life in cells <v.",,",md 1996). This is further supported by our data 
obtained with ERa and the ICI compounds. The ligand-dose expeliments showed 
that ICI 164,384- and ICI I 82,780-incubated ERa was slightly more sensitive to 
trypsin compared to vehicle-incubated ERa while as it has been reported earlier 
ICI 164,384 impairs ERa dimerization IF""" ,m" resulting in reduced half-life of 
the receptor (Ih"'o" 1992'. Also, the observed loss of ER in uterine tissue ill vivo after 
ICI 164,384 treatment in mice was ascribed to an ICI 164,384-induced 
confOlmational change of ER, resulting in a reduced stability and proteolysis of 
the receptor ,G>wo '991). The effect of both ICI compounds on ERIl is in marked 
contrast with the effect on ERa. With ERP we observed a clear increased 
protease resistance. Interesting in this respect is the finding by Pace e/ al. tp." ,99]) 
showing that ICI 182,780 was not effective in preventing loss of ERa binding to 
an ERE when the incubation temperature was increased fi'Om 4°C to 37°C 
whereas elevating the temperature did not affect ERJl-ERE binding. Loss of a 
specific ERa confOlmation suitable for DNA binding after incubation with this 
ICI compound was put forward as an explanation for the decreased ERa-ERE 
binding. Their observation that ICI 182,780 did protect ERJl fi'om heat 
inactivation might result from a distinct effect on the conformation of ERP in line 
with our findings presented in this study. 
Both ICI 164,384 and ICI 182,780 are denoted as pure antagonists O'''''io,I992. 
Ni,""," ""', although some studies report an agonistic potency that could be based 
on an ER subtype-selective interaction (Paech 1997,Janu11991, Chetri!e 1991, B~m 1995, Sibonga 1998, Castro-Riwra 
1998'. However, it is yet not possible to directly translate the present data into a 
receptor subtype-selective agonistic or antagonistic potency of the ICI 
compounds. In this respect one should take into account that the agonistic effects 
of SERMs may be cell type specific, dependent on the presence or absence of 
certain transcription factors oY''''' '''S). Also, studies perfOlmed by Watanabe e/ al. 
(W'='" ''')) showed that the agonistic effect of tamoxifen was dependent on ER 
subtype, in combination with cell type and ERE promoter context. Therefore, 
conformational studies performed in a cellular context of different target cells 
might provide more insight. 
Finally, our protease digestion assays clearly demonstrated different ER 
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confOlmations induced by E, and the synthetic ER ligands with both ERa and 
ERp. Furthermore, there was a marked difference between the ER conformations 
induced by leI 164,384 and leI 182,780 and the ER conformations induced by 
tamoxifen (Figures 6.1 and 6.2) and other synthetic ER ligands with partial 
agonistic/antagonistic properties (4-hydroxytamoxifen, idoxifen and L Y 
117,0 18-Hel; data not shown). Also in line with observations by McDonnell et 
al. Q""'-" "'" we could not discriminate between tamoxifen and other ER ligands 
with partial agonistic/antagonistic activities (data not shown). 
In conclusion, the present study shows that ERa and ERn respond to both 
leI 164,384 and leI 182,780 with a distinct confOlmational change: ERa 
conformation changes into a less stable, more protease sensitive form, whereas 
ERfl confol1nation is changed into a more stable, less protease sensitive form. On 
basis of these clear opposite effects of the leI compounds which were not 
observed with E, and tamoxifen it is tempting to speculate that the leI 
compounds are ER subtype selective ligands. The observed Iigand- and receptor-
specific effect on receptor stability, together with the tissue specific distribution 
of ERa and ERn may be part of the mechanism that determines tissue specific 
agonistic/antagonistic properties of ER ligands. 
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CHAPTER 7 
SUMMARY AND GENERAL DISCUSSION 
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7.1. INTRODUCTION 
Both ER and VDR belong to the same superfamily of nuclear receptors and both 
receptors are activated by interaction with their ligands. Via a complex cascade 
of events already discussed in Chapter I this interaction will eventually lead to 
regulation of target gene h·anscription. Conformational changes and 
phosphorylation of the receptor, as well as interaction with dimer-partners, 
cofactors, basal h'anscription factors, and specific sites in the DNA are major 
events in this cascade. 
1,25-(OH),DJ and E" the natural ligands for VDR and ER, respectively, 
have potential therapeutic properties. However, their use as therapeutic agents 
is limited because of certain side effects (Chapter I, Sections 1.3.1 and 1.6.1). 
The search for compounds with a more beneficial therapeutic profile initialized 
the development of synthetic ligands for VDR (I,25-(OH),DJ analogs) and ER 
(SERMs). In case of VDR ligands this means that the dissociation between 
calcemic effects and effects on cell proliferation and differentiation is enlarged, 
in case of ER ligands this means that the beneficial agonistic effects of E, (e.g. 
maintenance of bone mass, improved cognitive function) are mimicked, while 
undesirable effects (e.g. increased risk for breast and uterine cancer) are 
antagonized. Indeed, several of the newly synthesized compounds have 
improved characteristics compared to the natural ligands. An explanation for 
the changed biological profile is not completely clear and obviously not similar 
for all synthetic ligands. It probably lies in specific interactions with one or 
more of the events in the cascade mentioned above (see also Sections 1.3.3. and 
1.6.3.). 
The aim of the studies presented in this thesis was to extend the knowledge 
on the mechanism of action of the VDR and ER, and their modified ligands in 
particular. Therefore we evaluated the differences in effect of 1,25-(OH),DJ and 
a selection of its analogs on differentiation and growth of osteoblast-like cells 
and on ill vitro bone resorption (Chapter 2), and investigated the role of VDR 
affinity (Chapter 2), confonnational change of the VDR (Chapter 3), VDR 
stability (Chapter 3), VDRE binding (Chapter 4), and metabolism of 1,25-
(OH),D3 analogs (Chapter 5). In Chapter 6 the effect of a selection of SERMs on 
ER conformation was studied. In the Sections below the results are discussed and 
suggestions for further research are given. 
7.2. THE VITAMIN D RECEPTOR, 
1,25-DIHYDROXYVITAMIN D3, AND 
1,25-DIHYDROXVITAMIN D3 ANALOGS 
The first part of this thesis focusses on ligand interaction with the VDR. 
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Strikingly, most investigations studying 1 ,25-(OH)2D3 analogs do not use cells of 
bone origin - a classic target tissue - but rather nonclassic target cells like breast 
cancer cells and cells of the immune system. However, in our view also the 
effects on bone should be evaluated to establish an accurate biological profile of 
the analogs. Therefore, the rat osteoblast-like cell line ROS 17/2.8 and the human 
osteoblast-like cell line MG-63 was used as a model to evaluate the effect of 
several side chain-modified 1,25-(OH)2D3 analogs on growth and differentiation 
of these cells and to compare their potency with that of 1,25-(OH)z03' 
FurthemlOre, isolated long bones from fetal mice were used to study the capacity 
of 1,25-(OH)z03 and the analogs to release calcium fi'om bone. 
EFFECTS ON CELL GROWTH AND DIFFERENTIATION 
AND ON IN VITRO BONE RESORPTION 
All 1,25-(OH)z03 analogs examined in this thesis exhibited agonistic activity in 
all responses tested: like 1,25-(OH)2D3 the analogs stimulated the synthesis of the 
bone matrix proteins osteocalcin and type I procollagen. FUlthermore, the 
analogs mimicked the nahlralligand in their effect on osteoblast-like cell growth 
and in their stimulatOlY effect on ill vitro bone resorption (Chapter 2). Some 
analogs (OCT, MC903, CB966) exhibited an ill vitro biological potency 
comparable to that of 1 ,25-(OH)2D3. whereas others (KH 1049, KHI 060, EB 1089) 
were much more potent than 1,25-(OH)2D3' This observation is supported by 
almost evelY ill vivo and ill vitro study published so far: 1,25-(OH)2D3 analogs 
are super, full, or partial agonists of 1,25-(OH)2D3' However, recent data from 
Arai et al., Ishizuka et al., and Miura et al. indicate that a metabolite of 1,25-
(OH)2D3; I ,25-(OHlz-26,23-lactone D3, and its analogs might have antagonistic 
properties (An;lm.l;hiruhl997.~I. Although these data are preliminmy, they indicate 
that VDR ligands with specific antagonistic propelties can be developed. 
We found that the potency of the 1,25-(OH)2D3 analogs was related to the 
biological response. In some responses their potency (compared to 1,25-
(OH)2D3) was only moderately increased, while in other responses the increase in 
potency was much more striking. In Table 2.3 this differential effect on gene 
regulation is expressed as the ED,o ratio for stimulation of ill vitro bone 
resorption and stimulation of extracellular bone matrix protein synthesis. It 
clearly demonstrates that for EBI089 and KHI060 the ED,o ratio is increased 
compared to the ED,o ratio for 1,25-(OH)2D3' The finding that for some analogs 
the ED,o ratio between bone formation parameters (stimulation of osteocalcin 
and type I collagen synthesis) and bone resorption parameters (stimulation of 
calcium release) is increased compared to the ED,o ratio for 1,25-(OH)2D3 
might support a therapeutic potential of these analogs in the treatment of 
metabolic bone diseases, i.e. osteoporosis. A relationship between increased 
bone tumover and the risk for metastasis of cancer to bone has been reported 
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(Ag'" 1976, Orr 1993), The ill vivo potency of these analogs to induce bone resorption 
must therefore be examined with great care, 
The studies presented in Chapter 2 show cell type-specific differences in 
sensitivity for 1,25-(OH),DJ and some of the analogs. For instance, in MG-63 
cells maximal stimulation of osteoca1cin production by EB1089, KH1049, and 
KH 1060 was almost two-fold increased compared to 1,25-(OH),D3 and the 
analogs with moderate activity (OCT, MC903, CB966), while no difference in 
maximal stimulation was observed in ROS 17/2.8 cells. However, in general, 
MG-63 cells were considerably less sensitive than ROS 17/2.8 cells. For 
instance, in MG-63 cells the ED,o for osteocalcin synthesis induced by 1,25-
(OH),D3, OCT, CB966, or EB 1089 was reached at 100-600 times higher 
concentrations than in ROS 17/2.8 cells. Cell type-specific differences in VDR 
content andlor function might underly this phenomenon. We found that MG-63 
cells have a much lower VDR content compared to ROS 1712.8 cells and do not 
show homologous VDR up-regulation (data not shown). In addition, cell type-
specific differences in presence andlor dish'ibution of cofactors might playa role. 
We also observed that the ED,o's for both KHI049 and KHI060 (both 20-epi 
analogs) were comparable between the two cell lines, indicating that for these 
analogs cell type-specific differences might be of less importance. Another 
possibility is that KHI049 and KHI060 are metabolized more efficiently by ROS 
1712.8 cells, (or less efficiently by MG-63 cells) in relation to 1,25-(OH),D3 and 
the other analogs. This could lead to relatively high concentrations of KH 
analogs in MG-63 cells or relatively low concentrations of these compounds in 
ROS 17/2.8 cells. 
With most cell types 1,25-(OH),D3 has an inhibitOlY effect on growth; a feature 
that gave rise to the thought to use 1,25-(OH),DJ or its analogs for the treatment 
of hyperproliferative diseases (Co.", 1981, At< 1981), Likewise, with the human 
osteosarcoma cell line MG-63 and the human breast cancer cell lines MCF-7 and 
ZR75-1 our laboratOlY observed dose-dependent inhibition of proliferation by 
1,25-(OH),D3 and its analogs (Chapter 2). 1V"",Vw "Ho,,.,,, 199" However, the rat 
osteblast-like ROS 1712.8 cells were stimulated in their growth. Interestingly, the 
analogs exhibited a similar order of potency in their growth inhibitOlY activity (in 
MG-63 cells) and in their growth stimulatory activity (in ROS 17/2.8 cells). The 
observed 1,25-(OH),D3- and analog-induced growth stimulation of ROS 17/2.8 
cells is in line with other reports ~1,;"h 1982, V"A""rr 199". 1,25-(OH),D3 also caused an 
increased growth of ROS 17/2.8 cells inoculated into athymic nude mice (yW",ig 
-. However, others have shown an inhibitory effect of 1,25-(OH),D3 on the 
growth of these cells, although they also observed a statistically nonsignificant 
stimulation of cell growth at a lower 1,25-(OH),D3 concenh'ation (0.1 nM) ~ 
198". An explanation for this discrepancy could be the subc10ne heterogeneity 
within this cell line (Gri,ori"" 1985), while also experimental conditions (serum 
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composition, differences in cell densities or differentiation state of the cells) 
could playa role. Also in several other studies with other cells 1,25-(OH),03 and 
1 ,25-(OH),03 analogs have shown to exert growth stimulatOlY effects (Goll',1997.J'!!&! 
!2!l,~,~, Gmc/rJeoo5hua 1999, l>hld! ]993, D.!lim!<k 1993, Gache 1999, Gnilde(ki 1995) 
An explanation for the induced cell growth is still not revealed. Yamaoka 
et al. showed that presence of the VOR seems essential to observe growth 
stimulation by 1,25-(OH),03 since tumor weight in mice inoculated with VOR 
deficient ROS 2411 cells or with 0-361 melanoma cells with low VOR levels 
was not affected by 1,25-(OH),03 (y=ou I"". A 1,25-(OH),03"induced increase of 
ErbB 1, ErbB2, and ErbB3 -proteins that mediate signal transduction by EOF 
receptor ligands- was proposed as a possible mechanism (G_~Id"ilim 1m,. Also, the 
1,25-(OH),03"induced lise in c-myc mRNA expression was put forward as an 
explanation for the stimulatOlY effect on cell growth (G"~, '995). Nevertheless, our 
data and the reports mentioned above indicate that caution is needed in the use of 
1,25-(OH),03 or its analogs in the treatment of cancer. 
VDR CONFORMATION AND VDR STABILITY 
One of the key events in the cascade leading to regulation of gene transcription is 
the ligand-induced conformational change of the VOR. To study the effects of 
1,25-(OH),O) and KH1060 on VOR conformation pal1ial proteolytic digestion 
analysis was used. The method is based on the idea that accessibility of potential 
protease cleavage sites within a receptor molecule alters as a result of ligand-
induced changes in receptor conformation. Consequently, changes in receptor 
conformation will lead to changes in the protease digestion pattern of the 
receptors. We found that in the absence of ligand il/ vitro synthesized VOR is 
rapidly degraded by proteases. In contrast, 1,25-(OH),03 and the analogs 
changed the VOR conformation, resulting in enhanced protease resistance of 
distinct VOR fragments. In general 1,25-(OH),03 analogs can be regarded as 
agonists (Bowl'" )9'", although the potency by which they mimic the natural ligand 
differs between tissues, cells, and responses studied. This probably explains why 
we could not establish qualitative differences in the VOR protease digestion 
profiles of 1,25-(OH),03 and the analogs: the sizes of the protease resistant VOR 
fragments were not distinct, only the intensity of the preserved fragments was 
different. Also other investigators could not discriminate in a qualitative way 
between 1,25-(OH),03 and 1,25-(OH),03 analogs using this technique (V_o '997. 
Interestingly, we and others found that treatment of unliganded il/ vitro 
synthesized VOR with low trypsin concentrations resulted in preservation of 
VOR fi'agments with a similar size as the fi'agments observed with liganded VOR 
(Chapter 3) ",,,ri )996. ,,,,ri )997'. When protease digestion was intensified (by 
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increasing the tJypsin concentration or the tJ'ypsin incubation time) these 
fragments disappeared, whereas the fragments of liganded VDR were still 
protected. Nayeri e/ al. suggested that this might indicate that ligand interaction 
has more impact on VDR stability (by preserving the conformation) than on the 
confotmation itself iN"" '997). However, partial protease digestion analysis is a 
rather insensitive method and based on findings obtained with other techniques it 
is clear that ligand-induced changes in VDR confotmation do occur 'u" (997). 
Therefore, we think that both stabilization as well as induction of a 
conformational change are import in the interaction of analog and receptor. 
Nayeri e/ al. found a correlation between the transcriptional activity of a 
defined series of 20-epi-analogs with closely related structures and their 
potency to change/stabilize the VDR conformation (i.e. the functional receptor 
affinity) iNm' 1996'. Our observation that 1,25-(OH),DJ analogs and metabolites 
with strong biological activity are also strong inducers of a VDR conformation 
with increased protease resistance and vice versa is in line with their finding 
(Chapters 2, 3, and 4). However, one should be cautious in overestimating the 
quantitative differences obtained by limited protease digestion analysis. For 
instance, the strong biological effect of EBIOS9 (an analog with normal 
configuration at C-20) is not reflected by a stJ'ong increase in the intensity of 
protease resistant VDR fragments (data not shown) (O""k 1996. Kom»" """. One can 
not exclude the possibility that some potent 1 ,25-(OH),DJ analogs might induce 
a conformational change of the VDR that does not lead to increased protease 
resistance but even to increased protease sensitivity. 
Clystal stJucture analysis revealed that liganded nuclear receptors adopt a 
more compact structure, obviously less sensitive to protease activity ""',," ''''I. In 
cells this property could lead to increased VDR stability. Indeed, our studies 
presented in Chapters 3 and 5 show that 1,25-(OH),DJ, analogs and specific 
metabolites of the analog KHlO60 prolong VDR half-life in ROS 17/2.8 cells. 
These observations are consistent with findings by others (IV;'" ''''. ~. u" '997. 
""~= 199". Recently it was reported that protesomes are involved in VDR 
degradation """"'= "98', and that chymotJypsin-, and tJypsin-like proteasome 
activities are observed in human osteoblast-like cells ffi="",", M=y ''''', indicating 
that our observations obtained with nypsin and chymotJypsin in the partial 
digestion analysis also might playa role in intact cells. Recently it was reported 
that 1,25-(OH),D,-induced up-regulation of the VDR might be due to inhibition 
of proteasome-mediated VDR degradation (U ""'. In proteasome-mediated 
receptor degradation the cofactor SUG 1 is probably important. Interestingly, it 
was found that SUG 1 binds the VDR in a 1,25-(OH),DJ-dependent manner and 
enhances its proteosome-mediated degradation """,,,~ 1998,. So, on the one hand 
ligand interaction leads to a confotmational change of the VDR by which the 
receptor becomes less vulnerable for proteasome-mediated degradation, whereas 
on the other hand ligand interaction seems to stimulate proteosome-mediated 
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degradation of the receptor. Although this seems contradictory, it is thought that 
just because of its increased stability, the liganded VDR requires a more 
specialized mechanism to control its h'anscliptional activity 0'""",= "98'. Therefore, 
besides ligand metabolism also receptor degradation might be a mechanism to 
control the biological activity of VDR ligands. 
DNA BINDING 
The ligand-indnced conformational change of the VDR probably fascilitates 
dimerization with RXR """ "'" and enhances binding to specific regulatory 
elements (VDREs) in the vicinity of 1,25-(OH),DJ target genes. In Chapter 4 the 
potency of KH I 060 was compared with the potency of 1,25-(OH),DJ to induce 
binding of the VDR to VDREs. Both ill vitro synthesized VDRlRXR as well as 
nuclear extracts of ROS 1712.8 cells were used to investigate VDR binding to 
VDREs from three different target genes: rat osteocalcin, human osteocalcin and 
mouse osteopontin. Both 1,25-(OH),DJ and KH1060 induced VDR binding to 
these VDREs in a ligand dose-dependent manner, independent of the source of 
VDRs (ill vitro synthesized or nuclear extracts). All three VDREs are of the DR3 
type: two hexameric half-sites separated by three nucleotides, and despite of 
minor differences in nucleotide sequence (see Table 4.1) large differences in 
VDR-VDRE affinity were observed. The VDR bound with lowest affinity to the 
rat osteoca1cin YORE, and with highest affinity to the mouse osteopontin VDRE. 
We further elaborated on this interesting finding and produced hybrid VDREs in 
which the rat osteocalcin VDRE half-sites were replaced by one or both mouse 
osteopontin VDRE half-sites. Gel mobility shift assays performed with these 
VDREs clearly showed that the proximal half-site of the mouse osteopontin 
VDRE (i.e. the OC/OP VDRE) was mainly responsible for the increased affinity. 
Transfection studies in ROS 1712.8 cells revealed that 1,25-(OH),Dr induced 
transcription of the OC/OP YORE-driven reporter gene was more effective than 
via the rat osteocalcin YORE-driven reporter. Further substihltion studies 
revealed that in particular the third and/or fourth nucleotides (both thymidine) 
detemlined the difference in VDR-VDRE affinity. 
We found that KHI060 was a sh'onger inducer of VDRlRXR binding to 
the mouse osteopontin VDRE than 1,25-(OH),DJ. However, surprisingly, when 
we studied binding of ill vitro synthesized VDRlRXR to the human and rat 
osteocalcin VDRE KHI060 exhibited no increased potency compared to 1,25-
(OH),DJ. In conh'ast, when VDR protein was extracted from ligand-h'eated cells 
KHI060 was a sh'onger inducer ofVORIRXR-VDRE binding than 1,25-(OH),DJ 
with all VDRE types tested. So, this indicates that the KH1060-induced 
confmmational change of the VDR does not necessarily result in enhanced 
VDRE binding, but in addition depends on the YORE nucleotide sequence and 
furthermore underlines the importance of a cellular context (e.g. presence of 
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co factors) to obtain optimal VDR-VDRE binding. Therefore, it seems justified to 
speculate that KHI060 changes the VDR conformation in such a way that, 
compared to the 1,25-(OH),Drinduced VDR conformation, cofactor binding is 
fascilitated or that other KHlO60-specific cofactors are involved and that this 
will lead to increased VDR-VDRE binding. 
ANALOG METABOLITES 
Formation of biologically active metabolites might be a cause for concern. 
Obviously, Ii-om a therapeutic point of view rapidly acting analogs with inactive 
metabolites are much better to control than analogs that are metabolized into one 
or more active metabolites. For each of these metabolites the mechanism of 
action and possible side effects should be established before safe clinical use can 
be guaranteed. Chapter 5 focusses on the potential conuibution of metabolites of 
KHI060 to the biological potency of the parent compound. Earlier was shown 
that ill vitro KHlO60 is metabolized into at least 22 different compounds (DilM"" 
=. The metabolites 24a-OH-KHl060, 26-0H-KHI060, and 26a-OH-KHI060 
were potent inducers of osteopontin mRNA expression, rat osteocalcin VDRE-
driven reporter gene transcription {Oil""",, 19''', and active stimulators of osteocalcin 
synthesis (Chapter 5). The same metabolites were also active inducers of VDR 
binding to rat osteocalcin and rat cytochrome P450 (CYP24) VDREs (Chapter 
5). Next, we investigated whether the biological potency of these metabolites was 
correlated with their potency to induce a conformational change of the VDR with 
enhanced protease resistance. Indeed, partial protease digestion analysis showed 
that the biological active metabolites changed the VDR conformation resulting in 
enhanced protease resistance, whereas a metabolite with weak biological activity 
was inactive in the protease digestion analysis. A corresponding pattern was 
observed studying the effect of the metabolites on VDR stability in ROS 1712.8 
cells. 
KHl060: THE MECHANISM OF ACTION RESOLVED? 
KH 1060, one of the most potent analogs was studied in more detail. TIle studies 
enclosed in this thesis present several indications of differential interactions of 
KH 1 060 with the cascade of events leading to gene transcription. Based on these 
investigations and the studies of others we consu'ucted a scheme depicting 
potential explanations for the increased biological activity of KHlO60 (Figure 
7.1). 
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Figure 7.1. Possible explanations for the increased biological potency of 
KH1060. l1ze numbers refer to the section below. Arrows ill bold indicate that a process takes 
place willi illcreased efficiellcy compared 10 llie 1,25-(OH) 2D3 silllalioll. 
1. The effect of KHI060 on the conformational change and stability of the 
VDR 
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In Chapter 3, using partial digestion analysis, we showed that the KH1060-
induced VDR conformation is more resistant against protease activity than the 
1,2S-(OH),D,-induced VDR conformation. Similar observations were 
obtained by others "d,S 1995. Nmri 19961. The conformational change is probably the 
trigger of the changes in all subsequent steps. The KH 1060-induced increase 
in receptor stability in cells is in parallel with the KHlO60-indnced increase in 
protease resistance in the partial digestion analysis. These and recent findings 
by Brochmann Munay e/ al. indicate that resistance for enzymes like trypsin 
and chymotrypsin might reflect the resistance for enzymes involved in 
receptor processing in cells ffi=horuomM=y l9981. 
2. The effect ofKHl060 on dimel'ization 
Peleg et al. showed that KHI060 was more potent than 1,25-(OH),D3 in 
stimulating VDR-RXR dimerization (P,k,I99". 
3. The effect of KH1060 on VDRfRXR binding to VDREs 
KH 1060 was more potent than 1,25-(OH),D] in stimulating the binding of 
VDRlRXR to different VDREs. The variations in nucleotide sequences 
between these VDREs had an impact on the affinity of the VDRIRXR 
complex, but also on the relative potency of KH1060 compared to 1,25-
(OH),D] to induce this binding. This might underly the differential effects of 
KH1060. As illustrated in Figure 7.1, at genes of the 'A' type, KHI060 is 
only moderately more potent than 1,25-(OH),D]. while at 'B' genes KH1060 
has a much stronger activity. The importance of a cellular context to VDR-
VDRE binding was also demonstrated in these studies (Chapter 4). 
4. The contribution ofKHl060 metabolites 
Some of the metabolites exert biological activities comparable to or stronger 
than those of 1,25-(OH),D] (Chapter 5) ,nil",,," 19"'. Like the parent compound, 
these KHI060 metabolites decreased the protease sensitivity of the VDR, 
increased the VDR stability in cells, and enhanced VDRIRXR binding to 
VDREs. Together these data indicate that certain metabolites might contribute 
to the overall biological activity ofKH1060. 
Although other mechanisms are not excluded we think that these aspects are of 
major importance in determining the increased biological activity ofKH1060. 
7.3. THE ESTROGEN RECEPTOR, 17~-ESTRADIOL, AND 
SELECTIVE ESTROGEN RECEPTOR MODULATORS 
The second part of the thesis focusses on ligand interaction with the ER. We 
studied the effect ofE, and several synthetic ER ligands on the conformation of 
both ER SUbtypes: ERa and ER1l. One of the tested ER ligands, tamoxifen, is a 
SERM with tissue-dependent partial agonistic/antagonistic activities: it mimics 
E, with anabolic effects on bone, protective effects on the cardiovascular 
system, and beneficial effects on cognitive function, whereas it counteracts the 
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stimulatory effect of E, on breast tumors (See Section B.S.2.). An explanation 
for the tissue-dependent partial agonistic/antagonistic activition of SERMs is 
still unknown. 
Using partial protease digestion analysis we showed that tamoxifen changed the 
confotll1ation of both ERa and ERP differently from that induced by E,. Also 
other partial agonists/antagonists (4-hydroxytamoxifen, idoxifen, and the 
raloxifene derivative L Y 117,0 18-Hel) had a similar effect as tamoxifen. Like 
other investigators we could not discriminate between different SERMs based on 
the protease digestion profiles ",,",,~"" "95'. Other teclmiques, like phage enzyme-
linked immunoassays have shown to be more suitable for this purpose IF,)" 19991. 
Furtelmore, it is difficult to translate the intensity of the preserved fi'agments 
obtained with the partial protease digestion analysis into a functional receptor 
affinity as was done for VDR analogs "",,<oi 1996). Therefore, protease resistance (as a 
tool to study ligand-induced confOimational changes of a receptor) can only be 
used to calculate a functional receptor affinity as was done by Nayeri et al. when 
the investigated ligands exert agonistic activities. However, for nuclear honnone 
receptors like the progesterone receptor and ER (partial) agonistic/antagonistic 
ligands are known. Interaction with these ligands lead to a conformational 
change of the receptor that is clearly distinguishable by partial digestion analysis 
fi'om the conformational change induced by ligands with pure agonistic action 
(Allln 1991. ~lcD..'I1!1e!ll995). 
ICI 164,3841ICI 182,780: THE MECHANISM OF ACTION RESOLVED? 
leI 164,384 and leI 182,780 are generally considered as pure antagonists of E, 
(lV,(,"", 1992) and, therefore, no real SERMs. However, data are accumulating that 
show SOQ1e agonistic effects of leI compounds. In Table 7.1 the agonistic effects 
of the ICI compounds both ill vivo and ill vitro are summarized. 
Table 7.1. III vivo and ill vitl'o agonistic effects of ICI 164,384 and ICI 
182,780 
GENE I RESPONSE 
AP~ 1 reporter gene 
Collagenase reporter gene 
Creatine kinase B reporter gene 
Progesterone receptor level 
Progesterone receptor level 
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CELL I TISSUE I SPECIES 
different celllypes 
different cell Iypes 
human endometrial cancer cells 
human endometrial cancer cells 
guinea pig vagina, uterus cells 
(REF) 
CPaech 1997) 
(Webb 1995) 
(Castro·Rivera 1998) 
(JamBI99!) 
(Chetflte 1991) 
Quinone reductase 
Retinoic acid receptor a-I 
TGFp3 reporter gene 
ERE reporter gene 
ERE reporter gene 
ERE reporter gene 
Oxytocin / prostaglandin Flu 
Cancellolls bone tumover 
Bone mahlration 
human breast cancer cells {Montano 1991) 
human breast cancer cells, liver cells (E1gort 1996,7.ou 1999) 
human osteosarcoma cells (Yang 1996) 
human kidney epithelial cells (Barkhem 1998) 
chinese hamster ovary cells (Montano 1995) 
yeast (Lyttle 1992, 
blood; ewes 
bone; ovariectomized rats 
bone; immature mice 
McDonnell 1992, 
Kohno 199-1) 
(AI-Matubsi 1998) 
(Sibonga 1998) 
(Gunther 1999) 
An explanation for the agonistic properties of the TCT compounds is not known. 
Webb e/ al. suggested that the low number of reports showing agonistic effects 
of TCT compounds is due to the fact that most studies focus on classic ERE-
controlled genes while agonistic properties of ICI can be observed with AP-l 
responsive genes <,I·<l. 19'>5). However, others reported also with ERE-controlled 
genes agonistic activities of the leI compounds /L11t1e 1992, MdNnne111992,~, Montm:> [9')5, 
B,Thh<m '""'. Montano e/ al. only observed agonistic activity of TCT 164,384 at 
concentrations lower than 10.8 M, whereas higher concentrations were not active 
probably because of the observed Ter-induced ER degradation ~Ioo""" ,9>". Tn line 
with this, Webb e/ al. found that induction of the collagenase promoter by ICI 
required supraphysiological ER levels, and concluded that because of this 
requirement il/ vivo agonistic activity of TCI compounds will be rare ow'" 1995'. 
Tn the partial protease digestion analysis presented in Chapter 6 we found a 
receptor subtype-dependent effect of the Tel compounds: the ERa confOimation 
was changed in such a way that increased protease sensitivity was observed, 
whereas with ERP increased protease resistance was induced. It is tempting to 
speculate that the agonistic effect of the ICI compounds might be exerted via 
ERP and not ERa. However, Barkhem e/ al. showed an agonistic effect of ICI 
164,384 through ERa and not ERP IBllih<m '""'. An explanation for this discrepancy 
is not known, but might be due to differences in cellular context (e.g. cofactors) 
in which these and our studies were perfonned. 
Our observation of Ter-induced enhanced protease sensitivity of ERa fits 
nicely with the findings of a decreased ER half-life in cells and tissues after 
treatment with the ICI compounds 'G.b~ ''',. R~" ''''. -='. As an explanation for 
the decreased ER half-life Ter-induced impaired ER dimelization was suggested 
IDam'Qisl993), although others could not confinn this (Wang 1995,Mdl.gerl995). Assuming that ER 
binding to EREs only takes place as dimers, we also find no indication for 
impaired ER dimerization by the ICI compounds, since we did not find that the 
ICT compounds decreased ERE binding of ill vitro synthesized ERa and ERP 
(data not shown). It was suggested by Dauvois e/ al. that the reduced ER half-life 
induced by the TCT compounds also might result from disruption of 
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nucleocytoplasmic shuttling (0,","" 1991l. Unpublished data of Alarid et al. indicate 
that in pituitary lactotrope cells the rapid degradation of ER by the ICI 
compounds occurs through a proteasome-mediated mechanism (referred to in ,,,rid 
!222). Although this might be a relevant factor in intact cells, our data obtained in a 
cell fi'ee system indicate that reduction in half-life might be a direct consequence 
of increased protease sensitivity due to the ICI-induced confOlmational change of 
the ER. 
Based on these findings we conclude that the ICI compounds can be 
considered as SERMs, although their agonistic activity is only limited. In certain 
conditions, i.e. in certain cells, via certain DNA interaction sites, and possibly via 
ERP the ICI compounds might exert agonistic effects. However, in most tissues 
and most responses, the ICI compounds lack any estrogenic activity and 
counteract E, and, therefore, these compounds remain useful in the h'eatment of 
patients with advanced breast cancer resistant to tamoxifen (H""n """. 
7.4. SUGGESTIONS FOR FURTHER RESEARCH 
In conh'ast to the ER and other steroid hormone receptors, for the VDR no 
ligands devoid of biological activity were discovered for a long time (Born",," 199". 
However, recent data showed that 1,25-(OH),D,-26,23-lactone analogs exert 
antagonistic activities ~(;'" 1997, A"' 1997, 1.'_ 199n, These analogs bind the VDR with 
moderate affinity (10 times less than 1,25-(OH),D3) and counteract in a dose-
dependent manner induction of cell differentiation by 1,25-(OH),DJ' In the 
absence of 1,2S-(OH),D3 these analogs did not affect cell differentiation. With 
respect to the search for VDR ligands with an enlarged dissociation between 
calcemic activity and cell proliferation-/differentiation-inducing activity, the 
finding that antagonistic VDR ligands exist or can be developed, is promising, 
The underlying mechanism by which these compounds act antagonistic is 
presently unknown. Therefore, it would be velY interesting to study the effect of 
these 1,25-(OH),D3 analogs with antagonistic activities on VDR conformation, 
half-life and DNA binding properties as performed in this thesis. Similar studies 
perfOlmed with the ER (as presented in Chapter 6) and other steroid hormone 
receptors demonstrated that ligands with (partial) antagonistic activity also 
change the receptor conformation and that this also results in increased protease 
resistance of receptor fi'agments, albeit of sizes distinct fi'Olll those protected by 
agonists, However, our studies with the pure antagonists ICI 164,384 and ICI 
182,780 show that increased protease sensitivity of the receptor is also possible 
(Chapter 6), 
The importance of the cofactor SUGl in 1,25-(OH),D,-mediated VDR 
degradation has already been mentioned "'I"",~ 1995), Based on the observed 
stabilizing effect on the VDR by KH1060 it would be interesting to investigate 
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the role of this and other cofactors in the action of 1,25-(OH),DJ analogs on VDR 
stability. 
A specific role of the ER subtypes (ifthere is any) should be resolved. The 
observed ER subtype-specific tissue distribution ~. K,iW 1m" together with our 
findings with the partial protease digestion studies (Chapter 6) and studies of 
others ITremblar 1997, PJe.:h 1997, Walan.lbe 1997, :'1C!n;'~y 1993, KolxIri 1998, BlIkhoWl 1993, lou 1999, ~, Glido 1999) indicate 
that specific functions are not unlikely. Evaluation of data obtained by knockout 
models (both naturally occurring and generated) might provide more insight. In 
addition, investigations should focus on the search for ER subtype-specific target 
genes and regulatOlY elements (ERp-specific EREs?). Finally, ligands with a 
preferential affinity for either one of the receptors are known IKw,,, 1997. K"i~, 1998, and 
points out that ER subtype-selective ligands can be developed. 
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SAMENVATTING 
1,25-Dihydroxyvitamin D, (l,25-(OH),D,) en 171l-oestradiol (E,) zUn door het 
lichaam uit cholesterol gevormde steroidhormonen die, na binding aan een 
specifiek receptoreiwit, respectievelijk de vitamine D receptor (VDR) en de 
oestrogeen receptor (ER), een breed scala van processen aansturen en 
controleren. De bekendste functie van 1,25-(OH),D, is de regulatie van de 
calcium- en fosfaat-huishouding en het botrnetabolisme. Van E2 zijn vooral de 
effecten op de vrouwelijke geslachtsorganen bekend. Echter, beide hormonen 
spelen ook een belangrijke rol bij de groei, differentiatie en functie van diverse 
andere cellen, weefsels en organen. 1,25-(OHhD, heeft bUvoorbeeld een 
groeiremmend en differentiatie-indueerend effect op cellen; een eigenschap die 
mogelijkheden suggereert voor de klinische toepassing van 1,25-(OHhD, bij de 
behandeling van (hyper)proliferatieve aandoeningen (bijvoorbeeld kanker en 
pSOliasis). E2 heeft een gunstig effect op het functioneren van het hart en 
vaatstelsel, het centraal zenuwstelsel en het skelet. Het belang van E2 voor het 
skelet wordt het duidelijkst gei'llustreerd met het dalen van de botmassa en het 
toenemen van het risico op botbreuken bij vrouwen na de menopauze 
(postmenopauzale osteoporose). Echter, de toepassing van zowel 1,25-(OH)2D, 
als E2 wordt belemmerd door het optreden van bijwerkingen. Door de hoge 
dosis 1,25-(OH),D" noodzakelijk om de effecten op celgroei en differentiatie te 
induceren, ontstaat het tisico op te hoge calciumspiegels in het bloed 
(hypercalcemie). Bij de behandeling van bijvoorbeeld postmenopauzale 
osteoporose patienten met E2 is er vcrhoogd risico op het optreden van borst-en 
baarmoederkanker. Er zijn dan ook meerdere onderzoeken die zich richten op de 
ontwikkeling van synthetische VDR en ER liganden die weI de gunstige, maar 
niet de ongunstige eigenschappen van de natuurlijke hormonen bezitten. 
Inmiddels zijn er vele synthetische VDR liganden (l,25-(OH)2D, analoga) en 
synthetische ER liganden (Selective Estrogen Receptor Modulators; SERMs) 
ontwikkeld, waal'van verschillende een veelbelovend werkingsprofiel hebben en 
al daadwerkelijk worden toegepast als therapeuticum. Echter, een 
mechanistische verklaring voor de veranderde eigenschappen van deze 
synthetische hormonen is over het algemeen niet bekend. Onderzoek naar de 
wel'kingsmechanismen geeft inzicht in de mogelijke oorzaken van steroid 
honnoon-gereguleerde fYsiologische en pathologische processen en zal 
uiteindelijk kunnen leiden tot de ontwikkeling van synthetische receptor 
liganden met sterk verbeterde klinische toepassingsmogelijkheden. In dit 
proefschrift worden een aantal onderzoeken beschreven die de mogelijke 
werkingsmechanismen van 1,25-(OH),D, analoga en SERMs nader bestudeert. 
De Hoofdstukken 2 tot en met 5 handelen over 1,25-(OH),D, analoga, Hoofdstuk 
6 beschtijft een onderzoek met SERMs. 
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In het onderzoek beschreven in Hoofdstuk 2 werden een aantal 1,25-
(OH)2D3 analoga onderzocht op hun effecten op de groei en differentiatie van 
botcellijnen: de humane osteoblast-achtige cellijn MG-63 en de ratten 
osteoblast-achtige cellijn ROS 17/2.8. De richting van de effecten van al de 
onderzochte analoga was gelijk aan die van 1,25-(OHhD3: In beide cellijnen 
werd de productie van het botmattixeiwit osteocalcine gestimuleerd, evenals de 
synthese van procollageen type I door de MG-63 cellen. De groei van de MG-63 
cellen werd door 1,25-(OH)2D3 en de analoga geremd en van de ROS 1712.8 
cellen gestimuleerd. Verder stimuleerden zowel 1,25-(OHhD3 als de analoga de 
afgifte van calcium (een maat voor de bott'esorptie activiteit) uit 
vrijgeprepareerde pijpbeentjes van foetale muizen. Echter, er was een 
aanzienlijk verschil in de sterkte van de effecten: enkele analoga waren al bij 
veel lagere concentt'aties dan 1,25-(OH)2D3 actief. Het mogelijk 
werkingsmechanisme van een van de meest actieve analoga uit dit onderzoek, 
KH 1060, werd nader bestudeerd. Een mogelijke verhoogde affiniteit voor de 
VDR bleek geen rol te spelen: KH1060 bindt de VDR met een lagere affiniteit 
dan 1,25-(OH)2D3. 
Receptor binding van een steroidhormoon leidt tot verandering in de vorm 
van de receptor. Door deze zogenaamde receptor conformatieverandering, wordt 
een reeks van processen in gang gezet, die tot veranderde expressie van 
specifieke genen en uiteindelijk tot veranderde celfunctie leidt. In Hoofdstuk 3 
werd het effect van 1 ,25-(OHhD3 en KH 1060 op de conformatieverandering van 
de VDR bestudeerd. De partiele protease assay die hierbij werd toegepast is 
gebaseerd op de veronderstelling dat de bereikbaarheid van bepaalde 
knipplaatsen voor een protease (= een eiwit afbrekend enzym, bijvoorbeeld 
trypsine) in de VDR zal veranderen ten gevolge van zo'n 
conformatieverandering. Omdat wordt uitgegaan van radioactief-gelabeld VDR 
zullen de fi'agmenten die ontstaan door het knippen met een protease ook 
radioactief-gelabeld zijn. De receptor fi'agmenten worden met behulp van een 
gel op grootte gescheiden en door middel van r6ntgenfilm zichtbaar gemaakt. 
Deze experimenten toonden aan dat VDR onder invloed van KH 1 060 een 
conformatieverandering had ondergaan die, in vergelijking met 1,25-(OH)2D3 
gebonden VDR tot verhoogde beschenning tegen de activiteit van de proteases 
leidde. Vervolgens werd onderzocht of de verhoogde bescherming tegen 
proteolytische afbraak ook in intacte cellen kon worden waargenomen. In de 
ROS 1712.8 cellen werd de nieuwe vorming van eiwitten (waaronder VDR) 
geblokkeerd, waama de cellen voor 1 uur werden behandeld met 1,25-(OHhD3 
ofKH1060. Vervolgens werd met behulp van een immunologische bepaling op 
diverse tijdstippen het VDR gehaJte in de cell en gemeten. Het bleek dat het 
VDR gehalte in de cellen behandeld met KH 1 060 veellanger hoog bleef dan het 
VDR gehalte in de cellen behandeld met 1 ,25-(OH)2D3. Met andere woorden: de 
stabiliteit van de VDR neemt toe wanneer het KHI060 heeft gebonden. 
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Een volgende stap in het proces dat leidt tot stimulatie of remming van 
transcriptie van bepaalde genen is de binding van de VDR aan vitamine D 
respons elementen (VDREs); een serie specifieke nucleotiden (DNA 
bouwstenen) in de aanstuureenheid (de promoter) van het gen. Binding van de 
VDR aan een VDRE wordt gestimuleerd door 1,25-(OH),D3 en vindt in de 
meeste gevaIlen plaats als een complex met een andere steroid hormoon 
receptor: de retinoic X receptor (RXR). Of KH I 060 ook in staat is om 
VDRlRXR binding aan VDREs te stimuleren werd onderzocht in Hoofdstuk 4. 
De binding van VDRlRXR (zowel verkregen uit ill vitro synthese als uit 
celextracten) aan de VDREs van een drietal natuurlijk voorkomende genen: 
ratten osteocalcine, humaan osteocalcine en muizen osteopontine, werd 
bestudeerd. Er werd hierbij gebruik gemaakt van een bepaling waarbij 
radioactiefgelabelde VDREs worden behandeld met VDRlRXR en ligand (1,25-
(OH)2D3 of KH1060). Vervolgens wordt het mengsel op een gel gescheiden, 
waarbij het aan de VDRE gebonden VDRlRXR een tragere migratie van de 
VDRE in de gel veroorzaakt. Ondanks de grote mate van overeenkomst in de 
nucleotide volgorde van deze VDREs bleek er toch een aanzienlijk verschil te 
bestaan in de bindingsaffiniteit van VDRlRXR. Zowel 1,25-(OH),D3 als 
KH1060 stimuleerden de VDRlRXR binding aan alledrie de VDREs, echter de 
affiniteit voor de muizen osteopontine VDRE was hoger en die voor de ratten 
osteocalcine VDRE lager dan die voor de humane osteocalcine VDRE. Door 
gebruik te maken van synthetische VDREs met variaties in de nucleotide 
volgorde kon het belang van twee nucleotides voor het waargenomen verschil in 
VDRlRXR binding grotendeels worden verklaard. Bovendien toonden deze 
onderzoeken aan dat het stimulerend effect van 1,25-(OH)2D3 en KHI060 op de 
binding van ill vitro gesynthetiseerd VDRlRXR aan de VDREs van het humaan 
osteocalcine gen en het muizen osteopontine gen vergelijkbaar is. Interessant 
was de waameming dat, wanneer de binding van ill vitro gesynthetiseerd 
VDRlRXR aan de ratten osteocalcine VDRE werd bestudeerd, KH 1060 minder 
effectief was dan 1,25-(OH)2D3. Eehter, met VDRlRXR uit celextracten was 
KH I 060 niet aIleen via de humane osteocalcine VDRE en de muizen 
osteopontine VDRE, maar ook via de ratten osteocalcine VDRE een sterkere 
stimulator dan 1,25-(OH),D). Dit duidt op het belang van een ceIlulaire context 
(de aan- of afwezigheid van bepaalde cofactoren) voor de VDRlRXR-VDRE 
binding. 
Voor 1,25-(OH)2D3 is een complex afbraakmechanisme bekend dat zorg 
draagt voor het controleren van de concentratie en daarmee van de effecten van 
dit hormoon. Ook 1,25-(OH),D) analoga worden enzymatisch afgebroken. 
Sommige van die afbraakproducten (metabolieten) zijn mogelijk zelf ook 
biologisch actief. In Hoofdstuk 5 werd onderzocht of bepaalde metabolieten 
bijdragen aan de sterke biologische activiteit van KH1060. Hiertoe werden door 
huidceIlen gevormde metabolieten van KHI060 onderzocht op hun vermogen 
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om de conformatie van de VDR te veranderen, zoals dat reeds in Hoofstuk 3 is 
beschreven voor 1,2S-(OH)2D3 en KH1060. Het bleek dat bepaalde metabolieten 
het vermogen hadden om de VDR dusdanig van conformatie te doen veranderen 
dat de resistentie voor proteases toenal11. Dezelfde metabolieten bleken ook in 
staat om de stabiliteit van de VDR in ROS 17/2.8 cellen te verhogen. De 
biologische activiteit van deze metabolieten kwam ook tot uiting in het 
stimulerend effect op de binding van VDRlRXR complexen aan VDREs en uit 
de toegenomen productie van osteocalcine door ROS 17/2.8 cellen. Al deze 
waamemingen hebben geleid tot de conclusie dat ook metabolieten van KH1060 
bijdragen tot de uiteindelijk hoge biologische activiteit van dit analoog. 
In Hoofdstuk 6 werden de effecten van een aantal SERMs op de 
conformatieverandering van de ER onderzocht. De ER komt voor als twee 
subtypen: ERa en ER~. De receptoren vertonen grote overeenkomsten in 
structuur en functie, maar het is niet onwaarschijnlijk, of zelfs te verwachten dat 
de subtypen naast een gemeenschappelijke functie, ook een eigen, specifieke 
functie bezitten. De SERMs die in het onderzoek werden gebruikt zijn: 
tamoxifen, dat in bepaalde weefsels en op bepaalde genen het effect van E2 
nabootst (de agonistische werking) en in andere wcefsels of andere genen de 
effecten van E2 tegenwerkt (de antagonistische werking), en leI 164,384 en leI 
182,780, die over het algemeen worden beschouwd als pure antagonisten van E2, 
hoewel een aantal agonistische effecten zijn beschreven. In de protease assay, 
zoals die ook voor de VDR werd gebruikt, bleek dat bij behandeling van beide 
ER subtypen met tamoxifen een protease patroon werd verkregen dat duidelijk 
afweek van dat verkregen met E2. De partiele agonist/antagonist tamoxifen 
veroorzaakte bij zowel ERa als ER~ een andere conformatieverandering dan de 
pure agonist ~. Echter, opvallender was de waameming met de leI 
componenten. Met ERa veroorzaakte zo\vel leI 164,384 als leI 182,780 een 
dusdanige conformatieverandering dat de receptor een verhoogde gevoeligheid 
voor de proteases verwierf, terwijl met ER~ een toegenomen resistentie tegen 
proteolytische afbraak werd waargenomen. Hoewel er geen direct biologische 
activiteit aan dit ER-subtype-specifieke verschijnsel kan worden verbonden, is 
een mogelijke betrokkenheid van ER~ in de (zeldzame) agonistische effecten 
van de leI componenten niet uitgesloten. 
De onderzoeken met 1,2S-(OHhD3 analoga en SERMs beschreven in dit 
proefschrift tonen aan dat veranderingen in chemische shuctuur van een ligand 
kunnen leiden tot veranderingen in de reeks van processen die de uiteindelijke 
mate van gentranscriptie bepalen. Onderzoeken met de 1,2S-(OHhD3 
superagonist KH1060 of de "pure" E2 antagonisten, leI 164,384 en leI 182,780, 
tonen aan dat deze en andere synthetische liganden niet aileen een mogelijke 
klinische relevantie hebben, maar ook van grote waarde zijn voor het ophelderen 
van de werkingsmechanismen van natuurlijke en synthetische receptor liganden. 
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